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Abstract 
Hepatitis C virus (HCV) is a major cause of viral hepatitis. The World Health Organiza-
tion (WHO) estimates the global prevalence of HCV to be approximately 2.2–3.0% with 
130– 170 million infected individuals worldwide. HCV has the ability to evade the im-
mune system and to establish persistent infections, which often result in chronic liver dis-
ease. HCV encodes a long polyprotein which contain structural and non-structural pro-
teins. The Non-structural protein NS3 is likely to be involved in viral RNA replication by 
interacting with viral and host components. In this study, a purified recombinant full-
length NS3 protein expressed in  E. coli was examined for its ability to interact with 
biotinylated full length HCV JFH-1 genomic RNA and the 3’ terminal of HCV negative 
strand RNA. The results showed that NS3 could bind to both full length and the 3’ end 
negative strand RNAs. RNA interference (siRNA) studies were also carried out to inves-
tigate the role of host genes RAB40B, RAB27B, TXNIP and Staufen 1, which had previ-
ously been shown to be important for HCV replication, on NS3 and NS3/4A proteins ex-
pressed by adenovirus vectors using quantitative real-time polymerase chain reaction 
(qRT-PCR) and FACS analysis. While there were reductions in the levels of the NS3 and 
NS3/4A transcripts when the expression of these host genes was knocked down by 
siRNAs, the NS3 and NS3/4A proteins appeared to be more stable when RAB40B, 
RAB27B, but not TXNIP or Staufen 1, were knocked. One possibility is that although si-
lencing of these host genes may reduce HCV replication, this may also increase in the 
stability of NS3 or NS3/4A proteins by altering their location within the cell due to the 
absence of these host proteins. Previously it has been shown that NS3 and NS3/4A pro-
tein expression decreased the level of expression of several proteins, which were part of 
the innate immune response, leading to interferon  production. In this study, it was found 
that the expression of NS3 and NS3/4A proteins, using adenovirus vectors, restored RIG-
I, MDA5 and MAVS expression levels in response to dsRNA stimulation, indicating that 
the NS3 protein may have a role in regulating the expression of these host genes. 
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1. Introduction 
1.1 Background  
Hepatitis C virus (HCV) is a small, enveloped positive-sense single-strand RNA virus be-
longing to the Flaviviridae family. It is a blood-borne pathogen affecting the liver, and 
causes chronic hepatitis, liver cirrhosis, and HCV hepatocellular carcinoma (HCC) [1, 2]. 
Presently, the treatment of HCV infection is a combination of peglyated interferon (peg-
IFN-α) and the nucleoside ribavirin. This is effective in approximately 40% of patients 
affected by the HCV genotype 1, as well as 80% of patients with the HCV genotype 2 or 
3. Currently, there is no protective vaccine available for HCV [3-5]. The existence of the 
virus was first indicated in the mid-1970s, where a new agent was implicated in causing 
post-transfusion hepatitis, which was acknowledged as being different from the Hepatitis 
A or Hepatitis B virus, or indeed any other viral infection. All attempts to isolate the 
Non-A, Non-B (NANBH) hepatitis agent or visualise it by electron microscope failed, 
and the agent remained elusive for over a decade [6]. In 1989, a group of investigators 
successfully cloned a cDNA sequence encoding an antigenic component of the Non-A, 
Non-B agent from the RNA molecules of the infectious agent. This cDNA clone was 
used to identify the rest of the approximate 9,500 nucleotides, of a positive-stranded 
RNA virus genome, which showed similarities with Togaviridae and Flaviviridae. Fol-
lowing this discovery, the Non-A, Non-B agent was renamed as the Hepatitis C virus and 
accordingly allocated to the Flavivirus family on the basis of its genome organisation [7]. 
The origin of HCV is unknown owing to the lack of stored blood samples dating back 
more than 50 years; however, genotypes 1 and 4 appear to share a common origin.  Addi-
tionally, a Bayesian analysis suggests that the major genotypes diverged approximately 
300–400 years ago from the ancestor virus, whereas the minor genotypes diverged 
roughly 200 years ago from their major genotypes. However, all of the extant genotypes 
appear to have evolved from genotype 1 subtype 1b [8, 9]. 
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1.2 Classification and genetic variation 
There are three genera classified as being members of the Flaviviridae: Flavivirus, Pesti-
virus and Hepacivirus. The Flavivirus genus includes yellow fever virus (YFV), dengue 
fever virus (DFV), and tick borne encephalitis virus; pestiviruses includes bovine viral 
diarrhoea, classical swine fever, and border disease virus. HCV has been classified as a 
member of the hepacivirus genus, which also includes the GB virus B (GBV-B) and GB 
virus C [10, 11]. HCV can be classified into 7 genotypes, each of which is further classi-
fied into subtypes (a, b, c, etc.). Furthermore, it has also been shown that HCV circulates 
in infected individuals as a population of diverse but closely related types known as “qua-
sispecies” [12, 13]. Based on a phylogenetic relationship between the helicase and RNA-
dependent RNA polymerase (RdRP) trees of the family Flaviviridae, it was found that 
the helicase region within NS3 share amino acid sequence identity in six domains, 
whereas the RdRp protein contains eight conserved motifs. Alignments were performed 
by hand, based on  Koonin et al., alignments [14, 15] that were used as a guide. Helicase 
sequences of members of the family Flaviviridae fall within the helicase supergroup II, 
and their RdRp sequences place them into the RdRp supergroup II. Further analysis of 
the six conserved helicase domains and eight conserved RdRp motifs with their dominant 
sequences of HCV, GBV-A, GBV-B, GBV-C and GBV-D confirmed that these viruses 
were related to the Pestivirus and Flavivirus genera within the family Flaviviridae. 
Therefore, it is proposed to classify GBV-A-like viruses, GBV-C and GBV-D as mem-
bers of a fourth genus in the family Flaviviridae, named Pegivirus (pe, persistent; g, GB 
or G); it is also proposed to rename ‘GB’ viruses within the tentative genus Pegivirus to 
reflect their host origin. (Figure 1.1) [16, 17]. 
 
1.3 Epidemiology  
The World Health Organization (WHO) estimates that up to 160 million individuals 
around the world are chronically infected with HCV. In addition, prospective studies 
have shown that more than 75% of HCV-infected individuals become chronic carriers,   
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Figure  1.1. Phylogenetic tree deduced from the analysis of amino acid sequences of 
Flavivirus genomes. The Flavivirus family are more closely related to HCV and include 
tick-borne encephalitis virus (TBEV); yellow fever virus (YFV); West Nile virus 
(WNV); dengue virus (DEN), than the pestiviruses: bovine viral diarrhoea virus 
(BVDV). The Hepacivirus include, HCV (genotypes la, lb, 2a, 2b, and 3a) and the most 
closely related viruses to HCV, GBV-A, GBV-B, GBV-C and HGV [16, 17]. 
 
and within 20–30 years, 10–20% of these patients will develop complications, including 
liver cirrhosis, with 1–2% developing hepatocellular carcinoma (HCC) [18].The preva-
lence of HCV around the world varies (Figure 1.2). In Europe the prevalence is approxi-
mately 1%, whilst in the United Kingdom at least 200,000 adults carry HCV [19]. The 
highest prevalence has been recorded on the African continent. In Egypt, it was estimated 
that 15–20% of population are infected with HCV which has been attributed to the im-
munisation programme against the parasitic infection Schistosomiasis [20]. Blood prod-
ucts were found to be the main route of transmission until 1992, since then improved 
screening tests for HCV have greatly reduced this. Risks of transmission also include in-
travenous drug use, high risk sexual activity, haemodialysis and occupational exposure 
[19]. 
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Figure  1.2. A map of a worldwide prevalence of Hepatitis C virus based on WHO up-
date 1999 [21].  
 
1.4 The disease  
HCV mainly infects hepatocytes leading to immune-mediated inflammation. The acute 
phase of hepatitis C is usually asymptomatic, however, patients may experience symp-
toms such as jaundice, nausea, malaise, dark urine and liver pain [22]. Patients with hepa-
titis C can be diagnosed 8–12 weeks after initial infection by a rise in alanine aminotrans-
ferase (ALT) levels. At that time, HCV specific antibodies and T cells become detectable, 
and the appearance of HCV-specific T cells in the liver coincides with the first decrease 
in HCV titre [23, 24]. About 60%–80% of patients will develop chronic hepatitis, which 
is associated with an increase of membranoproliferative glomerulonephritis (7-fold in-
crease), cryoglobulinemia (11-fold increase), skin disease such as lichen planus (2-fold 
increase) and porphyria cutanea tarda. Approximately 15–25% of patients will recover 
spontaneously, whereas the majority will develop to chronic hepatitis. Once the infection 
has become chronic, patients are less likely to have symptoms, but fatigue, nausea, dark 
urine can occur [25, 26]. 
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 The most common serious complication resulting from a chronic HCV infection is the 
development of cirrhosis. In cirrhosis, the normal liver tissue is replaced by scar tissue, 
resulting in liver dysfunction. Approximately 10– 15% of patients with chronic hepatitis 
C will ultimately develop cirrhosis; which may take decades to develop [18]. Further 
progression of the infection can lead to end-stage liver disease and hepatocellular carci-
noma, conditions that require liver transplantation [22]. The outcome of the disease is de-
termined by the efficiency of the host’s antiviral immune response, and the presence of 
viral escape mutants has been suggested to contribute to the persistence of the virus.  
Several other features can contribute to severity of the disease e.g. male sex, older age at 
infection, alcohol consumption, human immunodeficiency virus (HIV) coinfection and 
hepatitis B coinfection seem to accelerate the progression of the disease [27-29].  
 
1.5 Molecular biology of Hepatitis C virus 
Most of the Flavivirus family members share a number of basic characteristics; all pos-
sess positive-strand RNA with a nucleotide size ranging from between 9.6 k and 12.3 k 
nucleotides (nt). Moreover, they all have a lipid bilayer envelope in which the envelop 
proteins are anchored. A single long Open Reading Frame (ORF) which is flanked at the 
5’ and 3’ ends by untranslated regions encodes the viral proteins. The N-terminal part of 
the ORF encodes the structural protein and the non-structural proteins, are encoded by the 
remaining C- terminal part of the ORF., HCV shows a number of differences to other 
Flaviviruses: for example, in contrast to members of the Flavivirus genus where transla-
tion is cap-dependent, the 5 ‘UTR in HCV is cap-independent as is the case of of mem-
bers of the pestivirus genus [30, 31]. 
HCV genome is a positive-strand RNA, which is 9.6 kb in length, encapsulated by an 
icosaheadral capsid comprised of core protein capsomeres. The genome encodes a long 
polyprotein precursor of approximately 3000 aa, which is co- and post-translational proc-
essed via cellular and viral proteases into 10 structural and non-structural proteins.  The 
ORF that encodes the polyprotein is flanked by 5’ and 3’ untranslated regions (UTR). 
The structural proteins comprise core and envelope proteins E1 and E2 [32]. The non-
structural proteins are NS2, NS3, NS4A, NS4B, NS5A and NS5B. Importantly, the N 
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terminus of NS3 and NS2 encode a metalloprotease enzyme. The N terminus one-third of 
NS3 encodes a serine protease, which, along with NS4A, is responsible for cleavages at 
the NS3-NS4A, NS4A-NS4B, NS4B-NS5A and NS5A- NS5B junctions. The NS3 C-
terminal part comprises an NTP/helicase domain (Figure 1.3) [32].  
1.5.1 Untranslated regions  
1.5.1.1 5’ UTR 
The 5’ untranslated region of HCV RNA 341(nt) and is highly conserved amongst HCV 
subtypes. The 5’ UTR comprises 4 highly ordered domains designated I to IV. The first 
40 (nt) consists of domain I, which plays a role in RNA replication. Domains II, III and 
IV, with the first 12-30 nt of the core, constitute the Internal Ribosome Entry Site (IRES) 
[33-35]. The IRES plays an important role in HCV replication, directing translation by 
binding eIF3 and ribosomal S40 ribosomal subunit directly to the mRNA [36]. Further-
more, it can bind 40S ribosomal subunits without the elF3, eIF4A, eIF4B and eIF4F [37]. 
Importantly, a genetic interaction between a liver-specific micro RNA, mir-122 and the 
5’ UTR region was found to play a role in HCV replication [38-40].  
1.5.1.2 3’ UTR 
The HCV 3’ UTR region, ranging in length from 200–235 nucleotides in the direction 5’ 
to 3’, contains three distinct regions: a short V variable region of approximately 40 nt, 
which shows variability between different HCV genotypes; a poly (U) and/or poly (UC) 
region; followed by a highly conserved sequence X region of approximately 100 nucleo-
tides. The X region forms three stable stem-loop structures designated as SL-1, SL-II and 
SL-III [41-43]. The 3′ UTR interacts with the NS5B RdRp and with two of  
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Figure  1.3 The HCV genome structure. The figure shows (A) the location of the 5′ and 
3′ UTR regions, the HCV IRES in the 5′ UTR is also indicated. (B) The approximate lo-
cation of the ATG start codon in the 5′ UTR and termination codon following the NS5B 
protein coding sequence are indicated by asterisks. The HCV polyprotein diagram colors 
the structural proteins in purple. White diamond (site of signal peptide peptidase cleav-
age in the core protein). Black diamonds (signal peptidase cleavage sites in the core, E1, 
E2, p7, and NS2 proteins). (C) The NS2-3 auto-protease cleavage is designated by the 
double arrow, indicating cleavage of the NS2-3 bond in cis. The NS3 protease domain, 
in conjunction with NS4A then cleaves all the remaining polyprotein junctions, as indi-
cated by arrows. The putative functions and amino acid numbering of the mature HCV 
proteins (numbers on the basis of the Con1 1b isolate of HCV). Circles indicate the loca-
tion of glycosylation sites in the E1 and E2 proteins [44].  
 
the four stable stem-loop structures located at the 3′ end of the NS5B. The 3′ X region 
and the 52 upstream nt of the poly(U/C) tract were found to be essential for RNA replica-
tion, whereas the remaining sequence of the 3′ UTR appears to enhance viral replication 
[45-48]. 
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1.5.2 Structural proteins 
1.5.2.1 Core protein 
The core is a structural protein of 23 kD, located at the N terminus of the polyprotein. 
The mature form of the core protein contains 191 amino acids [49]. It is divided into 
three general domains: N-terminal hydrophilic domain I, a hydrophobic domain II, which 
comprises approximately two-thirds of the C terminal of the protein; and a highly hydro-
phobic domain III. These domains perform different functions in the HCV lifecycle. Do-
main I binds RNA and mediate caspsid assembly; Domain II mediates the interaction 
with lipids and membrane proteins; whilst Domain III is believed to form an α-helix at 
the distal C-terminus of the immature core protein, with the domain cleaved and disap-
pearing from the mature form of the HCV core after translation [50]. The core protein 
plays an essential role in HCV pathogenesis, interacting with a number of cellular pro-
teins that affect cellular processes, such as lipid metabolism, apoptosis and signalling 
pathways [50]. Markedly, the HCV core protein possesses both pro and anti-apoptotic 
functions; it stimulates hepatocyte growth in Huh 7 cells through the transcriptional up 
regulation of growth-related genes, and it has been implicated in tissue injury and fibrosis 
progression. 
 It can also induce the formation of lipid droplets and may play a direct role in the devel-
opment of steatosis [51-53]. Moreover, it has been found to induce insulin resistance 
through the impairment of insulin signalling. HCV core activates SOCS-3 by inducing 
the expression of TNF-α, leading to the impairment of the insulin signalling cascade, re-
sulting in insulin resistance [54]. Furthermore, the core of N-terminal Domain I has a po-
tent RNA chaperone activity, which prevents the misfolding of HCV RNA (Figure 1.3) 
[55]. 
 1.5.2.2 Envelope proteins 
HCV virus has two envelope proteins designated E1 and E2, with molecular weights of 
33–35 kDa and 60–72 kDa, respectively, and are localised to the endoplasmic reticulum 
[56].  
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The envelope proteins E1 and E2 are important constituents of the HCV virion envelope, 
with each known to play a role in virion entry into host cells through direct binding to the 
receptors CD81 and scavenger receptor class B type (SR-BI) [57-59]. E1 and E2 are 
highly glycosylated Type 1 transmembrane proteins, forming two types of stable het-
erodimeric complexes: a disulfide-linked form of misfolded aggregates, and a non-
covalently linked heterodimer, most likely corresponding to the pre-budding complex 
[60]. The two hypervariable regions, HVR1 and HVR2, respectively and each region can 
stimulate the production of virus-neutralising antibodies. However, it is recognised that 
the virus can escape from the neutralising antibodies by inducing random mutations in 
HVR1 during the course of infection [61-63]. 
1.5.2.3 Protein p7 
The p7 protein is a member of viroporin group of transmembrane proteins. These are 
membrane ion-channel proteins encoded by different viruses, e.g. HIV-1 and Influenza-A 
virus, which promote virus release and possibly viral entry. HCV p7 is required for the 
assembly and release of HCV particles from liver cells [64, 65]. The p7 is a highly hy-
drophobic polypeptide 63 amino acids in length, which oligomerises to form a hep-
tameric cation channel in vitro. The protein is located in the HCV polyprotein between 
E2 and the carboxy terminus of NS2, although it is not yet classified as either a structural 
or non-structural protein. Evidence suggests that the ion channel activity can be specifi-
cally blocked by several synthetic small molcules, and it could be a possible target for 
antivirals [66, 67] 
1.5.2.4 ARFP/F protein 
Alternative reading frame protein of F protein, which is 160 amino acids, is synthesized 
in the core region by an alternative reading frame. Currently there is little evidence that 
the F protein plays an important role in the HCV replication cycle [68].    
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1.5.3 Non-structural proteins 
1.5.3.1 NS2 
NS2 is a hydrophobic protein with a molecular mass of 23 kDa with cystein protease ac-
tivity [69, 70]. The NS2 is responsible for the cleavage of the junction between NS2 and 
the amino terminal domain of NS3 by an autoprotease comprising NS2 and NS3, whilst 
the cleavage of the N-terminus of NS2 from the C-terminus of p7 is mediated through 
host signalase enzymes (Figure 1.3) [71-73]. NS2 forms a homodimer. In addition, NS2 
has also been shown to interact with all the other HCV non-structural proteins [74]. A 
study shows that the expression of NS2 in Huh 7 cells resulted in up regulation of tran-
scriptional factor sterol regulatory element-binding protein 1c (SREBP-1c) and fatty acid 
synthesis, which indicates that NS2 may be involved in steatosis. NS2 has also been sug-
gested as participating in the virus particle assembly [13, 75].   
1.5.3.2 NS3 
NS3 is a bifunctional, hydrophobic protein of 72 kDa. The mature NS3 comprises five 
domains: the N-terminal 2 domains form a serine protease which is associated with the 
NS4A cofactor and the C-terminal three domains, which form an RNA helicase. NS3 
protease cleaves at the NS3/NS4A junction and forms a tight, non-covalent complex with 
NS4A; this is fundamental for the processing of the polyprotein [76]. 
1.5.3.2.1 The NS3 serine protease domain 
NS3/4A serine protease is a non-covalent, heterodimer complex formed by the catalytic 
subunit located in the N-terminal of NS3 and the activation subunit of the NS4A cofactor. 
The NS3/4A serine protease cleaves the junctions of the HCV polyprotein precursor at 
NS3/4A, NS4A/NS4B, NS4B/NS5A, and NS5A/NS5B. The NS3 serine protease domain 
enhances the activity of the NS3 helicase RNA binding, which is required for RNA un-
winding [77, 78]. A conserved sequence is present in all serine proteasess comprising the 
amino acids histidine (His57), aspartate (Asp81) and serine (Ser139), known as the catalytic 
triad. A substitution of any of these catalytic triad amino acids in HCV NS3 will suppress 
the cleavage of NS3/4A, NS4/4B, NS4B/ NS5A and NS5A/NS5B within the polyprotein 
[77-81]. Several studies have reported the role of HCV NS3/4A serine protease in break-
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ing down the host antiviral response; for example, the HCV NS3/4A blocks the activation 
of TLR3-dependent and TLR3-independent signal transduction cascades, thus blocking 
the IFN-induced antiviral response against HCV RNA replication [82]. Importantly, 
NS4A has been shown to play the role of cofactor with NS3 protease to cleave peptide 
substrates more efficiently particularly at the NS4B/NS5A junction [80]. 
1.5.3.2.2  NS3 helicase domain 
The C-terminal of HCV NS3 encompasses the helicase domain. The crystal structure of 
HCV helicase, viewed as a Y-shaped protein, comprises three domains, the most N- ter-
minal domain (Domain1) and the middle domain (Domain2) are above the C-terminal 
domain (Domain3) [83-85]. In general, helicases share similarities between each other: 
for example, they all carry the classical Walker A (phosphate binding loop) and Walker B 
(Mg+-binding aspartic acid) motifs [86]. The helicases are classified into five superfami-
lies ( SF1-SF5) [87]. Based on the sequence homology, the HCV NS3 helicase belongs to 
the DEAD-box RNA helicases, and is classified as a member of the DExH family of 
RNA helicase proteins of superfamily II, which also includes helicases from bovine diar-
rhoea pestivirus, plum pox potyvirus, and vaccinia virus. Many amino acid sequence mo-
tifs can be found conserved amongst RNA helicases of both superfamily I and super-
family II. Furthermore, all helicases possess Rec-A like motor domains, which functions 
as the core of the helicase molecular motor [87, 88]. However the exact biological role of 
NS3 helicase remains unclear; it is believed to be involved in several activities such as (i) 
binding and hydrolyzing nucleoside triphosphates, (ii) interacting with both RNA and 
DNA, (iii) translocation in a 3′-to-5′ direction, (iv) separating nucleic acid base pairs and 
(v) displacing nucleic acid binding proteins [86]. The HCV helicase requires a single-
stranded region to initiate unwinding with a 3′-end overhang on which to load, and the 
energy from ATP hydrolysis is believed to fuel both translocation and unwinding. 
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Figure  1.4. Crystal structure of the HCV NS3 helicase domain complexed with 
ssRNA.The helicase domain has three distinct domains; Domain 1 (blue), Domain 2 
(red) and Domain 3 (green), ssRNA is shown in (yellow) [85]. 
 
In contrast to other helicases, HCV helicase cleaves ATP more rapidly in the absence of 
RNA. This basal ATPase activity is stimulated up to 100-fold by nucleic acids, depend-
ing on the nucleic acid sequence and whether or not the protease region is present (Figure 
1.4) [89-91]. The most likely role for HCV helicase is assisting the NS5B RNA-
dependent RNA polymerase with viral replication by resolving RNA secondary structures 
and/or double-stranded replication intermediates [92-94]; however, there is the possibility 
that cellular helicases may perform this function, and recently HCV NS5B has been 
shown to recruit and interact with cellular RNA helicase p68, which in turn assists in the 
synthesis of minus-strand HCV RNA [95]. In addition, the NS3 helicase domain has been 
reported to participate in an early step of viral assembly, suggesting it may have addi-
tional or alternative roles [96]. 
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Figure  1.5. Ratchet model of RNA helicase mechanism of action.The binding of a 
polynucleotide by NS3 Helicase in the absence of ATP leaves a large cleft between do-
mains 1 and 2. Binding of ATP occurs with the β-phosphate binding to residues in motif 
I (GSGKT) and the γ-phosphate with Mg2+ binding to the conserved acidic residues in 
motif II (DECH). This results in the closing of the interdomain cleft and the binding of 
conserved arginines in motif VI (QRRGRTGR) to the ATP phosphates. Val432 and 
Trp501 disrupt base stacking at either end of the single-stranded region. Closure of the 
interdomain cleft leads to translocation of the single strand in the 5′ to 3′ direction and 
forces several bases to slip past Trp501. Hydrolysis of ATP facilitates opening of the 
cleft and release of ADP. The orientation of Trp501 favors movement of the polynucleo-
tide in only one direction such that opening of the gap results in net movement of the 
helicase in a 3′ →5′ direction [85].  
 
1.5.3.3 NS4A 
NS4 is a small protein of 54 amino acids. It encodes an N-terminal hydrophobic alpha-
helix that anchors NS3-4A to cellular membranes, a middle “cofactor” peptide that forms 
a beta-strand which facilitate the proper folding of the NS3 serine protease domain, and a 
C-terminal acidic region that forms an alpha-helix at low pH [97-100]. NS4A has been 
reported to have additional functions, e.g. Interacting with NS5A and regulating NS5A 
phosphorylation [101, 102]. Moreover, NS4A overexpression in the absence of NS3 in-
hibits cellular translation process [103, 104], and can lead to mitochondrial apoptosis 
through activation of caspase-3 [105]. 
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1.5.3.4 NS4B 
NS4B is a 27 kDa protein, with both hydrophobic transmembrane (TM) and amphipathic 
helices [106, 107]. It is an integral membrane protein which localise to the ER-derived 
membranous compartment. 
 The expression of NS4B induces membrane proliferation designated as the membranous 
web, which is an essential structure required for the formation of the viral RNA replica-
tion complex [108]. In addition, a cellular protein localized in the early endosome, 
RAB5, was found to be associated with NS4B in replicon cells and may also play a role 
in the formation of the replication complex [109]. 
1.5.3.5 NS5A 
NS5A is a phosphoprotein that may exist in two different forms: basal phosphorylated 56 
kDa and hyperphosphorylated 58 kDa forms [110]. NS5A is anchored to the membrane 
of the ER by its N-terminal 30aa, which forms an amphipatic alpha- helix [111]. The role 
of NS5A remains unclear, although, it has been reported that NS5A plays an important 
role in virus replication through interaction with other HCV nonstructural proteins as well 
as various cellular proteins. The interaction with NS5A leads to the assembly of the viral 
replication complex and may also regulate RNA replication [112-114].  
A study showed that the X-ray crystal structure of domain I has a zinc binding domain, 
which forms a homodimer with contacts at the N-terminal ends of the molecules; sug-
gesting a location of protein, RNA, and membrane interaction sites at the dimeric inter-
face suggested to be involved in RNA binding during viral replication [115, 116]. Addi-
tionally, NS5A has been shown to interact with 3’ end of the HCV positive- and nega-
tive-strand RNAs suggesting that NS5A may affect the efficiency of RNA synthesis by 
NS5B. Moreover, NS5A also has been shown to bind with uridylate and guanylate rich 
RNA, specifically with the large U/G stretches in the 5’ IRES, suggesting a role of NS5A 
in HCV translation and genome multiplication [113, 117, 118].  
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1.5.3.6 NS5B 
NS5B is a 68 kDa tail-anchored protein and is the RNA-dependent RNA polymerase 
(RdRp) responsible for synthesising the complementary negative strand of the genome as 
the replication intermediate, and then genomic RNA using the negative strand as the tem-
plate. Its C terminal 21-aa is responsible for post-translational targeting to the cytoplas-
mic side of the endoplasmic reticulum [119].        
The NS5B organisation is a “right-hand” structure with three sub-domains: thumb, fin-
gers and palm, which is similar to other polymerases such as HIV-1 reverse transcriptase 
[120, 121]. The NS5B RNA-dependent-RNA polymerase (RdRp) activity plays a princi-
ple role in HCV replication, and is the key enzyme required for the synthesis of new 
RNA genomes. NS5B can initiate RNA synthesis in two way  de novo initiation from the 
3′-end of RNA template [122, 123] or primer-dependent initiation [124]. An interaction 
between NS5A and NS5B has been reported [113], suggesting that NS5A might serve as 
a cofactor for NS5B [112]. Protein interaction between NS5B and cellular proteins that 
are involved in HCV replication has been reported. PRK2 (protein kinase C-related 
kinase 2) binds to the fingers domain and may regulate the phosphorylation of NS5B 
[125]. The glycine/arginine-rich domain of nucleolin mediates its interaction with NS5B, 
and siRNA (small interfering RNA) directed at nucleolin mRNA suppressed HCV repli-
cation in vitro [126]. Furthermore, NS5B also interacts with the NS5A-binding protein 
hVAP-B, which may be a component of the replication complex [127]. NS5B binds to 
the retinoblastoma susceptibility protein (pRb) through a site overlapping its polymerase 
motif, although such an interaction may contribute to the oncogenic property of HCV 
rather than the replicase function of NS5B [128]. 
1.6  HCV replication cycle 
A number of studies reported that HCV can infect peripheral blood mononuclear cells 
[129] and replicate in lymphocytes [130, 131]. However, the determinants of HCV-RNA 
replication process are still unclear. A study found that subgenomic replicon JFH-1 can 
replicate in non-hepatic cell lines, such as HeLa cells and 293A cells, indicating that the 
host factors required for HCV replication are not hepatocyte specific [132]. The life cycle 
of HCV begins once it attaches to the host cell. 
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Figure  1.6. The lifecycle stages of HCV. The interactions with the host cell are labelled 
as follows: (a) Virus attachment and internalization. (b) Cytoplasmic release and uncoat-
ing. (c) IRES-mediated translation and polyprotein processing. (d) RNA replication. (e) 
Packaging and assembly. (f) Virion maturation and release [44]. 
 
It is a multistep process and it can be summarized as: virus attachement and internaliza-
tion through specific receptors, release of the viral particle into the cytoplasm and un-
coating of the genome, RNA genome translation and polyprotein processing, synthesis 
of a negative strand intermediate from the positive strand genomic RNA to generate new 
positive strands, and finally virion maturation and release of new HCV viruses (Figure 
1.6). 
1.6.1 Attachment and entry 
The first step in the virus lifecycle is attachment to the host cell. Several cell surface re-
ceptors have been identified as being required to mediate the attachment and internalisa-
tion of the virus into the cell (Figure 1.7). The initial attachment of the virus initiates       
by  a low affinity interaction of E2 with heparan sulfate proteoglycans (HSPGs), on the 
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Figure  1.7. HCV attachement and entry. 1. HCV circulate as a lipo-viroparticles (LVPs), 
particles consisting of lipoproteins (yellow) in complex with HCV particles possessing 
E1 and E2 glycoproteins (green) on the surface; 2. Interaction with glycosaminoglycans 
(GAGs) and the low density lipoprotein receptor (LDLR) and specific interactions with 
SR-B1 and CD81 are mediated by the E1 and E2 glycoproteins; 3. Translocation of viral 
particles to regions of the membrane possessing tight junction proteins occludin and 
claudins-1, -6 or -9, forming a co-receptor complex that results in clathrin-mediated en-
docytosis of the viral particle; 4. the endocytic vesicle containing the virus particle trans-
fer through the cytoplasm where it proceed to mature into a low pH late endosome re-
sulting in conformational changes, which facilitate the fusion of the viral envelope and 
endosome membrane, which finally permits viral nucleocapsid to enter the cytoplasm 
[133]. 
 
cell surface and probably the LDL receptor, which may interact with HCV associated 
lipoproteins (LDL and VLDL) [134]. This is followed by a specific interaction between 
the Human CD81, scavenger receptor B type I (SR-BI) [58], tight junction proteins 
Claudin (CLDN)-1, 6, or 9 and Occludin [135-138]. This enables the virus to enter the 
cell through clathrin-dependent receptor mediated endocytosis. Envelope protein E2 has 
been observed to bind directly to SR-BI and CD81, thus forming a ternary complex. Fur-
thermore, E2 also binds to CD81 and Claudin, forming a co-receptor complex. Additional 
interactions may also occur between SR-BI and HCV associated lipoproteins including 
HDL and LDL [139].  
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These findings indicate that HCV entry may occur following the formation of a complex 
of these entry factors. Following attachment, the nucleocapsid is released into the cell cy-
toplasm through fusion between the viral and cellular membranes. This fusion process is 
controlled by viral surface glycoproteins, which induce changes for mediating fusion. 
The Flaviviruses enter target cells by receptor-mediated endocytosis and use Class II fu-
sion proteins [140]. Their resemblance to Flaviviruses, suggests that the HCV envelope 
protein are Class II fusion proteins [141]; however, in contrast to other Class II fusion 
proteins, HCV envelope glycoproteins do not appear to require cellular protease cleavage 
during their transport through the secretory pathway [142].  
1.6.2 RNA translation  
Once the virus is internalized, the viral nucleocapsid, releases HCV genomic RNA into 
the viral cytoplasm, which then localises to host ribosomes, at the endoplasmic reticulum, 
allowing the initiation of the genome translation process. Recent studies have reported 
that non-coding micro RNAs (miR) are important in controling gene expression and regu-
lation. Transcription of miR-122 stimulates HCV RNA translation and virus production 
via the direct interaction of miR-122 with two sites, S1 and S2 in the 5’ UTR, whereas its 
sequestration in liver cell lines strongly reduced HCV translation [143].  
HCV genome translation is under the control of the IRES, which spans domains II to IV 
of the 5′ UTR, and the first nucleotides of the core-coding region. The IRES mediates the 
cap-independent internal initiation of HCV polyprotein translation by recruiting both cel-
lular proteins [34, 144], including eukaryotic initiation factors (eIF) 2 and 3 and viral pro-
teins [145-147]. Experiments have shown the generation of three distinct translation ini-
tiation complexes (40S, 48S and 80S) [148]. In this regard, the IRES binds directly to a 
40S ribosomal subunit, thus forming a stable pre-initiation complex, with such binding 
potentially occurring even without the canonical translation initiation factors. The 40S 
subunit aggregates with elF3, forming a ternary complex, which further assembles with 
elF2, GTP, and the initiator tRNA to form a 48S particle, through which tRNA locates in 
the P site of the 40S subunit and base-pairs to the start codon of the mRNA. After GTP 
hydrolysis, eIF2 releases the initiator tRNA from the complex, additional GTP hydrolysis 
step involving initiation factor eIF5B then enables the 60S ribosomal subunit to associate 
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forming an 80S ribosome, which is responsible for protein synthesis initiation [37, 149, 
150]. Several cellular proteins, namely polypyrimidine tract-binding protein (PTB) [151] 
and La autoantigen [152] were reported to interact with 5’ UTR, and regulate translation. 
PTB interacts with three distinct pyrimidine-rich sequences within the HCV IRES, and 
with domain III of the IRES [153]. In addition to the IRES, PTB has also been shown to 
interact with the 3′ X region to enhance HCV IRES-mediated translation [47, 154]. 
Moreover, heterogeneous nuclear ribonucleoprotein I (hnRNP I), and several other pro-
teins of the hnRNP family have been shown to interact with the HCV IRES. hnRNP L 
has also been reported to interact with the 3′ border of the HCV IRES in the core-coding 
sequence; the binding correlates with the translation efficiency from the IRES [155]. In 
addition, IRES translational efficiency may also be affected by HCV proteins, including 
the core [156] and non-structural protein NS4A and NS5B [104].  
1.6.3 Post-translation 
As a result of the HCV genome translation, a large precursor polyprotein is generated, 
which is targeted to the ER membrane for the translocation of the E1 ectodomain into the 
ER lumen, a process mediated by the internal signal sequence located between the core 
and E1 sequences. The host signal peptidase cleaves the signal sequence, which yields an 
immature form of the core protein (P23) [157]. The signal peptide is further processed by 
a host signal peptide peptidase with the aim of yielding the mature form of the core pro-
tein (P21) [158]. The host signal peptidase also ensures cleavage at the E1–E2 junction in 
the ER lumen. An additional signal peptidase cleaves at the C-terminal end of E2 and be-
tween p7 and NS2 giving rise to p7. E1 and E2 subsequently undergo several maturation 
steps. The zinc-dependent NS2-3 auto-protease ensures cis-cleavage of NS3 from NS2. 
NS3 needs to assemble with its cofactor NS4A to catalyse cis-cleavage at the NS3-NS4A 
junction and trans-cleavage at all downstream junctions, including NS4A-NS4B, NS4B-
NS5A, and NS5A-NS5B [159, 160].  
The cleavage sites recognised by the NS3-NS4A protease have the following sequence in 
common: Asp/GluXXXXCys/Thr-Ser/Ala, with trans cleavages occurring downstream of 
a cysteine residue and the cis cleavage occurring downstream of a threonine residue. 
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1.6.4 The HCV replication complex 
As has been shown for other positive-strand RNA viruses, HCV replicates in association 
with intracellular membranes. The HCV NS4B protein induces the formation of a mem-
branous web or membrane-associated foci [108] [161]. It is still unclear whether or not 
NS4B recruits cellular proteins responsible for vesicle formation or if it induces vesicle 
formation by itself. However, these are [162] thus required for HCV genome replication 
[109]. The membranous web contains large amounts of cholesterol and fatty acids and is 
derived from ER membranes [162, 163]. It is comprised of small vesicles embedded 
within a membranous matrix, forming a membrane-associated multiprotein complex con-
taining all of the non-structural HCV proteins [108]. HCV replication has been shown to 
occur in detergent-resistant membranes that co-localise with an essential component of 
lipid raft domains in the membranous web [164]. In addition, lipid rafts are known to be 
involved in the formation of the replication complex through protein-protein interactions 
between hVAP-33 and both NS5A and NS5B HCV proteins [164-166].  
1.6.5 HCV RNA replication 
The mechanism by which HCV genomic RNA replicates is still unclear.                             
In comparison with other Flaviviruses viruses, HCV replication is thought to be semi-
conservative and asymmetric in two steps, with the key control responsible for viral RNA 
synthesis being NS5B, the catalytic subunit of the replication complex, which has RNA-
dependent RNA polymerase (RdRp) activity. Firstly, RNA-positive strands serve as a 
template for the synthesis of a negative strand. In the second step, negative-strand RNA 
serves as a template for the production of several strands of positive polarity which are 
subsequently used for polyprotein translation, the synthesis of new intermediates of repli-
cation, or packaging into new virus particles [163]. RNA synthesis initiates at the 3′-end 
of the plus and minus strands and involves Domain I of the 5′ UTR, which can form a 
G/C-rich stem-loop, the 3′ UTR and a cis-acting replication element (5BSL3.2), compris-
ing 50 bases located in a large predicted cruciform structure at the 3′ end of the HCV 
NS5B-coding region [167]. The initiation of RNA-replication is triggered through an in-
teraction between the proteins of the replication complex, the 3′ X region of the 3′ UTR, 
and 5BSL3.2, which forms  a pseudoknot structure with a stem-loop in the 3′ UTR [167-
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169]. A phosphorylated form of PTB was found in the replication complex, PTB was 
shown to interact with two conserved stem-loop structures of the 3′ UTR an interaction 
thought to modulate RNA replication [170, 171]. The inhibition of PTB expression 
through means of small interfering RNAs reduces the amount of HCV proteins and RNA 
in HCV replicon-harbouring Huh7 cells [170]. 
1.6.6 Virus assembly and release 
The early steps of assembly are initiated through an interaction between core protein and 
lipid droplets (LDs), which are lipid storage organelles that store triglycerides and choles-
terol esters [172]. During translation process of the HCV polyprotein, the mature form of 
core protein is released by signal peptidase and signal peptide peptidase, at the ER mem-
brane allowing transport of the protein to LDs [157, 173, 174]. Core protein possesses 
two domains (D1 and D2), both of which mediate core LD interaction [175]. The D2 do-
main interacts with the phospholipid layer surrounding LDs [176]. Several studies have 
reported that, during infection, replication complexes and newly synthesised virus RNA 
localises to the lipid droplet surface through the interaction of NS5A with the lipid drop-
let localised core protein [177-179]. From the above evidence, it is thought that lipid 
droplets may become embedded in the HCV membranous web structure, allowing the ef-
ficient trafficking of the virus genome from replication complexes to virus assembly 
sites. Another mechanism has been proposed, whereby nucleocapsid formation occurs at 
the ER membrane, and this requires lipid droplets to function as a core protein transport 
vehicle, trafficking core from the translation site to where viral assembly takes place 
[180]. Following virus RNA packaging into the nucleocapsid, the virus undergoes bud-
ding to acquire an outer envelope containing envelope glycoproteins E1 and E2, which 
are embedded in a bilayer lipid. It is unclear where the process of virion-budding occurs; 
however, NS2 may play a role in this process as it is able to form complexes that are lo-
calised adjacent to the core coated lipid droplets, and contains replicase components 
(NS3 and NS5B), p7, and the envelope proteins (E1 and E2) [181].  
The maturation and release of HCV seems to be dependent on the VLDL pathway, based 
on the observations that the HCV particles isolated from chronically infected serum are 
often found in low-density forms in association with components of secreted VLDL in-
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cluding triglyceride, Apolipoprotein B100 (ApoB) and Apolipoprotein E (ApoE) [180, 
182]. The VLDL are produced in the ER following the fusion of newly translated ApoB 
protein, with lipid droplet derived triglyceride and cholesterol ester molecules in the lu-
men of the ER using the microsomal triglyceride transfer protein (MTP) [180, 183]. This 
process leads to the formation of a pre-VLDL particle, which can further interact with 
lipoprotein, ApoE which facilitates the fusion of the pre-VLDL particle with luminal 
lipid droplets, subsequently generating triglyceride-rich VLDL particles [180, 182]. The 
precise mechanism of pre-VLDL lipidation and localisation is, as yet, unclear, although it 
probably occurs within the ER or Golgi body. Subsequently, mature VLDL particles are 
then secreted from the cell using ER-derived COPII-dependent (coat protein complex-
dependent) transport vesicles, which are predicted to transfer through the Golgi body to 
leave the cell [184]. The role of lipid droplets in the VLDL synthesis pathway gives an 
indication that a specific mechanism, whereby HCV components localised to the surface 
of lipid droplet are delivered to the VLDL machinery for the process of HCV assembly, 
maturation, and subsequent secretion. Several studies support this idea: for example, 
knockdown studies of ApoB and ApoE and inhibition of MTP significantly reduces the 
titre of HCV [183-186]. Moreover, recent studies have shown that other host proteins in-
volved in VLDL synthesis, such as ACSL3 and ARF1 GTPase (ARF1), are essential in 
the process of HCV particle secretion. On the other hand, however, other researchers 
have established that ApoE alone is essential for both HCV assembly and secretion, and 
interacts directly with NS5A [186, 187]. Other cellular pathways have been implicated in 
HCV release, for instance; Endosomal cargo sorting is directed by ESCRT (endosomal 
sorting complex required for transport) protein complexes. Such complexes facilitate the 
sorting of ubiquitinated endocytosed cargo into intraluminal vesicles, which form within 
endosomes to create a multivesicular body (MVB). The MVB then fuses with lysosomes, 
thus allowing the degradation of the intraluminal vesicles and their cargo. ESCRT 0-II 
controls the process of cargo sorting and the recruitment of ESCRT III [188, 189]. 
ESCRT III complex is controlled by the ATPase protein, VSP4, which is required for 
proper functioning of the sorting and degradation process [188, 189]. Recent studies 
showed that there are several components of the ESCRT pathway may play an essential 
role in releasing the infectious HCV virions; including the ESCRT complex binding pro-
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teins, TSG101 and ALiX [190] ; ESCRT III complex proteins, CHMP1A, 2A, 3, 4B, 5 
and 6; and the ATPase, VSP4 [188, 190].  
1.7 The role of cellular host factors in the HCV life cycle 
Viruses have relatively few genes compared to their host cells. Even the largest virus ge-
nome size encodes only a few hundred genes, while those of host cells encode thousands 
of genes. Accordingly, during a virus life cycle there are interactions between a relatively 
few different types of viral components and a plethora of host factors. These host factors 
confer a suitable environment in which the virus can survive and are necessary resources 
for gene-poor viruses. Numerous host candidates have been selected and tested by using 
different methods such as bioinformatics approaches based on siRNA, and others, pro-
teomic approaches, interactome studies and microarray analysis. RAB GTPases and 
RNA-binding proteins such as Staufen 1 are example of these candidate host proteins.  
1.7.1 RAB GTPase proteins: intracellular localisation and function  
RAB GTPase proteins are small (20-29 kDa) monomeric Ras-like GTPases [191], they 
regulate the trafficking of membranes required for the assembly of membrane structures 
in eukaryotic cells. 
 In humans there are more than 60 RAB proteins (Figure 1.8), all of which are localised 
to particular regions of cellular membranes so as to facilitate the creation, trafficking, 
chaining and fusion of intracellular transport vesicles [192, 193]. Upon activation, the 
GTP-bound RAB proteins have the capacity to bind to certain effector proteins, namely 
motor proteins, sorting adaptors and tethering factors. A large number of the RAB pro-
teins recognised thus far have been mapped to a particular cellular location, which is 
commonly linked with either the trafficking vesicle or a specific intracellular organelle’s 
membrane; this provides each RAB protein with the potential to control and regulate a 
certain aspect of the membrane trafficking within the cell. Examples of membrane traf-
ficking events governed by RAB GTPase proteins include the formation of auto-
phagosomes, lipid droplets and melanosomes, protein degradation, protein sorting, and 
the regulation of endocytosis and exocytosis [193]. To enable these processes, RAB 
GTPase proteins have been found to behave in  a synchronised way through complicated 
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regulatory networks. For instance, different RAB proteins can be linked to more than one 
RAB at a time by RAB effect or proteins. Moreover, RAB proteins are also able to 
crosstalk through either restricting or initiating neighbouring RABs’ GEF and GAP pro-
teins in order to establish a flow of RAB protein activity [193]. 
1.7.1.1 Regulators of RAB protein    
To control the function of RAB GTPase proteins and their adequate control, a number of 
other host proteins are necessary to facilitate membrane localisation of RAB protein ac 
tivity. After the translation of a RAB protein, the GDP-bound RAB is delivered to            
a geranylgeranyl transferase enzyme (RABGGT) by the RAB escort protein (REP), and 
subsequently transfers a geranylgeranyl motif (Red wavy lines) (Figure 1.9), to either one 
or two RAB protein C-terminal cysteine residues [194]. 
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Figure  1.8. The intracellular localization of RAB proteins in mammalian cells. (CCV, 
clathrin-coated vesicle; CCP, clathrin-coated pit; EC, epithelial cells; IC, ER–Golgi in-
termediate compartment; M, melanosomes; MTOC, microtubule-organizing centre; SG, 
secretory granules; SV, synaptic vesicles; T, T-cell granules; TGN, trans-Golgi net-
work.), [195] 
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Figure  1.9. Regulators of RAB GTPase Protein Activity [194]. 
 
Following that geranylgeranylated GDP-bound RAB protein is delivered to the target 
membrane by the REP protein. The activation of the RAB protein is then initiated by a 
guanine nucleotide exchange factor (GEF) through the exchange of GDP for GTP, with 
the latter GTP-bound RAB protein then becoming affixed to its particular effector pro-
teins, namely motor proteins, sorting adaptors and tethering factors, so as to carry out its 
membrane trafficking function. Subsequently, there is interaction between the activated 
GTP-bound RAB protein and the GTPase-activating protein (GAP), which thus catalyses 
the GTP hydrolysis to GDP through the RAB GTPase protein (Figure 1.9). This results in 
the release of the RAB protein from its associated effectors. Thus, there is the removal of 
the inactive GDP-bound RAB from the membrane, which is achieved through interacting 
with a RAB GDP disassociation inhibitor protein (GDI), which subsequently becomes at-
tached to GDP-bound RAB proteins, which are then removed from the membrane. The 
re-insertion of the GDI-bound RAB protein into the target membrane can be achieved by 
the interaction with a RAB GDI displacement factor (GDF), which recognises and identi-
fies GDI-bound RAB proteins and the subsequent release of the GDI protein from the 
GDP-bound RAB. Following this there is the reactivation of the membrane localised 
GDP-bound RAB through the interaction with a GEF protein, at which point the entire 
process of RAB activation repeats [194]. 
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1.7.2 The RAB27 family  
The RAB27 subfamily comprises two isoforms RAB27A formerly designated Ram 
[196], and RAB27B formerly designated c25KG [197]. RAB27A and RAB27B which 
form the RAB27 subfamily share 71% amino acid homology [198]. RAB27A is ex-
pressed in a wide variety of secretory cell types, including exocrine, endocrine, ovarian, 
and hematopoietic cells, most of which function specifically in regulated exocytic path-
ways [199], whereas , RAB27B expression is less abundant and is expressed in platelets, 
the stomach, large intestine, pancreas, pituitary, and bladder [200], where it exert its regu-
latory effect on these organs e.g. the function of pituitary hormone secretion, zymogen 
secretion from the pancreatic acinar cells, amylase secretion from the parotid acinar cells 
and controls the process of mast cell degranulation [201]. RAB27B is less well character-
ized, however, it was found to regulate invasive growth and metastasis in Estrogen Re-
ceptor-positive breast cancer cell lines [202]. A recent study showed that RAB27A and 
RAB27B expression were closely correlated with tumor metastasis and can be prognostic 
indicators for HCC patients [203]. In general, several effector proteins have been shown 
to bind to activated RAB27A/B to coordinate vesicle trafficking during exocytosis. Some 
of the effector proteins are able to bind to the actin cytoskeleton, allowing RAB27 coated 
vesicles to traffic via actin filaments to the cellular periphery e.g. melanophilin in the 
trafficking of melanosomes [201, 204]. Other effector proteins mediate the docking of 
RAB27 bound vesicles at the plasma membrane by binding to the SNARE proteins in-
volved in membrane fusion e.g. granuphilin, which binds to the syntaxin 1a SNARE pro-
tein at the plasma membrane during insulin secretion [205]. 
1.7.3 The RAB40 family  
RAB40 family GTP-binding proteins, a member of the Ras oncogen family, comprises 
RAB40A, RAB40B, and RAB40C, which are highly homologus [206]. The RAB40 fam-
ily was distinguished from other RABs by possessing the suppressor of cytokine signal-
ling (SOCS) box. It is known that SOCS box-containing proteins interact with an E3 
ubiquitin ligase complex (with elongins B and C) that polyubiquitinates target proteins 
for subsequent degradation [207].  
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Little is known about the biological function of the RAB 40 family, although, one study 
has shown that Human RAB40C is regulated directly by a cancer-related miRNA, let-7a, 
and mediates the biological effects of let-7a in gastric tumorigenesis. Thus, RAB40C pro-
teins have diverse functions in embryogenesis, ubiquitination and cancer [207]. RAB40B 
was found expressed in the zebra fish brain, embryonic and adult mouse brain, inner ear 
and heart tissues suggesting a role in neurodevelopment [207]. Although, RAB40A and C 
are up-regulated in neuronal ganglions and nodes, up-regulation of RAB40B is confined 
to brain tissue with an expression profile nearly identical to that of RAB3A. RAB40B 
may define an as yet uncharacterized RAB-regulated hub modulating a linked step in the 
RAB3A -dependent synaptic vesicle cycle in the brain [208]. 
1.7.4 Staufen 1 
Staufen is a dsRNA-binding protein, which was initially recognised in Drosophila 
through the trafficking and subsequent translation of cellular mRNAs during the process 
of embryonic development. In the case of mammalian cells, two different Staufen ho-
mologs, namely Staufen 1 and Staufen 2 have been identified, with 51% amino acid ho-
mology. These proteins have been found to bind certain motifs on cellular mRNA mole-
cules, to enable the creation of ribonucleoprotein complexes, which are concerned with 
controlling mRNA trafficking, degradation and translation [209]. Despite the fact that the 
two mammalian Staufen homologs are believed to perform similar intracellular roles, it is 
nevertheless known that there are marked differences in terms of their expression pat-
terns, with Staufen 1 expressed universally, whilst the expression of Staufen 2 is neuron 
specific [209, 210]. Furthermore, a number of different protein isoforms have been rec-
ognised for both Staufen homolog genes by alternative splicing, including, for example, 
the 55KDa and 63KDa isoforms derived from Staufen1, and the 52KDa, 56KDa, 59KDa 
and 62KDa isoforms derived from Staufen 2. These isoforms are known to differ in terms 
of their overall ability to bind mRNAs, and many therefore develop distinct ribonucleo-
protein complexes in cells [209]. 
Both Staufen1 and Staufen 2 have been observed to become localised to the rough endo-
plasmic reticulum in ribonucleoprotein complexes while carrying out their roles of deg-
radation, translation and trafficking of mRNA molecules [209]. Furthermore, it has also 
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been found that Staufen 1 and Staufen 2 are transported between the cytosol and nucleus 
to control the localisation of newly synthesised mRNAs [209]. The trafficking role of 
Staufen proteins is facilitated through its structure which is a tubulin-binding sphere, and 
thus has the capacity to form complexes encompassing cytoskeletal control proteins 
(CDC42 and RAC1), cytoskeletal filament proteins (tubulin and actin), and cytoskeletal 
motor proteins (myosin and kinesin) [211]. Staufen 1 binds to the 3’UTR of cellular 
mRNAs, which are then targeted for degradation through ‘staufen-mediated decay 
(SMD) [212],  this relies on the recruitment of the up-frameshift suppressor 1 protein 
(UPF1) a cellular host factor commonly concerned with the process of nonsense-
mediated decay (NMD), which is known to degrade mRNAs comprising incorrect se-
quences of translation termination. On the other hand, Staufen 1 binding to the 5’UTR of 
cellular mRNAs is known to improve overall translation efficiency [213], with Staufen1 
also able to further enhance translational activity through its capacity to govern and me-
diate the balance between polysomes, which implement cellular mRNA translation; and 
stress granules, which, through translation, repress cellular mRNAs throughout periods of 
cellular stress [214]. 
Staufen 1 has been implicated in the replication of a number of viruses with RNA ge-
nomes, including Influenza A and the Human Immunodeficiency Virus-1 (HIV-1). In the 
case of the replication cycle relating to HIV-1, Staufen 1 has been recognised as binding 
to the HIB Gag precursor protein (Pr55Gag) and the HIV-1 RNA genome, and is present 
in the HIV-1 virions. Such interactions enable the Gag precursor protein’s multimerisa-
tion and facilitate HIV RNA encapsidation during the construction of the nascent HIV-1 
particles. Staufen 1 has been observed to relocalise in combination with the HIV-1 RNA 
and HIV-1 Gag protein to where the assembly of HIV takes place, e.g. the plasma mem-
brane’s lipid raft domains [215]. Moreover, Staufen 1 is also known to adopt a distinct 
role in the replication cycle of HIV-1 by regulating the rate at which the translation of the 
HIV-1 Gag protein is carried out [214]. In the replication cycle of Influenza A, Staufen1 
is recognised as being part of a viral ribonucleoprotein complex containing viral RNA, 
viral polymerase and nucleoprotein. Its presence in this complex may enable viral RNA 
genomic RNA encapsidation into nascent virus particles since reduced expression of 
Staufen 1 by siRNA decreases the production of the influenza virus particle without im-
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pacting the level of virus protein expression or otherwise affecting virus replication.           
The interaction between the influenza A non-structural protein 1 (NS1) and Staufen 1, 
remains unclear [216]. In addition to the evidence highlighting the fact that Staufen1 is 
involved in the replication cycle of both influenza A and HIV-1, Staufen 1 has also been 
shown to directly bind to the 3’NTR of the HCV genome and the 5’NTR of the negative 
HCV RNA strand [217, 218]. This clearly suggests that Staufen 1 may be involved in the 
HCV replication cycle, and that it may also regulate certain processes, including genome 
replication or encapsidation, throughout the process of nascent virus particles assembly. 
1.7.5 Thioredoxin-interacting protein (TXNIP) 
The Thioredoxin-interacting protein (TXNIP) is a 50kDa protein, it is also known as vi-
tamin D3 upregulatd protein (Vdup1) [219], which inhibits the function of thioredoxin 
(TRX). TXNIP binds to thioredoxin and prevents it from carrying out its function which 
is to reduce proteins by cystine thio-disulfide exchange [220]. It is believed that the major 
role of TXNIP is the inhibition of the redox protein thioredoxin; however, other molecu-
lar functions of TXNIP such as transcriptional regulation have also been proposed. 
TXNIP mutations have effects on lipid metabolism, glucose metabolism, and also the 
NADH/NAD+ ratios [221]. There is increasing evidence that TXNIP may play a causal 
role in tumorgenesis. Several studies have shown that TXNIP expression is downregu-
lated in breast and gastric cancers, as well as in various cell lines [222-225].  
In vitro studies indicate that TXNIP overexpression can inhibit the proliferation of pro-
myelocytic leukemia cells and stomach cancer [226, 227]. In a tumor transplant model, 
TXNIP overexpression suppressed melanoma metastasis [227]. Recently, it was shown 
that TXNIP interacts with and inhibits Jun activating binding protein (JAB1), a protein 
that promotes the degradation of p27 (kip1), a cyclin-dependent kinase inhibitor whose 
expression is reduced in many tumors [228]. Moreover, thioredoxin-interacting protein 
(TXNIP) has been involved in the development of both type I and II diabetes and its vas-
cular complications [229]. Deficiency of TXNIP leads to improved glucose tolerance and 
insulin sensitivity in mice fed with a high-fat diet, protects against diabetes, and inhibits 
glucose-induced pancreatic β-cell apoptosis [229]. TXNIP also induces caspase-1 in-
flammasome and innate immune response in pancreatic β-cell and macrophage [229]. 
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Most significantly the levels of TXNIP expression were shown to increase by about 40 
fold during interaction withthe human hepatocyte cell line. Huh 7 with HCV using 
siRNA to target TXNIP reduced HCV replication by 90% indicating that it may play an 
important role in the replication of the virus [230]. 
 
1.8 RNA Binding proteins  
RNA binding proteins play an essential role in several biological processes e.g. mRNA 
splicing, mRNA export, translation, RNA stability and mitochondrial gene expression.  
RNA binding proteins are mainly classified according to RNA binding domain these in-
clude; zinc- finger proteins, dsRBD proteins and RNA helicases. RNA helicases are RNA 
binding proteins that belong to the DEAD box family, these proteins are involved in sev-
eral cellular processes, including mRNA splicing, ribosomal assembly, initiation of trans-
lation, and RNA transport [231-234]. RNA helicases are thought to be involved in most if 
not all ATP-dependent processes involving rearrangement of structured RNAs. They are 
RNA-dependent ATPases with high degree of similarity to DNA helicases [235]. RNA 
helicase activity has been detected in several viral proteins including the NS3 protein of 
hepatitis C virus [30], and the NS3 (p80) protein of the pestivirus bovine viral diarrhoea 
virus BVDV [236].  
It is reported that the related NS3 of Kunjin and yellow fever virus as well as pestiviruses 
such as bovine viral diarrhea virus are involved in formation of infectious viral particles. 
The mechanism of how NS3 is involved is still unclear, but there is evidence that the hel-
icase domain is important. However, there is genetic evidence for the involvement of two 
major subdomains of HCV NS3 helicase in the early steps of the assembly process, and 
this study revealed that the helicase is engaged in particle assembly in a way which is in-
dependent of its associated enzymatic activities in a similar way to YFV NS3[237] . The 
role of HCV NS3 RNA helicase in assembly occurs after interaction of NS5A and NS3 
with core protein decorating intracellular lipid droplets and prior to the formation of 
dense intracellular core protein and non-structural viral protein complexes. It is believed 
that the role of NS3 in assembly may involve critical interactions of the NTPase and 
RNA binding domains with one or more other viral or cellular proteins. However, the na-
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ture of NS3 interactions and the identity of their binding partners is still under investiga-
tion [96]. Host encoded RNA helicases are also involved in HCV replication, for in-
stance, DDX3, a DEAD-box RNA helicase was shown to bind to the HCV core protein 
[238]. A knockdown study reported the requirement of DDX3 in the HCV replication cy-
cle [239]. 
 
1.9 Innate immune responses to HCV infection  
Innate immune responses to infected hepatocytes are recognised by cellular proteins 
known as pattern recognition receptors (PRRs), which contain three major classes of re-
ceptors: Toll-like receptors (TLRs), RIG-I-like receptors (RLRs), and nucleotide-binding 
oligomerization domain-like (NOD-like) receptors. Viral interactions with TLRs and 
RLRs initiate signalling cascades, which leads to the activation of latent transcription fac-
tors, including IFN regulatory factors (IRFs) and nuclear factor- ҝB (NF-ҝB), and which 
accordingly culminates in the induction of IRF target genes, Type I IFN, and pro-
inflammatory cytokines. TLRs are expressed in endosomes and on the cell surface mem-
brane, and detect viral pathogen associated molecular patterns (PAMPs) in various im-
mune cells, such as macrophages, dendritic cells, B cells, and some types of T cells [240, 
241]. Amongst the eleven members of the human TLR family, TLR 2, TLR 3, TLR 4, 
TLR 7, TLR 8, and TLR 9 are involved in detection of viral PAMPs, e.g. TLR9 recog-
nises unmethylated CpG DNA. TLR3 recognises dsRNA and TLR7/8, recognise ssRNA 
either on the surface of the cell or most likely in intracellular endocytotic vesicles [240]. 
The TLRs consists of three family members; retinoic acid inducible gene-I (RIG-I), 
melanoma differentiation associated gene 5 (MDA5) and LGP2 (Laboratory of Genetics 
and Physiology 2). RLRs are expressed in the cytoplasm of most cells, including hepato-
cytes. All RLRs contain 2 N-terminal caspase and recruitment domains (CARD). In addi-
tion, all RLRs carry a DExD/H RNA helicase domain and bind to RNA ligands. In this 
regard, RIG-I has been shown to be important in detection of ssRNA viruses, such as pi-
cornaviruses, flaviviruses, orthomyxoviruses, and rhabdoviruses, whilst MDA5 is recog-
nised as essential in the detection of picornavirus, such as encephalomyocarditis virus 
[242, 243]. The host innate responses to HCV are triggered when conserved PAMPs are 
Introduction 
50 
 
produced during infection. These are then recognised by TLR3 which recognises viral 
dsRNA in endosomes, and RIG-I which detects the polyuridine motif of the HCV 3’ 
UTR in the cytoplasm [244]. Signals from TLR3 stimulate IRF-3 and NF-kB through a 
MyD88-independent process, which requires the adaptor molecule Toll-IL1 receptor do-
main, containing adaptor-inducing IFN-β (TRIF). RIG-I, on the other hand, recruits the 
adaptor molecule IFN-β promoter stimulator protein 1 (IPS-1; also referred to as CARD 
adaptor interferon, CARDIF, virus-induced signalling adapter [VISA], and mitochondrial 
antiviral signalling protein [MAVS]). Both pathways result in downstream signalling and 
nuclear translocation of IFN regulatory factor 3 (IRF3) [244] which activates the expres-
sion of the IFN-β gene. The production of IFN-β from the infected cells drives autocrine 
and paracrine signalling process by binding to the IFN-α/β receptors of the infected cells 
and cells in local adjacent tissue. This leads to the activation of the JAK/STAT pathway, 
which results in the activation of interferon stimulated genes (ISGs), such as the 
OAS1/RNAse L system, which degrades viral RNA, and the RNA-specific ADAR1, 
which converts adenosine residues to inosine residues in dsRNA strands, thus mutating 
and destabilising viral RNA secondary structures. ISGs also include P56 and PKR, both 
of which inhibit viral and host RNA translation [244].  
 
1.10   Strategies of HCV to evade immune response 
HCV uses several strategies to regulate and escape the host response. The NS3/4A pro-
tease blocks IRF-3 activation by inhibiting the host RIG-I network by the protease-
dependent disruption of CARD-homology domain signalling, which is induced during 
RIG-I binding to the HCV RNA PAMP ligand. Moreover, NS3/4A also blocks RIG-I 
signalling to ablate virus activation of NF-kB. This indicates that NS3/4A inhibits IRF-3 
and NF-kB by targeting common factors involved in both IRF-3 and NF-kB activation. 
The NS3/4A protease also targets TLR3 signalling by cleaving the TRIF adaptor pro-
tein. NS3/4A cleavage of TRIF blocks TLR3 signalling, thus inhibiting IRF-3 and NF-
kB activation and preventing IFN production [245]. The HCV core protein is also in-
volved in HCV evasion of innate immune responses. Over-expression of the core pro-
tein in the cell culture interferes with JAK/STAT signalling and ISG gene activation by 
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inhibiting STAT 1 activation, through the induction of SOCS3 an inhibitor of 
JAK/STAT pathway and protein phosphatise 2A (PP2A) and by inducing other inhibi-
tory molecules.  
 
 
Figure  1.10. Invasion of innate immune response by NS3/4 HCV protein NS3/4A elimi-
nates antiviral signalling by cleavage of MAVS and TRIF [246].  
 
This reduces the transcriptional activity of IRF-3 and inhibits its binding to IFN stimu-
lated response elements. Moreover, HCV NS5A was also found to interfere with ISGs 
function by the inhibition of 2′-5′-oligoadenylate synthetase (2′-5′ OAS) and the induc-
tion of IL8, which subsequently inhibits ISG expression. NS5A also forms heterodimers 
with protein kinase R (PKR) [245] directly inhibiting its ability to switch of F protein 
translation. Production of dsRNA by HCV during infection will lead to the synthesis of 
IFN-β, which in turn leads to production of antiviral proteins known as ISGs. PAMP re-
ceptors RIG-I and TLR3 signal through kinases IKKε and TBK1 to activate IRF3 and 
cause the phosphorylation and degradation of IκB, which allows nuclear translocation of 
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NF-κB (Figure 1.10). HCV overcomes this response and establishes chronic infection 
through cleavage of MAVS and TRIF [246]. 
 
1.11 Adaptive immunity 
Following infection, it is usually 8–20 weeks before HCV antibodies appear, subse-
quently remaining throughout the remaining course of the chronic infection. On the other 
hand, HCV-specific T cells, are usually identified between 5 and 9 weeks following in-
fection [245].  HCV neutralising antibodies were first identified in an experimental infec-
tion targeting chimpanzees. The antibodies were found against HVR-1 epitope of HCV 
envelope glycoprotein E2. It has been found that the production of antibodies is at high 
titre, with cross-reactivity between HCV genotypes upon the progression of the infection 
to a state of chronicity. Nevertheless, the antibodies’ high titres are not successful in 
eradicating the virus at this stage with the emergence of virus quasispecies. Furthermore, 
the frequency of IgG-secreting B cells and the total concentration of IgG are also higher 
in chronic Hepatitis C, although the majority of the B cells that secrete the IgGs, as well 
as the IgGs themselves, are not specific to HCV; thus, suggesting that B cells are stimu-
lated by HCV in a B cell-receptor-independent way [245]. This is supported by other 
findings, which highlight that CD27+ B cells of HCV-infected patients show greater con-
version into IgG secreting cells, in addition to a lesser degree of rapid apoptosis and pro-
liferation [245].  
The clearance of HCV keenly relies upon HCV-specific T cells [245], with the decline of 
viral titre beginning with the presence of HCV-specific T cells and the expression of IFN-
γ in the liver, thereby highlighting the fact that viral clearance is T cell-facilitated. How-
ever, it is important to emphasize that it is not yet known whether or not IFN-γ levels 
have a strong link to HCV clearance and ultimately, it may be merely a marker for other 
T cell functions [245]. 
During the phases of the production of HCV-specific immune responses, HCV-specific 
CD4+ T cells are critical. During the process of ALT elevation and clinical presentation, 
HCV-specific CD4+ T cells, with associated IFN-γ and IL-2 production, vigorously pro-
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liferate, and this can easily identified in the blood of patients who subsequently recover 
by eradication of the virus. On the other hand, however, HCV-specific CD4+ T cell re-
sponses are seen to be either weak or entirely lacking amongst those individuals who go 
on to develop chronic infection. Moreover, there has been a link established between re-
current viremia occurring many months following the perceived control of the virus and 
the loss of initially strong CD4+ T cell responses [245]. When comparing CD8+ T cells 
with HCV-specific CD4+ T cells, the former are known to be identifiable in the blood of 
those patients severely infected, irrespective of the virological outcome. Throughout the 
process of acute HCV infection, it has been seen that CD8+ T cells appear paralyzed, 
show reduced or damaged proliferation and IFN-γ production, and with the presence of 
cytotoxicity and due to increased levels augmented degrees of programmed death–1 (PD-
1) protein [245].  
It is not yet known whether the paralysis of the phenotype is a state induced through a vi-
ral factor, or whether such a situation derives as a result of a natural progression in terms 
of the migration and/or maturation of HCV-specific CD8+ T cells. Importantly, through-
out this stage of the infection, antiviral therapy causes a significant and rapid decay of the 
responses of CD8+ T cells, thereby suggesting that the majority of HCV-specific CD8+ T 
cells are antigen-dependent, short-term cells as opposed to being self-sustaining memory 
T cells. Nevertheless, HCV-specific CD8+ T cells’ dysfunction ultimately resolves, with 
the detection of IL-7 receptor α–positive (i.e., CD127+) memory CD8+ T cells becoming 
possible upon the development of HCV-specific CD4+ T cell responses and the decline of 
HCV titre [245]. In further support of this finding, the decline of CD4+ T cells in vivo in 
the instance of HCV-recovered chimpanzees repeals protective CD8+ T cell–mediated 
immunity during the case of re-challenge, thereby suggesting that there is the need of 
help from CD4+ T cell concerning the generation and subsequent maintenance of protec-
tive CD8+ T cells [245]. 
 
1.12 Current HCV therapy 
The standard current therapies consist of (peglyated) interferon alpha and the nucleoside 
analogue ribavirin for a period of 24-48 weeks. However, many HCV infected patients do 
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not achieves sustained virological responses with this therapy which is also associated 
with serious side effect. Moreover, the effect of this treatment is virus genotype specific 
[247, 248]. Interferon alpha induces the host to initiate innate immune responses. Ribavi-
rin is a guanosine analogue that acts against several RNA and DNA viruses. Several 
mechanisms have been proposed for the mechanism of action ribavirin, including inhibi-
tion of inosine monophosphate dehydrogenase (IMPDH) by ribavirin 5’–monophosphate, 
inhibition of the HCV polymerase activity by ribavirin 5’-triphosphate or induction of a 
so called error catastrophe as the result of the accumulation of a lethal number of muta-
tions in viruses that have been cultured with ribavirin. [249]. In yellow fever virus 
(YFV), a flavivirus with similarity to HCV, ribavirin may inhibit inosine monophosphate 
dehydrogenase leading to depletion of intracellular GTP pool. However, it is still unclear 
whether in HCV ribavirin acts only by inhibiting IMPDH, as there is some evidence that 
ribavirin may modulate the Th1 response [249]. 
The regimen recommended by NICE (National institute for Health and Clinical Excel-
lence) in the UK for patients with genotype 1 or 4, was 180µg of peglyated interferon al-
pha 2a (Roferon, Roche) per week plus 1000-1200 mg ribavirin per day for 48 weeks. Pa-
tients infected with genotype 2 or 3 were advised to be treated with 180µg of peglyated 
interferon alpha 2a (Roferon, Roche) per week plus 800 mg ribavirin per day for 24 
weeks.  
 However, adverse events have been reported with this treatment such as flu-like symp-
toms, depression and nausea, often leading patients to decline or stop treatment. With this 
combination of treatment a sustained virological response (SVR) will be achieved in 40-
50% of those with genotype 1 or 4 and in 80% of those with genotype 2 or 3 [250]. The 
NS3 protein is one of the most intensively studied targets for new anti-HCV treatment. 
The HCV NS3 protease domain together with the cofactor NS4A forms a heterodimeric 
protease, which cleaves the viral polyprotein into single functional proteins. Although the 
NS3/4A protease is analogous to trypsin, a serine protease, the substrate specificity is dif-
ferent from that of host cell proteases. The substrate binding region of NS3 protein is 
considered to be shallow or flat, which makes it difficult to design selective inhibitors. 
HCV persistence depends on the inhibition of host immune response. It has been shown 
that HCV inhibits phosphorylation and effector action of interferon regulatory factor -
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3(IRF-3), a key cellular antiviral signaling molecule. Interference of NS3/4A function by 
mutation or peptidomimetic inhibitor relieved this blockade and restored IRF-3 phos-
phorylation after cellular challenge with unrelated virus. Moreover, dominant-negative or 
constitutively active IRF-3 mutants, respectively, enhanced or suppressed HCV RNA 
replication in hepatoma cells, therefore, NS3/4A protease can be targeted in two ways, 
the inhibition of which may both block viral replication and restore IRF-3 control of 
HCV infection [251]. The macrocyclic peptidomimetic inhibitor BILN 2061 (also known 
as Culoprevir Boehringer Ingelheim), is a non covalent reversible complex forming ser-
ine protease inhibitor. The protease inhibitor activity of this compound has been demon-
strated in a HCV subgenomic replicon cell model, and it was found that the polyprotein 
processing was inhibited at all NS3-dependent cleavage sites. Based on these results, 
BILN 2061 was the first HCV protease inhibitor to enter clinical trials. After oral admin-
istration of this compound the patients showed decline in HCV titers within hours. Also, 
the efficacy of BILN 2061 is higher against genotype 1 than genotype 2 or 3. On the oth-
er hand, it was found that replicons containing single mutations in the NS3 protease gene 
(A156V or D168V), showed high resistance levels to BILN 2061. 
 However, BILN 2061 was shown to be cardiotoxic, therefore the development of this 
compound was halted [249]. VX-950 (Telaprevir) is another peptidomimetic inhibitor of 
the NS3 viral protease; it forms a covalent reversible complex with HCV NS3/4A by a 
slow binding and slow dissociation mechanism with a half life of about 1hr, which may 
confer a sustained inhibitory antiviral effect. Moreover, VX-950 shows good activity 
against HCV genotype 2.  
Several other related HCV protease inhibitors are under study in clinical trials including 
VX-500 (phase I), VX-813 (phase I), MK-7009 (phase II) [249]. Polymerase enzymes are 
also considered another target for anti-viral drugs. Several nucleoside inhibitors have 
been used as inhibitors for HCV (NS5B) RNA-dependent RNA polymerase enzyme for 
instance; NM-283 (Valopicitabine), a nucleoside analogue. It is a prodrug of the nucleo-
side analog 2’-C methylcytidine; the compound undergoes intracellular phosphorylation 
of the 5’-triphosphate which results in the formation of the active inhibitor of the viral 
polymerase. Oral administration of Valopicitabine 800mg daily for 2 weeks results in a 
dose dependent decline in HCV RNA in patients infected with HCV genotype-1. Combi-
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nation of Valopicitabine with interferon resulted in a further decline of detectable viral 
load, and absence of viral RNA [249]. Other selective inhibitors are also being consid-
ered for instance; Non-nucleoside inhibitors such as benzothiadiazines, benzimidazoles/ 
diamides. However, a number of treatments are also in development targeting the host 
factors required for virus  replication these include cyclophillin inhibitors SCY-
635(Scynexis) and DEBIO-25 (Debio) which are still under clinical trials [249]. 
 
1.13 Vaccination 
Several approaches have been used to produce vaccines against HCV. Among the earliest 
attempts HCV peptide-based vaccines with different adjuvants have been used to induce 
Th1 and cytotoxic T cell response in chronic HCV patients. One of these is IC41, which 
consists of 5 conservative peptides from HCV core, NS3 and NS4 proteins, which are 
conserved within genotypes 1 and 2, and includes 4 known HLA-A2 epitopes and 3 pro-
miscuous CD4+  epitopes. However, the clinical trials showed that the response was not 
sufficient to clear the viral load [252]. Another vaccine candidate which was delivered by 
attenuated virus vectors induced effective CD4+ and CD8+ T cell responses. Modified vi-
rus of Ankara is one of the vectors, a highly attenuated poxvirus strain; it has been used 
in several vaccine designs, such as HIV, tuberculosis, colorectal cancer, and melanoma. 
Vaccines based on MVA vector expressing HCV antigens including NS3, NS4, and 
NS5B have been shown to induce IFN- -secreting CD4+ T cells and specific CD8+ T  
cells capable of secreting IFN-  and killing in vitro and in vivo when tested in transgenic 
mice [252]. A recent study using adenovirus based HCV protein expression showed T-
cell responses against CD4 + and CD8+ cell subsets, which recognized HCV genotypes 1a 
and 3a. Moreover, the T cell response was found to be sustained for at least 12 months. 
These findings indicate that adenovirus vector strategy can induce a sustained T cell re-
sponse of a magnitude and quality associated with protective immunity and may open the 
way for studies of prophylactic and therapeutic vaccines for HCV [253].  
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1.14 HCV cell culture systems 
Several attempts have been made to propagate HCV virus in cell culture. Replication was 
detected in hepatoma, B and T cell lines, primary cultures of human and chimpanzee 
hepatocyte. However, the replication titers were very low and could not be detected by 
stringent RT PCR and thus were not amenable for further HCV replication studies [254]. 
The first subgenomic replicons described were based on genotype 1b HCV (an isolate 
called Con1) [255]. Subsequently new replicons were developed using a genotype 1a 
HCV consensus clone called H77 [256]. The subgenomic replicon consist of HCV 5’ 
UTR (containing the IRES) to initiate RNA translation of neomycin resistance gene (neo) 
gene for antibiotic selection. The replicon also contains  the coding sequence of the HCV 
non-structural proteins, from NS3 to NS5B under the translational control of an EMCV 
(Encephalomyocarditis virus) IRES. The 3’ UTR is also included in the replicon. During 
the development of HCV replicons, it was found that mutations are required for sufficient 
levels of replication. Adaptive mutations were found in NS3 and NS5A. The function of 
these mutations was to enhance HCV polyprotein cleavage, and HCV interaction with 
cellular components of the replicase complex or by inhibiting the cellular anti-viral de-
fence [256]. In 2003 a genotype 2a clone isolated from a patient with fulminant hepatitis 
designated as JFH-1, was found to replicate without the requirement of adaptive muta-
tions and transfecting JFH-1 clone into Huh-7 cells was found to produce virus (desig-
nated as HCVcc for cell derived HCV) that is infectious for Huh-7 cells and allowing the 
study of the full replication cycle of HCV [257, 258]. 
 
1.15 Methods of detecting RNA-protein interaction in vitro 
Proteins interact with RNA through electrostatic interactions, hydrogen bonding and hy-
drophobic interactions. Protein-RNA interactions are dependent on the secondary and ter-
tiary structure of the RNA molecule, which means both RNA and protein, must be folded 
correctly to permit precise binding. Several approaches can be used to detect protein 
RNA interactions which all have advantages and disadvantages in their application.  
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1.15.1 RNA Electrophoretic mobility shift assay 
Electro mobility shift assay (EMSA), or simple gel shift assay, is a sensitive technique 
used to detect Protein-RNA interactions. In EMSA, a 32P–labeled or biotinylated nucleic 
acid fragment containing a specific DNA or RNA sequence is incubated with a target 
DNA or RNA binding protein. The protein–nucleic acid complexes are then separated 
from unbound nucleic acid by electrophoresis through non-denaturing polyacrylamide 
gel. The protein- nucleic acid complexes migrate more slowly than a free DNA/RNA 
probe through the acrylamide gel. EMSA has a number of advantages. The technique is 
simple to perform; it can be used either with radioisotope or biotin labeled nucleic acid, 
with a wide range of nucleic acid size and structures. On the other hand, there are limita-
tions for this assay such as Protein-DNA/ RNA complexes that are not at chemical equi-
librium during the electrophoresis step, so that some complexes may dissociate rapidly 
during electrophoresis which prevents detection of the complex. Moreover, EMSA does 
not provide detailed information about the location of the nucleic acid sequences that are 
bound by proteins [259].  
1.15.2 RNA Pull-down assay 
RNA pull down assays selectively extract RNA-protein complexes from a cellular ex-
tract. The protein is expressed as a fusion protein. An RNA probe can be biotinylated, 
then the complex extracted from a cell lysate and than purified using magnetic beads or 
agarose, then evaluated by Northern blotting or through RT-PCR , whereas the protein 
can be detected by Western blotting or mass spectrometry [260]. 
1.15.3 Fluorescent in situ hybridization co-localization 
Fluorescent in situ Hybridization (FISH/ISH) co-localization techniques can be used to 
detect both an RNA transcript and a protein of interest using RNA probes and antibodies. 
FISH/ISH detects the position and abundance of a RNA and protein in a cell or tissue 
sample. The reaction can be visualized by microscopy and a co-localized signal for both 
the RNA and protein of interest to indicate possible complex formations. A labeled RNA 
probe must be generated for detection of a particular sequence of RNA and the protein 
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may be detected using antibody staining or by using fluorescent tagged proteins [261] 
[262]. 
1.16 Hypothesis and Aims 
NS3 HCV has protease RNA helicase and NTPase activities that are important for HCV 
replication. RNA helicases in other viruses have been found to interact with RNA and 
also have RNA chaperone activities and play a role in virus assembly. This project will 
investigate the hypothesis that HCV NS3 helicase also possesses these activities, by ex-
ploring the interaction of NS3 with viral RNA, and viral and host proteins. In addition, 
the role of the NS3 protein in regulating the expression of innate immune response genes. 
 
 To investigate whether there is an interaction between the recombinant HCV 
NS3-1a with the full length HCV JFH-1 RNA and the 5’ end of JFH-1.  
 
 To investigate the effect of the gene silencing of four host proteins RAB27B, 
RAB40B, TXNIP and Staufen 1 on HCV NS3 expressed using adenovirus vec-
tors, and whether they have a direct role in gene expression. 
 
 To investigate the effect of the HCV NS3 protease inhibitor BILN 6021 on NS3 
from different HCV genotypes expressed in adenovirus vector and the effect on 
RIG-I, MDA5 and MAVS.  
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2. Materials and Methods 
2.1 Materials  
2.1.1 Chemicals 
Chemicals Supplier 
Acetic acid BDH 
Agarose Bioline  
Ammonium persulphate Sigma 
Ampicillin Sigma 
Bromophenol blue Sigma 
Bovine Serum Albumin (BSA) Invitrogen 
Boric acid BDH 
Buffered phenol Sigma 
CHAPS A.G.Scientific,INC 
Chloroform BDH 
DABCO (1,4-diazabicyclo-[2,2,2]-octane) Sigma  
DAPI (4'-6-Diamidino-2-phenylindole) Invitrogen 
Diethylpyrocarbonate Sigma  
Dimethyl sulphoxide Sigma 
DTT Invitrogen 
EDTA BDH 
Ethanol  Analar, Normapur 
Formaldehyde Analar, Normapur 
Glycerol Analar, Normapur 
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Glacial acetic acid BDH 
Hydrochloric acid BDH 
IPTG CHALBIOCH 
Imidazole Sigma  
Isoprpanol BDH 
Magnesium chloride BDH 
Methanol  BDH 
MOPS Sigma 
Mowiol 4-88 Sigma 
Neutral red Sigma  
RNA Zap Ambion 
Sodium dodecyl sulphate (SDS) BDH 
Sodium di hydrophosphate BDH 
Sodium hydroxide BDH 
Sodium chloride BDH 
N,N,N‟,N‟-tetramethyl-ethylenediamine  Sigma 
Tris base BDH 
Triton-X Invitrogen 
Tween 20 Sigma 
Urea  Sigma 
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2.1.2 Tissue culture materials and reagents   
Dulbeco’s modified Eagle’s medium (Invitro-
gen) 
 DMEM growth medium supple-
mented with 2 mM L-glutamate, 
10% fetal calf serum (FCS), 100 
IU/ml penicillin and 100µg/ml strep-
tomycin. 
 
Fetal calf serum (FCS) (Invitrogen) 
 
Inactivation of complement in FCS, 
by incubation 56ºC for 60 minutes. 
 
Trypsin – EDTA (TE) (Invitrogen) 
 
1X (TE-EDTA) 
 
Penicillin-streptomycin (Gibco, Invitrogen) 
 
10,000 units penicillin, 1,000µg 
streptomycin. 
 
2.1.3  Reagents used for siRNA, RNA extraction and miscellaneous as-
says  
Lipofectamine 2000 Invitrogen 
Opti-MEM  Invitrogen 
Geneticin (50mg/ml) Invitrogen 
Proteinase K solution Invitrogen 
poly (I:C) (polyinosinic-polycytidylic acid dsRNA) 
10μg/ml 
Sigma 
Trizol  
  
Invitrogen 
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Ni-NTA agarose  
 
Qiagen  
Bradford Reagent 
 
Sigma  
Nuclease- free water  
 
Ambion 
Mung bean nuclease (10u/µl ) 
 
New England Biolab 
2.1.4 Buffers and solutions 
All solutions were prepared with Milli Q water unless otherwise stated. For pH calibra-
tion, a pH meter 3320 (Jenway) was used. 
 
Agarose 4%  4g of agarose was dissolved in milli Q water to 
give a final volume of 100 ml. The solution 
was sterilized by autoclaving at 121°C for 20 
minutes. Before use the solution was 
prewarmed at 65°C in a water bath.  
DEPC water Milli Q water was treated with 0.1% v/v 
diethylpyrocarbonate (DEPC) (Sigma) for 24 
hours at 37°C and then autoclaved (at least 15 
min) to inactivate traces of DEPC. 
Buffer A 50 mM NaH2PO4, [pH8.0] 300 mM NaCl, 8 M 
Urea.  
Buffer B 50 mM NaH2PO4, [pH8.0] 300 mM NaCl, 8 M 
Urea, 20 mM imidazole.  
Buffer C  
50 mM NaH2PO4, [pH8.0] 300 mM NaCl, 8M 
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Urea,100mM imidazole.  
Buffer D  
50 mM NaH2PO4, [pH8.0] 300 mM NaCl, 8M 
Urea , 250mM imidazole.  
10X TBE  890 mM Tris base  
890 mM Boric acid  
20 mM EDTA [pH 8.0]  
1X    TE 10 mM  Tris-HCl 
 1 mM    EDTA     [pH 8.0] 
Mounting medium with DAPI 
 
2.4 g of Mowiol 4-88 was added to 6 g of 
glycerol and mixed well with a magnetic stir-
rer. 6 ml of milli Q water was added to the 
mixture and left at room temperature until dis-
solved. 12 ml of 0.2 M Tris-Cl [pH 8.5] was 
added to the mixture and heated to 50°C for 10 
min. After the Mowiol had dissolved, it was 
then clarified by centrifugation at 3000g for 15 
minutes. 0.72g DABCO 1,4-diazabicyclo 
[2.2.2] octane and 0.1% 4, 6-diamidino-2-
phenylindole, dilactate was added to the me-
dium . Aliquoted and stored at −20°C. 
10% Neutral red stock  1mg neutral red dye in 10 ml PBS.  
 
Protein refolding buffer 25 mM Tris-HCl [pH 7.2], 10% (v/v) glycerol,           
50 mM NaCl, 1 mM DTT, 0.1% CHAPS. 
Resuspending buffer  8 M urea in PBS,1mM DTT. 
 20 x SSC buffer 175.3g of NaCl, 88.2g of sodium citrate, ad-
justed to pH [7.0], sterilized by autoclaving. 
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2.1.5 Bacterial growth media and reagents 
Agar  Bacto-agar added to 2% (w/v) to required me-
dium. 
Luria broth (LB) 1% (w/v) tryptone, 0.5 (w/v) yeast extract, 1% 
(w/v) NaCl. 
SOC medium 2% Tryptone, 0.5% Yeast Extract, 10 mM NaCl 
2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4,  
20 mM glucose. 
Ampicillin stock 1000x 1 g of ampicillin was dissolved into 10 ml of 
milli Q water, then sterilized by using a 0.22 
µm filter ( Sterillin). Then aliquot and store at -
20°C. 
IPTG stock 1M IPTG dissolved in water, sterilized using     
0.22 µ filter. Stored 1ml aliquots at -20ºC. 
LB freezing solution LB broth with 50% glycerol (sterilized). 
Lysozyme stock solution 50 mM Tris-HCL, [pH 8.0], 10mg/ml ly-
sozyme. 
 
2.1.6 SDS-PAGE  
Coomassie blue statin 0.1% Coomassie R 250, 10% acetic acid (v/v), 
40% (v/v) methanol. 
Destaining buffer 12.5% (v/v) Isopropanol and 10% (v/v) glacial 
acetic acid in Milli Q water. 
Protein lysis buffer 
 
10 mM Tris-HCl  
150 mM NaCl  
0.5% Nonidet-P40 
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Halt Protease Inhibitor Cocktail 1mM, 800nm 
Aprotinin, 50 µM Bestatin, 15µM E64, 20µM 
Leupeptin, 10µM Pepstatin A). 
SDS-PAGE separation gel  
 
 
30% (w/v) acrylamide, 0.8 % (w/v) bis-
acrylamide (National Diagnostics) 1.5M Tris-
HCl, [pH8.8], 0.1% (w/v) Sodium dodecyl sul-
phate (SDS) 0.1% (w/v) ammonium persulphate 
(APS) 0.5% (v/v), 0.5% (v/v)N,N,N‟,N‟-
tetramethyl-ethylenediamine (TEMED). 
 
SDS-PAGE stacking gel  
 
 
 
30% (w/v) acrylamide, 0.8 % (w/v) bis-
acrylamide (National Diagnostics), 1M Tris-HCl, 
[pH 6.5] 0.1% (w/v) SDS 0.1% (w/v) ammonium 
persulphate (APS) 0.5% (v/v)N,N,N‟,N‟-
tetramethyl-ethylenediamine (TEMED). 
  
SDS-PAGE running buffer (10x) 25 mM Tris, 1.92 M Glycine, 3.5 mM SDS (Na-
tional Diagnostics).  
 
2.1.7 Western blot reagent 
Ammonium persulphate (APS) 10% 
(w/v)  
 
0.5 g of APS dissolved in 5ml of water, 
aliquoted and stored at -20°C  
10x Tris –EDTA reducing buffer  
 
Prepared by adding: 10% (v/v) Beta 
mercaptoethanol, 0.5 M Tris HCl, 8% 
(w/v) SDS. Aliquots and stored -20°C.  
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Bromophenol- blue/glycerol  
 
0.02% Bromophenol blue in EDTA = 
5ml  
5 ml glycerol + 5 ml bromophenol blue. 
Transfer Buffer  
 
25 mM Tris, 192 mM Glycine, 20% (v/v) 
Methanol  
PBS/Tween buffer solution  
 
1x PBS/0.1% (v/v) Tween  
PBS/Tween/skimmed milk 
 
1x PBS/0.1% (v/v) Tween/2% (w/v), 4% 
(w/v) skimmed milk powder. 
PBS/Tween/BSA 
 
1x PBS/0.1% (v/v) Tween/ 2% (v/v) 1% 
(w/v) BSA.  
2.1.8 Molecular biology kits 
Qiaprep spin miniprep  Qiagen 
T7 & SP6 MEGAscript kit  Ambion 
ECL wester blotting detection reagents and analysis system Thermo 
Quantitect SYBER Green PCR Qiagen 
Quantitect SYBER Green RT- PCR Qiagen 
5’ EndTag Nucleic Acid Labeling System Vectorlab 
3’ EndTag Nucleic Acid Labeling System  Vectorlab 
UltraSNAP Detection Kit for Nucleic Acid Blots  Vectorlab 
Wizard SV Gel and PCR clean up system Promega 
RNAeasy mini kit   Qiagen 
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2.1.9 Mammalian cell lines 
Cells Characteristics 
Huh 7 cell line Differentiated human hepatoma cell line estab-
lished from a hepatocellular carcinoma. Huh7 
cells were a gift from John Monjardino. 
293 A cell lines (Invitrogen) 
 
 
 
293A Cell line is a sub-clone of the cell line 293 
which established from primary embryonal hu-
man kidney transformed with sheared human 
adenovirus type 5 DNA . The genes encoded by 
the E1 region of adenovirus (E1a and E1b) are 
expressed in these cells and participate in the 
some viral promoters, allowing these cells to pro-
duce very high levels of protein. E1 also comple-
ments the E1-deletion in recombinant adenoviral 
vectors, allowing viral replication. 
Table  2.1. Mammalian cell lines 
 
2.1.10 Flow cytometry reagents  
FACS staining buffer PBS, pH 7.4-7.6, 2% (v/v) heat inacti-
vated FCS, 0.2% (w/v) sodium azide. 
Formaldehyde buffer (Fixation buffer) 14 ml of 37.5% formaldehyde, 57.2 ml 
PBS [pH 7.4].  
Permeabilization (PERM) Buffer FACS Staining + 0.5% saponin  
SUPERPERM buffer  75% (v/v) PERM buffer+ 25% (v/v) 
filtered).  
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2.1.11 Oligonucleotides 
All oligonucleiotides were synthesised by Invitrogen. The stock primers were dissolved 
in nuclease free water at a concentration of 100 µM and stored at -20ºC. 
2.1.11.1  Primers used for adenovirus quantification  
Table  2.2. Primers for adenovirus quantification 
 
2.1.11.2  DNA primers for qRT-PCR 
Target gene Primer sequences 
GAPDH  sense 5’TCTCTGCTCCTCCTTCGAC3’ 
GAPDH   antisense 5’CGGATTTGGTCGTATTGGG3’ 
JFH-1   sense 5’TCTGCGGAACCGGTGAGTA3’ 
JFH-1   antisense 5’TCAGGCAGTACCACAAGGC3’ 
RIG-I   sense 5’GGAAGAGGTGCAGUAUAUU3’ 
RIG-I   antisense 5’AAUAUACUGCACCUCUUCC3’ 
MDA5  sense 5’GGUGAAGGAGCAGAUUCAG3’ 
MDA5  antisense 5’CUGAAUCUGCUCCUUCUCC3’ 
Primer Sequence (5’-3’) Position bp 
NS3-2a qRT-PCR sense GGCGCCATAGTGGTGAGTAT 3473-3492                
131 NS3-2a qRT-PCR antisense TCCGTGGTAAACAGTCCACA 3585-3604 
NS3-1a qRT-PCR sense AGGGCTACAAGGTGTTGGTG 4081-4100       
      128 NS3-1aqRT-PCR  antisense GGCTGCCAGTGGTAATTGTT 4199-4209 
NS3-1b qRT-PCR  sense ATGGCGCCTATTACGGCCTA 3424-3437    
      152 NS3-1bqRT-PCR  antisense ACACACGCCATTGACGCAGG 3557-3576 
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MAVS sense 5’UAGUUGAUCUCGCGGACGA3’ 
MAVSantisense 5’UCGUCCGCGAGAUCAACUA3’ 
RAB 40B  sense 5’CATCTCAGATCCCGGTTCC3’ 
RAB 40B antisense 5’CAAGAGCTTCATGCACATCC3’ 
RAB 27B sense 5’AATCTGACACCTGCTCTCCC3’ 
RAB27B antisense   5’AGAAATGTTGTCTTCCCCACC3’ 
TXNIP sense         5’TAAAAGCCCTTTGAACCCC3’ 
TXNIP antisense  5’GCTCAGTGCTCTGACACAGG3’ 
Staufen 1 sense 5’GCTCACTCAGACACATTGGG3’ 
Staufen 1 antisense 5’GGTCACGCTGAGTAGGAAGC3’ 
Table  2.3. DNA primers for qRT-PCR 
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2.1.12 siRNA molecule sequences 
All siRNAs were purchased from Ambion, except for the HCV, Non-Targeting 1 and was 
purchased from Sigma.  
siRNA Sense strand 
RAB27 B sense 5’GACUUAAUCAUGAAGCGAAdTdT3’ 
RAB40 B sense 5’CGCUGGUCUUUUGACGGCAdTdT 3’ 
Stufen 1 sense 5’GAACGAAUUUGUAUCUCUUdTdT 3’ 
TXNIP sense 5’CAUCCUUCAAAGGAAAAUAdTdT3’ 
Non-Targeting 1  5’ GAUCAUACGUGCGAUCAGAdTdT 3’ 
Table  2.4. siRNA molecule sequences 
 
2.1.13  Restriction digestion enzymes  
Enzyme Source Incubation conditions Conc./dilution 
EcoR I Promega Buffer  H       37ºC       (10x) 1µl  (10u/µl) 
Apa I New England Biolab Buffer  3       37ºC       (10x) 1µl  (10u/µl) 
Bam HI Promega Buffer  E      37ºC      (10x) 1µl  (10u/µl) 
Nde I New England Biolab buffer   4      37ºC     (10x) 1µl  (10u/µl) 
Xba I (HC)  Promega Buffer  D      37ºC     (10x) 1µl  (100u/µl) 
Table  2.5. Restriction digestion enzymes 
 
  
Materials and Methods 
 73 
2.1.14 Antibodies 
Antibody Isotype Supplier Working concentra-
tion 
Anti - V5 Mouse IgG Invitrogen IF: 1:300, WB: 1:1000, 
FC: 1:300 
Anti -NS3 Mouse IgG Virogen IF: 1:100, WB 1:500 
Alexa Flour 488 donkey 
anti-mouse IgG  
Mouse IgG Invitrogen IF, FC:  1:1800 
Alexa Flour 594 donkey 
anti-mouse IgG  
Mouse IgG Invitrogen IF, FC:  1:1800 
Anti IgG2a  Isotype  control Mouse IgG Immunokontact FC: 1:300 
*IF: Immunofluorescence    FC: Flow cytometry     WB: western blot.  
Table  2.6. Antibodies 
 
2.1.15  Molecular weight markers and loading dyes. 
Bench Mark  protein ladder            
(Invitrogen) (Appendix 6.2.II)   
Ladder for SDS-polyacrylamide gel electrophoresis, 
the ladder consists of 15 engineered proteins ranging 
in molecular weight from 10 to 220  kDa.    
Pre-stained  protein ladder              
(Invitrogen)(Appendix 6.2.I) 
Ladder for SDS-PAGE, consists of 10 pre-stained 
protein bands in the range of 10-200 kDa.  
Millenium   RNA marker                
(Ambion) (Appendix 6.1) 
Contains 10 discrete RNA transcripts  
of 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, and 9 kilobases. 
Blue/Orange Loading Dye, 6X      
(Promega) 
0.4% orange G, 0.03% bromophenol blue, 0.03% xy-
lene cyanol FF, 15% Ficoll® 400, 10mM Tris-HCl 
[pH 7.5] and 50 mM EDTA [pH 8.0].  
Table  2.7. Molecular weight markers and loading dyes 
 
Materials and Methods 
 74 
2.1.16 Bacterial E. coli strains 
JM 109(DE3) 
 
endA1, recA1, gyrA96, thi, hsdR17 (rk
–, 
mk
+), relA1, supE44, λ–, Δ(lac-proAB), 
[F´, traD36, proAB, lacIqZΔM15], lDE3 
DH5α 
 
F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 
recA1 endA1 hsdR17 (rK–, mK+) phoA 
supE44 λ– thi-1 gyrA96 relA1 
Table  2.8. Bacterial E. coli strains 
 
2.1.17 Plasmids 
pJFH-1  Provided  by Dr. Takaji Wakita Department of 
virology, National Institute of Infectious Dis-
ease , Tokyo, Japan. 
pPAW3    Constructed in Dr. Michael McGarvey labora-
tory, Department of Hepatology, Imperial Col-
lege London (Wardell, 1999). 
pJFH_1   IRES Provided by Dr. peter karayiannis,  Department 
of Hepatology, Imperial Collage London.  
Table  2.9. Plasmids 
 
2.1.18  X- ray films  
Hyperfilm Blue film (GE healthcare) was used for Western blot and Electromobility shift 
assay. 
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2.2 Construction of non structural NS3 protein expression plasmid 
The full length HCV NS3 [1027- 1657] protein was constructed by Wardell, 1999 [263]. 
2.2.1 Preparation of chemically competent cells 
A starter culture was prepared by taking a loopfull of glycerol stock of E. coli JM 109 
(DE3) strain and streaked onto Luria agar (Invitrogen) plate. The next day, a single col-
ony was inoculated into 5 ml of Luria Broth (Invitrogen) and incubated at 37°C for 16 
hours, with shaking at 250 rpm. A 1ml aliquot of this culture was inoculated into 100 ml 
of LB and incubated at 37°C in orbital shaker, the cell density of the culture was meas-
ured using spectrophotometer CO 8000 Biowave, Biochrom. The spectrophotometer was 
blanked using LB broth. Every 30 minutes, a 1mL aliquot was sampled from the batch 
culture and transferred to a 10 mm cuvette, and the optical density was measured at 600 
nm, until the OD600 reached 0.4. The culture was cooled on ice for 10 minutes and centri-
fuged using a bench top centrifuge (Thermo scientific) for 10 minutes at 2,700 g at 4°C. 
The pellet was resuspended with 1.6 ml of ice cold  100 mM CaCl2 and incubated on ice 
for 30 minutes followed by centrifugation at 2,700 g for 10 minutes at 4°C. The cell pel-
let was the resuspended with ice cold 100 Mm CaCl2 containing 15% glycerol and incu-
bated on ice for 20 minutes where then frozen at -80ºC. 
2.2.2 Transformation of chemically competent cells 
Frozen competent cells were left on ice until just thawed and aliquots of 100 µl were 
transferred to fresh tubes. 56 ng of pAW3 DNA plasmid encoding NS3 protein in                
a volume of 6 µl, were added to the cells and placed on ice for 10 minutes. The cells were 
heat shocked at 42°C for 45 seconds in a water bath, thereafter; the tube was placed on 
ice for 2 minutes. 900 µl of SOC medium was added to the transformed cells and incu-
bated for 60 minutes at 37°C with shaking at 225rpm. The transformation reaction was 
then diluted 1:10 and 1:100 and 100 µl of each dilution were plated on Luria agar plates 
containing 100 mg/ml ampicillin and incubated at 37°C for 16 hours. 
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2.2.3  pAW3 DNA purification by QIAprep spin miniprep Kit 
pAW3 DNA was extracted with QIAprep miniprep Kit (Qiagen) from cultured cells ac-
cording to the manufacturer protocol. One colony of  E. coli containing a plasmid was in-
oculated in 5ml of Luria broth medium containing 100 mg/ml of ampicillin overnight at 
37°C shaking at 225 rpm. The cells were then pelleted by centrifugation at 6,800g for 3 
minutes at room temperature. The pellet was resuspended in 250 µl of resuspension 
buffer P1 and lysed with 250 µl P2 lysis buffer for 3 minutes. 350 µl neutralizing buffer 
P3 was added and centrifuged for 10 minutes at 13,000 g. The supernatant was applied to 
the DNA binding column and centrifuged for 30 seconds, then washed by adding 0.5 ml 
Buffer PB and centrifuged for 30 seconds. The column was then washed by adding 0.75 
ml of buffer PE and centrifuged for 1 minute. An additional 1 minute centrifugation was 
used to remove residual wash buffer. Finally, the column was placed in a clean microcen-
trifuge tube and the pAW3 DNA was eluted by adding 50 µl of water.  
2.2.4 Restriction enzyme mapping 
All enzymes used for pAW3 DNA restriction digestion were used according to the manu-
facturers recommendations. Generally, in a total volume of 20 µl, up to 1 µg DNA was 
digested with 0.5-1µl of restriction enzyme for 2 hours at 37ºC with the appropriate 
buffer. Double digests were performed by using a one step reaction containing both en-
zymes. Enzymes are inactivated at a temperature recommended by the manufacturer. For 
large scale digestions the enzyme concentrations and volumes were increased.  
2.2.5 Agarose gel electrophoresis  
Agarose gels were prepared using a Horizontal gel electrophoresis apparatus. 1.0 % - 
0.75% (w/v) agarose in 1X TBE-buffer was melted in a microwave oven. After cooling to 
approximetly to 65ºC ethidium bromide was added to a final concentration of 0.5µg/ml 
and poured into the preassembled apparatus. Once the gel had set 1x TBE buffer was 
poured on the surface of the gel and the combs were removed to reveal the wells. The 
DNA sample was mixed with of 6x Orange/blue loading dye (Promega) in a volume of 
10 µl , then the DNA samples were loaded in the wells along with 1kb DNA  (Promega) 
(Appendix 6.1). The DNA was then resolved by gel electrophoresis according to their 
Materials and Methods 
 77 
size at 10 Volt per centimeter of gel. The DNA fragments were visualised on a UV tran-
silluminator (GelDoc-It Image, UVP). 
2.2.6 Testing for plasmid stability 
Before induction cells were tested for plasmid stability. LB agar plates containing differ-
ent additions were used in plating: (i) with 100mg/ml ampicillin, (ii) with 1mM IPTG, 
(iii) with both ampicillin and IPTG, or (iv) with neither added to the plate. Cells were 
grown in LB broth  until they reached  OD600 0.5. 10-fold serial dilution of cell suspen-
sion was made including a 105 and 106 dilution. Cells were plated at a dilution of 105 on 
IPTG containing plates and on ampicillin and IPTG containing plates. Whereas, cells at 
106 dilution were plated on LB plates and on the ampicillin plates. 
 
2.3 Protein methods 
2.3.1 Recombinant protein overexpression 
Recombinant proteins were over expressed using the JM109 (DE3) E. coli strain bearing 
the pET16b expression vector carrying the gene HCV NS3 pAW3 [1027-1657] fused 
with a histidine tag (Appendix 6.3). An overnight culture was used to inoculate 4 liter of 
LB containing 100 mg/ml ampicillin and grown at 37ºC in orbital shaker incubator until 
reached OD600 of 0.5. The culture was then cooled to 30ºC. 500µl of the non induced 
sample was collected, pelleted and resuspended in sample buffer. NS3 protein expression 
was then induced by adding 0.5mM Isopropyl β-D-1-thiogalactopyranoside (IPTG). The 
culture then transferred to refrigerated orbital shaker incubator (Thermo scientific) and 
left for three hours at 25ºC, then 500µl of induced culture was collected, pelleted and re-
suspended in sample buffer. 
2.3.2 Purification of NS3 protein expressed in E. coli 
The expression of NS3 protein from pAW3 DNA expressed in E. coli, mainly resulted in 
insoluble protein called inclusion bodies. Inclusion bodies have high density and can be 
pelleted by centrifugation and this procedure enabled the separation of NS3 protein which 
formed inclusion bodies from the soluble fraction. Contaminating soluble proteins were 
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removed by a series of washes and sonication in a wash buffer, followed by centrifuga-
tion and to separate the inclusion body pellet from the supernatant which contaminated 
the soluble fraction. The final protein pellet which contained only inclusion bodies was 
solubilised with 8M urea containing 1mM DTT. High concentrations of chaotropic agents 
such as urea or guanidinium hydrochloride are needed to disrupt the non-specific interac-
tions between the protein molecules in inclusion bodies. After protein expression, E. coli 
cells were harvested by centrifugation (Thermo scientific) at 3000 g for 15 min at 4ºC 
and resuspended in 10 ml resuspension buffer containing (0.2 M NaCl, 50 mM Tris-HCl 
[pH 7.4], 1% Triton X-100 and 1mg/ml lysozyme) per 100 ml culture. The resuspended 
cells were then transferred to 30 ml Oakiridge tubes in 20 ml aliquots and kept on ice.  
The bacterial suspension was then disrupted with a (Sonifier 450, Ultrasonicson, Bran-
son) on ice (settings at 5 x 5 sec, 60% duty cycle, output 5. The cell lysate was then cen-
trifuged at 10,000g using an XL. 90 Ultracentrifuge (Beckman) for 15 minutes at 4ºC. 
This sonication/resuspension washing was repeated 7 times, and the final pellet of inclu-
sion bodies was resuspended in cold 8M urea in PBS, 1mM DTT and sonicated as before 
and centrifuged for 40 minutes at 4ºC. The supernatant that contain solubilised NS3 in-
clusion bodies was then collected. 
2.3.3. Protein quantification by Bradford assay 
The concentration of the protein was quantified by using the Bradford assay. The protein 
concentration was estimated by using a standard curve of bovine serum albumin (BSA) 
samples with a concentration range of 0.25- 1.25 mg/ml. Briefly, 5µl of protein sample 
was mixed with 250µl Bradford reagent (Sigma) in a 96-well plate (Nunc) along with the 
BSA, and mixed gently on a shaker for 5 minutes. The absorbance was measured at A 
595 nm by using VersaMax microplate reader.  
2.3.4.  Purification of small scale protein under denaturing conditions  
The expression of foreign genes in E.coli often results in the production of insoluble re-
combinant protein which forms inclusion bodies [264]. Inclusion bodies are aggregates of 
protein, but it is still not understood precisely how they are formed, although some stud-
ies indicate that the formation of these inclusions is due to specific intermolecular inter-
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action between proteins [265, 266] or can otherwise be attributed to the mis-folding of 
the expressed polypeptide, often involving the formation of unwanted disulphide bond 
bridges[267]. A borosilicate liquid chromatography column (Sigma) 1.0 cm internal di-
ameter × 10 cm in length, bed volume 8 ml, with a bottom cap was assembled according 
to the manufacturer’s instructions. A volume of 3 ml of 50% Ni-NTA agarose (Qiagen) 
was washed twice with milli Q water, and centrifuged using bench top centrifuge 
(Thermo scientific ) at 1,000 g for 50 seconds to pellet the resin. It was then equilibrated 
with denaturing buffer A (50 mM NaH2PO4, [pH8.0] 300 mM NaCl, 8 M Urea). 
 About 10 ml of the solubilised NS3 protein was mixed with 3 ml of Ni-NTA agarose and 
mixed gently by shaking on a rotary shaker at 10 rpm for 1 hour in a cold room. The su-
pernatant-Ni-NTA mixture was then loaded into the column with bottom cap still at-
tached. Once the resin had settled, the bottom cap removed and flow-through collected. 
The column was washed with 2 times the column volume of denaturing buffer B (50 mM 
NaH2PO4, [pH8.0] 300 mM NaCl, 8M Urea, 20mM imidazole), and the wash was col-
lected. The protein was then eluted with 4 ml of denaturing buffer C (50mM NaH2PO4, 
[pH8.0] 300mM NaCl, 8M Urea, 100 mM imidazole) in four separate tubes, and a final 
elution with 4ml of denaturing buffer D (50 mM NaH2PO4, [pH8.0] 300 mM NaCl, 8M 
Urea, 250 mM imidazole). SDS-PAGE analysis using 12.5 µl aliquots of the flow-
through, wash fractions and the elution fractions was performed. The elution fractions 
that contained significant quantities of a band at ~70 kDa were pooled and then subse-
quently used to refold the protein.  
2.3.5. Dialysis tubing 
A dialysis tube with an MW cut-off 12,000 (Invitrogen) and 30 mm width was boiled 
prior to use in 2% sodium bicarbonate (w/v) and 1mM EDTA for 10 minutes; it was then 
rinsed in Milli Q water and boiled again for 10 minutes in mM EDTA, then rinsed with 
milli Q water before use. 
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2.3.6. Protein refolding 
To produce soluble and enzymatically active NS3 from denatured protein, a refolding 
procedure was used. Urea is a strong denaturing chaotropic agent, it contains two amino 
acid groups which forms hydrogen bonds that interfere with intramolecular hydrogen 
bonds of proteins, thus denaturing and solubilising the insoluble protein. To refold pro-
teins solubilised in urea, it is necessary to remove the urea which then allows the proteins 
to reform intramolecular bonds and reforms their tertiary structure. Step-wise dialysis 
was carried out to refold the protein to its native state. The buffers used in refolding were 
those previously used by Wardell, 1999 et.al [268], to enhance protein refolding to the 
native confirmation, these buffers include; sodium chloride which prevent non-specific 
protein-protein interactions that may cause mis-folding and aggregation of proteins. DTT 
prevents the formation of disulphide bonds between cysteine amino residues. The pH was 
also adjusted to a physiological pH to mimic that of the mammalian cell cytoplasm. 
CHAPS detergent was added for optimal NS3 protease activity [269, 270] Stepwise di-
alysis was performed to remove the urea from NS3 protein preparations and all the puri-
fication process was performed at 4ºC when possible. 6 ml of NS3 protein solution was 
placed in the dialysis tube, the ends were sealed with plastic clips and the urea was re-
moved by stepwise dialysis using refolding buffer (25 mM Tris-HCl [pH 7.2], f (v/v) 
glycerol, 50 mM NaCl, 1M DTT, 0.1% CHAPS) containing 4M, 2M, and 1M urea, fol-
lowed by three buffer changes without urea. The dialysis changes continued for 2 hours 
for each change of buffer. The dialysed protein was clarified by refrigerated centrifuge 
XL. 90 Ultracentrifuge (Beckman) at 16,000 g for 1 hour at 4ºC and dialysed against re-
folding buffer containing 50% glycerol and stored at -20ºC. 
2.3.7. Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE)  
2.3.7.1 Resolving gel 
A Biorad (mini-gel) vertical apparatus was used to prepare SDS-PAGE gels. Two glass 
plates separated by 0.75 mm spacers were assembled after cleaning with 70% alcohol. 
10% resolving gel was made by the addition of 3.3 ml protogel (30% acrylamide, 0.8% 
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w/v bis-acrylamide, National Diagnostics), 2.5 ml resolving buffer (1.5M Tris, pH 8.8, 
0.1 ml of 10% SDS, National Diagnostics), 100 μl of 10% ammonium persulphate, 10μl 
TEMED (Sigma) and made up to 10 ml with milli Q water. The ingredients were mixed 
thoroughly and poured into the pre-assembled glass plates, and covered with 1ml isopro-
panol and left to polymerise for 30 minutes. Once the gel was set the top of the gel was 
rinsed with milli Q water. 
2.3.7.2 Stacking gel 
A stacking gel mixture was prepared by adding 1.5 ml of protogel (30% acrylamide, 0.8 
% w/v bis-acrylamide), 2.5ml stacking gel buffer (containing 0.5M Tris, 0.1 ml 10% 
SDS, National Diagnostics), 100 µl of 10% ammonium persulphate, 10μl TEMED and 
5.7ml of milli Q water. Again, all the ingredients were mixed, and then 1-2 ml applied on 
the top of the polymerized resolving gel, and a suitable well-forming comb was inserted 
into the stacking gel. Following polymerisation, the gel was transferred to the running gel 
apparatus (Bio-Rad) and 1x running buffer (1.92 M glycine, 0.25 M Tris and 3.5mM 
SDS) was poured into the upper and lower compartments of the tank and the combs re-
moved carefully from the stacking gels.  
2.3.8. Sample preparation 
A volume of 12.5µl of protein was added to sample buffer containing (2.5μl 10x Tris–
EDTA-reducing buffer and 10μl bromophenol blue/glycerol), and then loaded into the gel 
in a total volume of 25μl. The samples were boiled in a heat block at 90ºC for 5 minutes. 
15μl of SDS-PAGE prestained molecular weight marker (Invitrogen) (Appendix 6.2.I) 
was also loaded onto the gel. The gel was run at a constant voltage of 100V for 1 hour, or 
until the  dye front was ~ 0.5cm to the end of the bottom. The power was switched off 
and the gels were prepared for either Coomassie staining or Western blot. 
2.3.9. Commassie blue staining 
Commassie blue staining was performed by using (Coomassie blue stain 0.1%, 
Coomassie R250 (w/v), 10% acetic acid (v/v), 40% methanol (v/v)). This acid-methanol 
mixture acts as a denaturant to fix the protein in the gel, which prevents the protein from 
diffusing within the gel or being washed out while it is being stained. The gel was left to 
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stain for several hours with gentle agitation, at room temperature. Following the staining, 
the commassie stain was removed and the gel rinsed twice with H2O and destained by us-
ing a destain solution (12.5% isopropanol and 10% glacial acetic acid) for at least 3 
hours, or until the background stain has been removed from the gel. Once sufficiently de-
stained, the gel was placed on a transparent plastic sheet for scanning. 
2.3.10. Western blot and immunodetection 
Following electrophoretic protein separation, the gel was transferred to nitrocellulose 
Hybond ECL membrane (GE healthcare) which had been previously soaked in protein 
transfer buffer (1.92 M glycine, 0.25 M Tris and 3.5 mM SDS, 20% methanol). The 
transfer was performed by using a mini trans plot-cell (Biorad) according to the manufac-
turer’s protocol, then the transfer were carried out at 120V for 1 hour at 4°C. The nitro-
cellulose membrane was then blocked in a buffer containing 4% skim milk for 1 hour at 
room temperature to prevent non-specific antibody binding. The membrane was then in-
cubated with 3µg/ml mouse anti-HCV NS3 antibody (Virogen) diluted in       PBS/ 0.1 % 
Tween-20 /BSA  for overnight at 4ºC. Unbound antibodies were removed by washing the 
membrane 3 times  with 10 ml PBS/ 0.1 % Tween-20  for 10 minutes. The secondary an-
tibody horseradish peroxidase (HRP) labelled anti-mouse (Invitrogen) was added to the 
membrane at a dilution of 1:1000 in blocking buffer and incubated for 1 hour at room 
temberature before washing three times with PBST. Blots were visualized by using Su-
perSignal West Pico Chemiluminescent Substrate (Thermo scientific) and developed on 
autoradiography film (GE healthcare). 
2.3.11 ATPase activity assay 
ATPase activity was detected by using an ATPase colorimetric assay kit (Innova Biosci-
ence) the reactions was performed according to the manufacturer’s protocol. A substrate 
/buffer (SB) was prepared by mixing 20 µl of 0.5M Tris [pH 7.5], 5µl of 0.1M MgCl2, 10 
µl of 10 mM ATP and the reaction buffer made up to 100 µl. The reaction performed by 
mixing 100 µl of 1 nM protein plus 100 µl substrate. 50 µl of Gold mix reagent contain-
ing (Pi ColorLock Gold and accelerator) was added to stop the reaction. Two minutes 
later, 20 µl of stabilizer provided with the kit was added. After 30 minutes, the absorb-
ance was measured at a wavelength 650 nm on a microtiter-plate reader Veramax. Along-
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side, a standard curve was prepared using 0.1mM Pi standard stock as described by the 
manufacturer. To calculate enzyme activity a standard curve was performed by preparing 
a set of Pi standards using the 0.1mM Pi stock ( included in the kit). A duplicate set of 
wells containing 200 µl of each standard and 50 ml of Gold mix was prepared. Two min-
utes later 20 µl of Stabiliser was added. The plate was read after 30 minutes, using plate 
reader. 
2.3.12 RNA methods 
2.3.12.1 RNA transcription and purification (modified) 
18 µg of pJFH-1 DNA was linearized with (100U) of restriction enzyme Xba I (Promega) 
in a reaction mixture contains 5µl of 10x buffer D (Promega) and total volume of 50µl. 
The mixture was incubated for 2 hours in a water bath at 37ºC. After digestion samples 
were cleaned using a Wizard SV gel and PCR clean up system (Promega) according to 
the manufacturer’s recommendations. In a total reaction volume of 50 μl containing 43μl 
of digested DNA, 2μl (20U) of Mung bean nuclease (10 U μl), and 5 μl Mung bean nu-
clease buffer (10X) were added and the mixture was incubated for 30 minutes in a heat 
block at 30ºC. Then the DNA sample was treated with proteinase K by combining the 
50μl of Mung bean nuclease–treated solution, with 10% (wt/vol) SDS, 2μl Proteinase K 
solution (20μg μl) and nuclease free water to a total volume of 100μl, this was then incu-
bated for 1 hour in a heat block at 50 C°. Then the DNA sample was purified by using              
a Wizard SV gel and PCR clean up system and the pellet resuspended in 20 μl TE buffer. 
RNA transcripts of the JFH-1 plasmid and 3’ end JFH-1 negative RNA were synthetised 
using a T7 MEGA script and SP6 MEGA script RNA transcription kit (Ambion), respec-
tively as described by the manufacturer. In brief, 2- 4 μl ( 0.5-1 μg ) of linear template 
DNA were mixed with the following reagents 2μl of ATP (75mM), 2μl CTP (75mM), 2μl 
GTP (75mM), 2μl UTP (75mM), 2μl reaction buffer(10X), 2μl enzyme mix and the   to-
tal volume was adjusted to 20μl by adding 4-6µl of nunclease free water. The sample was 
incubated in a water bath at 37ºC for 4 hours. 1μl of DNAse was added and incubated for 
15 minutes in an incubator at 37ºC. The RNA was cleaned up by using QIAeasy RNA ex-
traction kit (Qiagen) following the manufacturer instructions. 
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2.3.12.2 Measurement of RNA concentration and integrity 
RNA concentration was measured by nano drop as described in section 2.15.3 and the in-
tegrity of the linearized RNA was assessed by formaldehyde agarose gel. 
2.3.12.3 Formaldehyde agarose gel for RNA 
RNA retains much of its secondary structure during electrophoresis unless it is first dena-
tured. The addition of formaldehyde to the agarose gel maintains the RNA in  a linear 
(denatured) form, by reducing secondary structure formation. Electrophoresis equipment 
was cleaned with RNA Zap (Ambion) and rinsed with DEPC treated water then rinsed 
again with Milli Q water. A 1.25% agarose gel was prepared by dissolving 1.2 g agarose 
in 81 ml autoclaved Milli Q water. The gel was cooled down to 65°C, 0.5 μg/ml ethidium 
bromide, 10 ml 10x MOPS buffer and 5 ml formaldehyde were added and the gel was 
immediately poured into preassembled electrophoresis apparatus (Flowgen ioscience) and 
equilibrated in running buffer (1x MOPS buffer, 12.3M formaldehyde) for 30 minutes. 
Approximately 3μl of the RNA sample (~ 2-10 μg) was mixed with equal volume of gel 
loading buffer II (Ambion). The sample was incubated at 65°C for 10 min and transferred 
on ice, and then loaded into the gel, Ambion Mellinium RNA ladder (Ambion) (Appen-
dix 6.1), were included for RNA size estimation. The gel was run at 75 volt and 100 mA.  
2.3.12.4  5’ Labelling end of RNA 
Full-length RNA was prepared for labelling at the 5´ end by using a 5´ end tag Nucleic 
acid labelling system according to the manufacturer instructions. Using the 5' EndTag 
Nucleic Acid Labelling System (Vectorlab) allows the covalent attachment of a variety of 
fluorescent dyes, haptens, or affinity tags to the 5' end of unmodified oligonucleotides or 
5'-OH modified RNA. 5’ end labeling is achieved by transferring a thiol group from 
ATPγS to the 5’ hydroxyl group of the RNA by T4 polynucleotide kinase. After incorpo-
rating of the thiol functional group, a thiol-reactive label is chemically coupled to the 5’ 
end of the RNA. To label the RNA, 1μl of universal reaction buffer was combined with 
0.6 nmols of 5’end in 8μl and 1μl alkaline phosphatise in a microcenrifuge tube. The total 
reaction was adjusted to 10μl with deionised water. After a 30-minute incubation period 
at 37ºC, the mix was combined with 2μl of universal reaction buffer, 1 μl of ATPγS, and 
2 μl of T4 nucleotide kinase. Then the total reaction was brought to 20μl with deionised 
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water and incubated for 30 minutes at 65ºC. 70 µl of water and 100μl of buffered phenol 
were added and it was then vortexed briefly. 
 The supernatant was removed to a clean centrifuge. 5µl of precipitant and 263 μl of 95% 
ethanol were added to the aqueous fraction and mixed. The precipitated nucleic acid was 
centrifuged at 13,000g in an eppendorf tube for 30 minutes. The pellet was dried and re-
suspended in TE buffer (10mM Tris, 1mM EDTA, [pH 8]. 
2.3.12.5 Detecting by dot Plot 
Labelling was confirmed by comparing dot blots of the reaction to those of the labelled 
DNA control supplied with the kit. 1µl spots of 82 ng of biotinylated RNA was two- fold 
in 6X SSC buffer were applied to a nitrocellulose membrane. After UV crosslinking us-
ing a transilluminator for 8 minutes and wavelength 250 nm. A Dulox chemiluminescent 
kit was used to detect the biotinylated RNA.                     
2.3.12.6 3’ end labeling 
The 3’end of the JFH-1 negative strand was labeled using a 3’End Tag DNA labelling 
system (Vectorlab) according to the manufacturer instructions. The kit contains terminal 
transferase (TdT) which catalyzes nucleotide incorporation at the 3' ends of single-
stranded or double-stranded DNA. Labeling is achieved in two steps: (I) TdT incorpo-
rates SH-GTP at the 3' end (SH-GTP is a modified guanosine triphosphate that contains a 
chemically active thiol group). (ii) After introducing the thiol functional group, a thiol-
reactive label is chemically coupled to the 3' end of the nucleic acid. The following com-
ponents were combined, 0.5 nmols of 3' ends, 2 μl 10x TdT reaction buffer, 2 μl SH-
GTP, 2 μl TdT in a total volume reaction of 20 µl. The mix was incubated for 30 minutes 
at 37ºC. To the reaction, 10µl of thiol-reactive label was added, mixed and incubated for 
30 minutes at 65ºC in a heat block. 70µl of water and 100 µl of buffered phenol was 
added, and vortexed. The mix was centrifuged for 5 minutes at 4,000g. The aqueous 
phase was transferred to clean tube, then 5µl of precipitant and 300 μl of 95% ethanol 
was added to the aqueous phase. The precipitated RNA was then centrifuged for 15 min-
utes at 13,000g. The pellet was left to dry and reusupended in TE buffer pH 8.0. The con-
centration of 5’ or 3’ RNA  was calculated as follows: 
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         A  X V     
                                       = nmols   of 5’ or 3’ ends/ μl 
         B X C 
 
A= nucleic acid concentration (μg/μl). 
B= average molecular weight of nucleotide. 
C= total number of bases or the number of base pairs. 
V= volume of nucleic acid. 
 
2.3.12.7 Electromobility shift a ssay 
2.3.12.7. 1 Native TBE polyacrylamide gel electrophoresis 
TBE polyacrylamide gels were prepared and used with the Bio-Rad mini Protean II elec-
trophoresis vertical apparatus. Two glass plates, which were separated by a spacer 
cleaned with 70% ethanol and clamped together and locked into the clamp assembly, then 
transferred to the casting stand. The composition of the polymerizing mixture was pre-
pared as given in Table 2.1, mixed well and poured gently into the glass plate assembly. 
A suitable well-forming comb was immediately inserted and the gel left to polymerise at 
least for 2 hours. After gel polymerisation the comb was removed and the well rinsed 
with 0.5x TBE. Before loading the samples, the gel was run for 1 hour. The samples were 
adjusted to 1x agarose gel sample buffer in a total volume of 20µl and loaded into the 
wells, then run at 10 mA for 1.30 hrs at 4ºC to prevent disruption of Protein-RNA inter-
actions. Progression of electrophoresis was monitored by the migration of xylene cyanol 
and bromophenol blue bands. 
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 Volume (ml for each gel)  
10% polyacrylamide gel 7% polyacrylamde gel 
40% Acrylamide bis (37.5:1)  2.5 1.75 
5X TBE 1 1 
Distilled water 6.39 7.14 
10% Ammonium persulphate 0.1 0.1 
TEMED, N,N,N,N tetrame-
thylethylendiamin 
0.01 0.01 
Total  10 ml 10 ml 
 Table  2.10. Solutions and volumes used for the preparation of a 10 and 7% polycryla-
mide gel 
 
2.3.12.7.2 Binding reaction  
Sample binding reactions were prepared by mixing different NS3 protein concentrations 
ranging from 100 nM, to 600 nM with 5’ and 3’ end biotinylated RNA, in 20 µl of 1X 
binding buffer (100 mM Tris-HCl [pH 7.5], 5 mM MgCl2, 2 mM DTT, 0.10mg/ml
-1 
BSA), 0.01µg Poly (I:C) as a non-specific competitor and finally 55 pmol of 5’ or 3’ end 
biotinylated RNA, then incubated for 30 minutes at 4ºC. 5µl of 50% (v/v) in PBS was 
added to each reaction mixture before loading onto a native polyacrylamide acrylamide 
bisacrylamide gel (37.5:1). Electrophoresis was carried out in 0.5x Tris-borate-EDTA 
(TBE) buffer at 80 Volt for ~ 2 hours.  
2.3.12.8 Transfer to nylon membrane 
Gels were blotted onto Hybond positively charged nylon membrane (GE healthcare) us-
ing a Mini Trans-Blot cell apparatus. In a gel holder cassette (10 x 7.5 cm), a sandwich of 
sheets which contained 1x sponge pad, 2x Whatman paper, the gel, a Nylon membrane, 
2x Whatman paper and 1x sponge pad, was assembled. Bubbles between the sheets were 
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removed by adding 0.5x buffer and carefully rolling the sheets with a pipette. After plac-
ing the sandwich in the transfer tank, a cooling unit was added and the tank was filled 
with 0.5x TBE buffer, then run at 120 Volt  for 1 hour at 4°C. 
2.3.12.9 UV Crosslinking 
The nylon membrane was placed face down on a transilluminator and exposed to UV 
light for 8 minutes at the 302 nm setting.  
2.3.12.10 Detection of biotinylated RNA 
An Ultrasnap detection kit (Vectorlab) was used to detect biotinylated RNA. The kit de-
tects biotinylated RNA with streptavidin coupled to alkaline phosphatase. The blot was 
blocked with 20 ml of 1x Polyblock reagent for 30 minutes at room temperature with 
gentle shaking, then the blot was incubated with 20µl of AP-streptavidin diluted in 20 ml 
1x Polyblock for 30 minutes at room temperature with gently shaking. Then the blot was 
washed with 30 ml of 1x wash A for 10 minutes at room temperature 3 times with gentle 
shaking, then the blot was rinsed in 30 ml of 1x Wash B, and excess reagent was re-
moved by touching the edges to filter paper. In a dark room, the blot was placed on a 
level surface and covered with 5ml of Dulox substrate (Vectorlab) and left for 5 minute. 
The blot was then washed in 30 ml of 1x Wash buffer for 1 minute at room temperature, 
then the blot was touched with filter paper to remove excess liquid, and wrapped in plas-
tic wrap and exposed to X-ray film. 
2.3.13 Adenovirus methods 
2.3.13.1 Growth and amplifying adenovirus  
Stocks of replication defective recombinant adenoviruses containing HCV NS3, or NS3/ 
from genotypes 1a, 1b and 2a and a LacZ expression cassette containing recombinant vi-
rus were used. All work with adenovirus was performed under Biosafety Level 2 (BL‐2). 
A crude viral stock was obtained from ( Al-hababi, 2008 ) used to generate a new high 
titre viral stock.  
A 25cm2 flasks of 293A cells which had previously been growing was trypsinized and 
3x106 cells in DMEM containing 10% FCS and 10% penicillin/streptomycin were trans-
fered to a new 25cm2 flask. The next day, a 300 µl inoculum of crude adenoviral stock 
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was added to the cells, which then incubated in humidified incubator at 37ºC and 5 % 
CO2. The infection was continued until 80-90% of the cells were rounded and detached 
from the flask, which indicates the cells contain adenoviral particles. The medium con-
taining detached cells was transferred to 15 ml falcon tube. This was kept at -80ºC for 30 
minutes, and then placed in a 37ºC water bath for 15 minutes to thaw. This step was re-
peated twice to lyses the cells. Finally, the cell lysate was centrifuged at 3,000 g for 15 
minutes at room temperature. The supernatant which contains the viral particles was ali-
quoted into cryogenic tubes, and stored at -80ºC. 
2.3.13.2 Tittering adenovirus stock by plaque assay 
In a 12-well plate, 293A cells were seeded such that they would be 80-90% confluent at 
the time of infection. On the day of infection, vials of each of adenovirus stocks were 
thawed for 10 min in a 37°C water bath. 10-fold serial dilutions ranging from 104 to            
1013 were prepared by dilution in 10% FCS DMEM with a final volume of 1ml. Addition 
of virus dilution to the wells in the plate was followed by incubation overnight at 37°C in 
a humidified CO2 incubator. The following day, medium that contained the virus inocu-
lums was removed. An overlay solution was prepared by mixing 12 ml of prewarmed 2% 
FCS DMEM at 37°C and 1.2ml of pre-warmed at 65°C 4% agarose in PBS. 1.5 ml of the 
pre-warmed agarose at 37ºC overlay, was then added to each well. The 12-well plate was 
then left in a tissue-culture hood at room temperature until the agarose overlay solidifies, 
and then incubated at 37°C in a humidified CO2 incubator. After two days, an additional 
0.75 ml of 4% agarose overlay solution was added to the wells, and left until solidified 
before returning the plate to the incubator. The plate was monitored until plaques were 
visible. For each well 300 µl of 1% neutral red in H2O was added to each well and incu-
bated for 3 hours at 37°C in a humidified CO2 incubator. Finally, the plaques were 
counted and the titer of adenoviral stocks was calculated and expressed as plaque forming 
units (pfu) per ml. The titer was calculated as follow: the number of plaques which ap-
pears as lytic areas were counted, then the following formula was used to determine the 
titer (pfu/ml) of each viral stock. 
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Number of plaques per well 
  The Viral titer =  ________________________________________          = pfu/ml 
Dilution factor X volume (ml) of diluted virus added to the well 
 
2.3.13.3 Determining the transduction efficiency (multiplicity of infection)  
A day before transduction, 1x105 of Huh7 cells were seeded so that their confluence at the 
time of transduction would be 50-70% in each well of a 24 plate prior to transduction and 
incubated at 37ºC in an atmosphere of 5 % CO2 for 48 hours. From each adenoviruse 
stock, different doses of MOI 1 to 100, were added to the wells, and then the plate was 
incubated at 37ºC overnight. Next day, the medium was replaced and left for a further 24 
hours incubation. The volume of virus stock needed to achieve for a particular MOI was 
determined as follows; 
I. Number of cells to be infected x desired MOI= total PFU needed.  
II. (total PFU needed) / (PFU/ml) = total volume (ml) of virus needed to reach the 
desired MOI. 
2.3.14 Cell culture methods  
2.3.14.1 Cell culture growth 
Human hepatoma cells (Huh7) were grown and maintained in Dulbecco’s modified Eagle 
(DMEM) medium (Invitrogen) supplemented with 1x non essential amino acids, 10% 
heat inactivated fetal calf serum, 100 units/ml penicillin and 100µg/ml streptomycin at 
37°C in a humidiﬁed incubator with 5% CO2. The cells were split at approximately 80% 
confluence and washed with phosphate buffered saline (PBS) (Invitrogen) and trypsinised 
with 0.05% Trypsin, 0.02% EDTA. Cells were then incubated for 2-5 minutes at 37°C in 
the CO2 and then resuspended in complete medium. The cell suspension was centrifuged 
at 1,000 g for 5 minutes. The supernatant was removed and the cell pellet resuspended in 
complete medium. Aliquots of this suspension was used to seed new tissue culture flasks. 
Additionally, G418 (Geneticin) (GIBCO, Invitrogen) at a final concentration of 50mg/ml 
was added to Huh7 cells harboring subgenomic HCV replicons. The cells were then in-
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cubated at 37 °C in 5% CO2. Cells were passaged 2 to 3 times per week or before the 
cells became confluent. 
2.3.14.2 Cell storage 
All of the cell lines were grown in T75cm2 tissue culture flasks until confluent and trypis-
insed as for passaging of cells and then counted using a haemocytometer. Cells were cen-
trifuged using at 1000 g for 5 min. The supernatant was decanted and the cells resus-
pended in freezing medium  ( DMEM containing 20% FCS and 10% DMSO) to an ap-
proximate density of 5.0 x106. Aliquots of 1 ml were transferred to cryovial tubes (Nunc) 
and frozen at -80ºC overnight, then transferred to cryogenic storage tubes for long-term 
storage in liquid nitrogen. 
2.3.14.3 Adenovirus transduction and siRNA knockdown of host genes 
A day before transduction with recombinant adenovirus, Huh7 cells were washed with 
phosphate-buffered saline (PBS), trypsinized and resuspended in complete medium. Cells 
were then seeded in 24-well plates at a density of 0.5 x105 cells/ml, in 10% FCS DMEM 
medium. The next day, the cells were transduced with adenovirus at an MOI of 50 or 100 
pfu/cell. The cells were incubated with adenovirus for 36 hours at 37ºC in a humidiﬁed 
incubator with 5% CO2. After 36 hours the medium was removed and the cells were 
washed with 1ml PBS and then 500µl of OPTI-MEM (Invitrogen) was added to the well. 
The optimal concentration of siRNA was determined [271]. Each siRNA used was ini-
tially diluted from the original stock of 20µM to obtain the desirable concentration of 
25nM. For each transfection sample, 1.5 µl siRNA was mixed with 48.5 µl OPTI-MEM 
medium. In a separate eppendorf tube, 1µl Lipofectamine 2000 (Invitrogen) was diluted 
in 49µl OPTI-MEM I reduced medium, mixed gently and incubated for 5 minutes at 
room temperature. This solution was then combined with the previously diluted siRNA 
solution and incubated for 20 minutes at room temperature to allow the formation of 
siRNA Lipofectamine 2000 complexes. After 20 minutes, the 100 µl of the transfection 
mixes were added to wells 500 µl of OPTI-MEM medium and then the cells were incu-
bated at 37 °C in 5% CO2 for 48 hours. Finally, after eight hours the OPTI-MEM me-
dium was replaced with 500 µl of DMEM medium supplemented with 10% fetal bovine 
serum, 100 units/ml penicillin and 100µg/ml streptomycin and the plate was incubated 
Materials and Methods 
 92 
for a further 48 hours. Alongside, controls containing GAPDH and non-targeting siRNAs 
were used to determine the efficiency of transfection.  
2.3.15 Sample preparation for RT-PCR 
2.3.15.1 RNA extraction  
Intracellular RNA was extracted using TRIzol reagent (Invitrogen) according to manufac-
turer instructions. Growth medium was removed from the 24 well plates, and 0.35 ml 
TRIzol reagent was added and left for 5 minutes to allow for complete dissolution of the 
cells. TRIzol-cell lysates were then homgenised by pipetting up-and-down and then trans-
ferred into 1.5ml eppendorf tubes. 250l of chloroform was added to each tube and the 
homogenate was shaken vigorously for 15 seconds and incubated at room temperature for 
5 minutes. The homogenate was then centrifuged at 12,000g for 15 minutes at 4ºC, which 
will separate the homogenate into different phases, the aqueous (upper) phase was care-
fully transferred to a 1.5ml clean tube. An equal volume of isopropyl alcohol was then 
added to the aqueous phase to precipitate the RNA. The mixture was incubated at room 
temperature for 15 minutes and then centrifuged at 12,000 g for 30 minutes at 4ºC. The 
RNA was pelleted, washed with 70% ethanol and resuspended in 30l of DEPC-treated 
water and stored at –80ºC until further use.  
2.3.15.2 DNase treatment 
DNase treatment was performed using a DNA-free DNAse Kit (Ambion), to remove ge-
nomic DNA. 3 µl 10x volume of DNase I Buffer and 1μl of DNase I (2units) were added 
to 0.5-2 µg of  RNA, and mixed gently by pipetting up and down and then incubated at 
37oC in water bath for 20-30 minutes. 0.1 volume of DNase Inactivation Reagent was 
added to the mixture, the mixture was then vortexed, and incubated for 2 minutes at room 
temperature and then centrifuged at 10,000 g for 1 minute to separate the DNase Inactiva-
tion Reagent from the RNA. The RNA was then transferred to a new tube and stored at -
80ºC. 
2.3.15.3 RNA concentration and quality  
The concentration and the purity of RNA samples were determined using a nanoDrop 
ND-1000 full spectrum (220-750nm) UV spectrophotometer (Thermo Scientific), which 
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calculates the concentration of a sample based on the absorbance detected using Beer’s 
law, and measures high concentrations of RNA without dilution. Before measuring the 
RNA concentration, RNase Free water was used to perform a blank reading. From each 
sample 2 µl of RNA was pipetted onto the nano Drop pedestal. A second pedestal was 
brought into contact with the liquid sample to allow the spectrometer to analyze the light 
that passes through the sample. The nanoDrop ND-1000 software calculate the quantity 
of RNA in the sample using an OD260 absorbance reading. It also simultaneously meas-
ured the OD280 of the samples allowing the purity of the sample to be estimated. The ratio 
of A260/A280 gives an estimation of the purity of the sample.  
2.3.15.4 qRT-PCR  
Quantitative Real–Time PCR analysis was performed using a QuantiTech SYBR RT-
PCR (Qiagen) kit. The principle of this kit is based on the fluorescent dye SYBR Green 
that binds to all double-stranded DNA molecules during the PCR reaction, emitting a flu-
orescent signal on binding. The fluorescent signal increases as the number of dsDNA 
molecules also increases. All reactions were performed in a final volume of 10µl. For 
each reaction, a master PCR mix was combined as follows: 5μl of SYBR Green, 0.1μl of 
RT enzyme, 0.5μl of (3.2μM) of each reverse and forward primers. The master mix was 
then distributed into 1.5ml eppendorf tubes, mixed and transferred into PCR capillaries 
(Roch). 150ng of each RNA sample was added to the individual capillaries and then cen-
trifuged for about 5 seconds and then loaded into a lightcycler machine (Roche).  
The conditions of the PCR were ; initial activation step at 95ºC for 15 minutes, denatur-
ing at 94°C for 15 seconds, annealing at between 55-60°C depending on the primer used 
for 30 seconds, and extension at 72°C for 30 seconds. PCR capillaries were placed in the 
LightCycler machine (Roche) and the cycling program was started. Finally, the results 
were plotted on graphs using PRISM software.  
2.3.15.5 Relative quantification 
Relative quantification measures the changes in mRNA levels of a gene across multiple 
samples and expresses it relative to the levels of an internal control RNA. Housekeeping 
genes are usually used as a reference gene and can be co-amplified in the same tube in  a 
multiplex assay or can be amplified sperately. Accordingly, relative quantification does 
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not require standards with known concentrations and the reference can be any transcript, 
as long as its sequence is known. To calculate fold change in expression, the cycle 
threshold (CT) values obtained following qRT-PCR analysis were used in the ΔΔCT 
equation [207]. 
The ΔΔCT equation: 
CT target gene – CT reference gene = ΔCT  
ΔCT adeno virus transduced sample – ΔCT negative infected sample = ΔΔCT 
 Fold change in gene expression = 2- ΔΔCT  
To normalise the gene expression data, GAPDH was used as the reference gene for all 
experiments. 
2.3.15.6 Primer design  
Primers for qRT-PCR were designed using online resources. The gene sequences were 
obtained from the National center for biothecnology information website 
(http://www.ncbi.nlm.nih.gov/). Primers for qRT-PCR were designed using Primer 3 
software to amplify a product between 100bp and 150bp in size. The annealing tempera-
ture used for all primer pairs was 58°C. Primers were synthesized by Invitrogen.  
2.3.16 Indirect immunofluorescence staining  
Indirect immunofluroscence staining was performed to detect protein expressed in either 
or Huh7 transduced with adenovirus containing V5 tag.   
2.3.16.1 Evaluation of Anti V5 by indirect immunofluorescence staining  
Glass cover slips (22 x 22 mm) (VWR) were sterilized by autoclaving and placed in the 
wells of 24 plate. Huh7 cells were seeded at 2 x 105 per well with complete DMEM me-
dium. Once the cells grown to 70% confluence they were transduced with the following 
adenovirus constructs; AdNS3-1a, 1b, 2a, AdNS3/4A-1a, 1b, 2a and Ad LacZ recombi-
nant adenoviruses at MOI 100. After 48-72 hours post infection the cells were washed 
with 500µl PBS followed by 2ml of 4% paraformadehyde in PBS fixation solution and 
incubated for 25 minutes at room temperature. The fixing solution was then discarded 
from the wells and the cells were carefully washed with PBS. The cells were permeabi-
lised by adding 1ml of 0.1% Triton X-100 in PBS for 15 minutes and then washed with 
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1ml of PBS. The cover slips were transfered from the wells and placed, cell coated face 
down, onto or 30µl of mouse anti tag V5 antibody (anti-V5) diluted 1:300 in 1% BSA in 
PBS on a strip of parafilm for one hour at room temperature. Unbound antibody was 
washed off three successive times in 1ml PBS and the coverslips were then placed face 
down onto 50µl of or AlexaFluor 594-conjugated anti-mouse IgG (Invitrogen), diluted 
1:800 in sterile PBS on a clean parafilm and incubated for one hour at room temperature. 
The cover slip was washed again three times in 1ml PBS, and placed face down on 15µl 
of Mowiol mounting medium with DAPI nuclear stain on a clean microscope slide. The 
cells were examined using oil lens 60x magnification using Fluorescence microscope, 
Nikon Eclipse TE2000-S. 
2.3.17  FACS analysis of HCV core intracellular staining  
One day prior to the infection, Huh7 cells were seeded in 24 well plates at a density of          
2x105, and were then subsequently infected with HCV JFH-1 at different MOI, as de-
tailed in (section 2.9.1). For FACS staining, all of the steps prior to fixation were carried 
out on ice. Subsequently, the cells were harvested through trypsinization for 2–3 minutes 
at 37°C, with the addition of 2 ml of PBS and cell suspensions were then transferred to 
Falcon 12x75 mm polypropylene tubes, and 1,500 g centrifuged at 4ºC for 5 minutes. 
Subsequently, the supernatant was discarded, and 1 ml of PBS was then added to the cell 
pellet, mixed gently, and again centrifuged at 1, 200 g at 4ºC for 5 minutes. Again the su-
pernatant was discarded, and 300μl of fixative (4% paraformaldehyde and formaldehyde 
in PBS) was added to each cell pellet, mixed gently, and incubated on ice for at least 30 
minutes. Following the period of incubation, each tube received 1 ml of PBS, which was 
mixed gently, and again centrifuged at 1500 g at 4°C for 5 minutes. Subsequently, the 
supernatant was discarded and the cell pellet was then re-suspended in 200μl PBS and 
transferred to a V-shape 96 well plate (Sarstedt). For intracellular staining, the same pro-
cedures as described above were carried out with the use of saponin containing buffers. 
Initially, 200μl PERM buffer (FACS staining buffer with 0.5% (w/v) saponin) was added 
to each of the wells, with thorough mixing and subsequent centrifuging at 1200 g for 5 
minutes with the use of a plate centrifuge (Sigma). This washing procedure was again re-
peated with a 200μl SUPERPERM buffer. The supernatants were then discarded, then 
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80μl (1:300 in PBS) of the mouse monoclonal anti V5 antibody (Invitrogen) added to the 
wells with the exception of the negative control. This was then left at room temperature 
for 1 hour. Following this stage, there was the washing of the cells with 200μl PERM 
buffer per sample, with centrifugation carried out as described before. Following the re-
moval of the supernatant, the cells pellets were resuspended in 100μl of the Alexa 594 
donkey anti-mouse IgG- secondary antibody (Invitrogen), diluted 1:800 in PBS, and left 
at room temperature for of 1 hour. As previously, the supernatant was removed by cen-
trifugation. The cell pellets were then washed with 200μl of PERM buffer, spun, and the 
supernatants discarded. Following the final stage, PBS was once again used to wash the 
cells, which were then re-suspended in 200μl of staining buffer (2% FCS in PBS), gently 
mixed and then transferred to FACS analysis tubes (BD). A FACS C6 Flow Cytometer 
(Accuri) was used to determine cell fluorescence signals. Sample analysis was carried out 
with the use Accuri software.  
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3. Results 
3.1 The interaction of NS3 with HCV RNA  
HCV NS3 protein has been shown to have a range of activities, including protease, AT-
Pase, helicase enzyme activities as well as RNA binding and protein- protein interaction 
activities. To investigate the interaction of NS3 with RNA, NS3 protein and HCV RNA 
were produced and used in cell free interaction studies. NS3 protein was characterised for 
enzyme activity and synthetic RNAs corresponding to full-length HCV genome and the 
3’UTR were synthesised. 
3.1.1 Expression and purification of NS3 protein 
To determine the presence of the full length HCV NS3 pAW3 [102-1657], the plasmid 
DNA was digested using  and Bam HI restriction enzymes. A 1% agarose electrophoresis 
gel was used to confirm that the correct plasmid DNA was present.  As shown in (Figure 
3.1) lane 1; contains the 1Kb DNA ladder, lane 2 contains the undigested plasmid, 
whereas lane 3 contains two fragments resulting from the double digestion, the parental 
(pET16b) is 5,711 bp, whereas the NS3 pAW3 plasmid insert is approximately 1,800 bp. 
3.1.1.1 Determination of plasmid stability  
To determine which fraction of the cells contain the functional NS3 pAW3 plasmid. Four 
plates containing different additives (i) 100mg /ml ampicillin, (ii) 1mM IPTG, (iii) both 
100mg/ml ampicillin and 1mM IPTG, or with neither (iv) were used to grow E. coli con-
taining pAW3. 10 -fold serial dilutions were made from 101 to 106. Then cells at a dilu-
tion of 105 were plated on 1mM IPTG or 1mM IPTG and ampicillin. Whereas cells at a 
dilution of 10 6 were plated on LB or 100mg/ml ampicillin. As seen in (Figure 3.2), bacte-
rial colonies grow on both LB medium and LB containing antibiotic, which indicates that 
these cells are still carrying the target plasmid. Whereas, no growth was detected on the 
plates that contains both 1mM IPTG and IPTG with antibiotic.  
 The absence of growth may be explained when the IPTG is present, because cells carry-
ing a protein production plasmid dedicated all their resources to the production of the re-
combinant protein instead of cell maintenance, only mutants that retain the plasmid but 
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have lost the ability to express the target gene can grow in LB medium contain IPTG and 
antibiotic. 
 
 
                                                      
                                              
 
 
 
 
 
 
 
Figure  3.1. 1% agarose gel electrophoresis shows restriction digestion of pAW3 plas-
mid. Lane 1; 1Kb DNA ladder, lane 2; undigested pAW3, lane 3; pAW3 digested with 
Nde1 and Bam H 1 enzymes. 
 
 
  
  1               2                 3 
 
5,711b
p 
1,800 bp 
6,000 bp 
Results 
 100 
 
  
 
Figure  3.2. Plasmid stability test. (i) LB plate contains viable cells, (ii)  LB plates with 
antibiotics wich contains  cells  still carry the  target plasmid,  (iii) LB  plate with IPTG 
with no growth, (iv) LB plate  with antibiotic and 1mM IPTG with no growth.  
 
3.1.1.2 Protein purification from inclusion bodies 
Inclusion bodies are formed from the expression of high levels of recombinant proteins in 
E coli which leads to protein aggregation. Proteins contained in inclusion bodies are 
biologically inactive and need to be solubilised, refolded and purified before they can be 
used. Solubilising protein aggregates is usually achieved by using high concentrations of 
a chaotropic agent e.g. Urea along with a reducing agent e.g DTT and then refolded by 
the gradual removal of the denaturant. 
 Inclusion bodies were isolated by repeated sonication and washes of samples 
corresponding to total protein extracts from cells induced with IPTG and uninduced cells. 
Soluble protein, from washes 3-6 and insoluble protein were examined by SDS-PAGE 
LB plate + 1PTG(1mM) LB plate + antibiotic 
+1PTG(1mM) 
iii 
ii 
LB plate LB plate + ampicillin 
i 
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Results 
 101 
(Figure 3.3). No protein bands were detected in the supernatant of the final wash prior to 
solubilisation of the inclusion bodies with a buffer containing 8 M urea and DTT. ( lane 
3-9 ), demonistrating the removal contaminating soluble protein. The final lane (10)  
shows the purified inclusion bodies containing undiluted NS3 protein prior to 
purification.  
3.1.1.3  Purification of NS3 protein under denaturing conditions by liquid chroma-
tography column  
Protein purification under denaturing conditions was performed using Ni -NTA agarose. 
A His tagged protein is an amino acid motif that consists of at least 6 histidine (His) resi-
dues either at the C-terminal or N-terminal of the tagged protein. The His tag attaches to 
the Ni+² ions on the column through the imidazole ring in the histidine residue of the 
6xHis tag. Applying imidazole which itself contains the histidine ring, displaces the His-
tag from nickel co-ordination, hence freeing the His-tagged proteins (Figure 3.4). 
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Figure  3.3. Purification of inclusion bodies containing NS3 protein. Samples were re-
solved by SDS-PAGE  on a 10 %  gel and stained with coomassie blue. Lane M;  mo-
lecular  weight   ladder, lane 1;uninduced cells, lane 2; induced cells, lane 3-9; wash, 
lane 10; inclusion bodies solubilized with  8M urea. 
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Figure  3.4. 10% SDS-PAGE of purification of 6xHis tagged NS3 protein   under dena-
turing conditions using Ni-NTA nickel-nitrilotriacetic agarose column. Lane M; molecu-
lar weight marker, lane 1; flow-through, lane; 2 wash 1  lane; 3 wash 2, lane; 4-6 eluted 
with buffer C, 8-9 eluted with buffer D. 
 
3.1.2 Protein refolding 
The purified NS3 protein was refolded to its bioactive form by stepwise dialysis of the 
urea solubilised protein to remove the urea and allow protein refolding. The protein sam-
ple was dialysed stepwise using refolding buffer (25 mM Tris-HCl [pH 7.2], 10% (v/v) 
glycerol, 50 mM NaCl, 1M DTT, 0.1% CHAPS) containing 4M, 2M, and 1M urea, fol-
lowed by three buffer changes without urea. The protein was then dialysed against buffer 
A containing 50% glycerol for 24 hours and stored at 20 °C. All dialysis steps were car-
ried out at 4ºC. During the dialysis there was a large amount of precipitated protein. 
However, this solution was clarified by high speed centrifugation at 16,000g for 30 min-
utes at 4ºC to remove the precipitate. The yield of soluble protein was ~ 0.7mg/ml. Figure 
3.5.A and B demonstrate the presence and purity of the NS3 protein after refolding, using 
a 10% SDS-PAGE and western blot.  
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Figure  3.5. A. 10% SDS-PAGE shows the differences between the uninduced, 1mM 
IPTG induced cells and the refolded NS3 protein. lane 1;un induced cells, 2; induced 
cells, lane 3; shows the refolded  NS3 protein. B. Western blot analysis shows these ex-
tracts with the anti NS3 antibody. Samples were resolved by SDS-PAGE on a 10% gel 
before western transfer .B.  Western blotting was performed with anti NS3 (3µg/ml)  
and  HRP conjugated antibody. Lane M; molecular weight marker, lane1; induced cells, 
2; refolded NS3 detected with anti NS3 antibody. 
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3.1.2.1 Determination of NS3 protein ATPase activity  
ATPase is an enzyme that catalyzes the decomposition of adenosine triphosphate (ATP) 
into adenosine diphosphate (ADP) and free phosphate. ATPase has a wide range of func-
tions e.g. Transmembrane ATPases import many of the metabolites necessary for cell 
metabolism and export toxins, wastes, and solutes that can hinder cellular processes. 
Plasmid pAW3 that encodes a full length HCV NS3 protein and was previously 
characterised for helicase, ATPase activity, the effects of Mg 2+, NaCl ions and pH on 
these enzyme activities . The ATPase activity of NS3 can therefore be used to assess the 
activity of NS3 protein after refolding. To do this, a colorimetric assay was used to 
measure the production of inorganic phosphate from ATP by ATPase activity.                      
A standard curve was created to calculate enzyme activity, then the OD260 of inorganic 
phosphate (Pi) was measured every 10, 20, 30, 50 and 60 minutes. Figure 3.6 shows the 
generation of Pi by NS3 protein ATPase versus time which shows a linear relationship. 
This indicates that the NS3 protein is enzymatically active.                    .  
 
Figure  3.6. Time course of HCV NS3 ATPase activity shows a linear relationship be-
tween ATPase activity of NS3 versus time. The experiments were carried out in the 
presence of 1mM NS3 (●), and the control contains reaction buffer without NS3 (▲). A 
standard curve was created to calculate enzyme activity, then the OD260 of inorganic 
phosphate Pi (mM) was measured every 10, 20, 30, 50 and 60 minutes.  
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3.1.3 Synthesis and analysis of full length JFH-1 RNA 
The discovery of the HCV genotype 2a isolate called JFH-1 has facilitated the study of 
the HCV life cycle from host-cell attachment and entry, through replication, to the as-
sembly and release of progeny virions. To investigate the binding activity of NS3 to HCV 
RNA, synthetic RNA corresponding to the full length HCV genome was produced. The 
preparation of in vitro transcribed RNA from plasmid DNA was performed as described 
by Wakita et al, 2006 [272]. Plasmid JFH-1 was grown in E. coli DH5α to generate p 
JFH-1 DNA . After extraction of pJFH-1, the plasmid were then linearized using Xba I 
enzyme to produce linear DNA (Figure  3.7). An agarose gel was used to confirm the size 
of both the plasmid and the linearized JFH-1 (Figure 3.8). The linearized pJFH-1 was 
used as a template to synthesize the full length JFH-1 RNA in vitro using T7 RNA poly-
merase. The plasmid was first purified by column-based clean up. The pJFH-1 DNA was 
then enzymatically treated with mung bean nuclease and proteinase K and purified. RNA 
was synthetized by in vitro transcription and further purified. The presence of the RNA 
transcripts of the desired size was confirmed by formaldehyde agarose gel electrophoresis 
(Figure  3.9). 
 
 
Figure  3.7. JFH-1 DNA plasmid map. pJFH-1 (Red arrow), Ampicillin resistance gene 
(Green arrow). 
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Figure  3.8. Linearization of pJFH-1. 1% agarose gel electrophoresis shows a restriction 
digestion of pJFH-1. Lane M; 1Kb DNA ladder, lane 1; undigested pJFH-1, lane 2; 
pJFH-1  linearized with Xba I. 
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Figure  3.9. Analysis of transcribed pJFH-1 RNA. Electrophoresis of 1% agarose-
formaldehyde gel stained with ethidium bromide. M; molecular weight ladder (1µg), 1, 
transcribed full length JFH-1 RNA (1µg). 
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3.1.4 Synthesis and analysis of the 3’ end JFH-1 negative RNA 
The 5’ end of the JFH-1 HCV genome was transformed in E. coli JM109 (DE3) cells 
(Figure 3.10). The DNA was then linearized with Apa I enzyme. Double digestion with 
Nde I and Ecor I was used to show the presence of the 5’ end. The size of the plasmid 
was estimated by agarose gel electrophoresis (Figure  3.7). The linearized DNA was then 
used as a template for in vitro SP6 RNA transcription, to produce the 3’end negative 
strand RNA. The transcript size was confirmed by formaldehyde gel electrophoresis 
(Figure 3.12). 
 
Figure  3.10. DNA plasmid of HCV IRES. IRES (Red). 
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Figure  3.8. Restriction digestion of 5’end. 1% agarose gel electrophoresis shows restric-
tion digest of JFH-1 5’ end. Lane M; 1Kb DNA ladder, lane 1; undigested  pJFH-1 5’ 
end, lane 2; double digest with EcoR I showing  cleaved   pJFH-1 5’ end and the insert 
(500bp) ; lane 3, linearised  pJFH-1 5’ end (3808 bp). 
 
 
Figure  3.9. Analysis of transcribed 3’end JFH-1 RNA. 1 µg  was loaded onto a 1% aga-
rose-formaldehyde gel and stained with ethidium bromide. M; RNA Millennium mo-
lecular weight ladder (2µg), 1, transcribed 3’ end JFH-1 HCV negative strand. 
 
  M         1         2        3 
 
pJFH-1 5’end 
       500bp 
     4,000bp 
5’ end   
         M              1 
3’ end 
3,000 bp 
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3.1.5 Detection of HCV RNA-NS3 protein interaction by electro mobili-
ty shift assay 
The electrophoretic mobility shift assay (EMSA) is a powerful and qualitative tool used 
to detect protein-RNA interaction. It is based on the observation that the electrophoretic 
mobility of a protein-nucleic acid complexes slower than that of the free nucleic acid. 
The sensitivity of the assay allows them to be performed with low protein and nucleic 
acid concentrations ranging from 0.1 nM or less. A wide spectrum of nucleic acid sizes 
from short oligonucleotides to several Kbp. It can be performed with different nucleic 
acid structures; single-stranded, duplex, triplex and quadruplex nucleic acids and small 
circular nucleic acid. The electro mobility shift assay can be performed with proteins 
ranging in size from small oligo peptides to protein complexes with Mr ≥ 10
6. On the 
other hand, it can be used with both highly-purified proteins and crude cell extracts. 
Moreover, the nucleic acid can be labeled with radio isotopes, covalent or non covalent 
flurophores or biotin. Biotin has several advantages comparing with radioactiove iso-
topes, it is safe and the shelf life is long. In this study biotin (Long Arm) maleimide was 
used to label HCV RNA. The presence of the 6-aminohexanoate spacer arm between the 
maleimide group and biotin reduces the possibility of steric hinderance. Biotinylated 
probes were detected using streptavidin coupled to alkaline phosphatase.  
3.1.5.1 Screening of biotinylated RNA 
 Figure 3.13 A shows the titration of the biotinylated RNA by dot blot. Labeled RNA was 
detected using dot blot assay as described in section2.3.12.10. 2-fold dilution of 1µl of 
25nM of in vitro transcribed biotinylated RNA was used. Visually the result showed 
strong signals at concentrations of 25 nM, 12 nm, 6 nM and 3 nM which gradually de-
crease in intensity from the concentration 1.5 nM. The densitometry of the dots was also 
analyzed using scanning integrated optical density software (Image J), and different con-
centrations are presented as relative percentages (Figure 3.13.B).  
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Figure  3.10. Titration of biotinylated RNA. A. Biotinylated RNA was titrated by Im-
munoblot technique. B. Shows relative intensity readings of biotinylated RNA concen-
tration. Image J software was used to measure blot density. 
 
3.1.5.2  Detection of the interaction between 3’end biotinylated HCV RNA and NS3 
protein 
The transcription process is the first step of gene expression and it begins with the forma-
tion of the pre-initiation complex. Once this complex has formed RNA protein interac-
tions takes place to splice, protect, translate or degrade the message. After transcription 
initiation, the complementary promoter sequence in the mRNA is cleaved and the cap-
ping machinery incorporates a “GpppN” cap at the 5’ end of the mRNA. Elongation of 
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the transcript then occurs through the recruitment of elongation factors to the message. 
Elongation is followed by 3’ end processing and splicing, resulting in a mature RNA 
transcript that is exported to the cytoplasm for translation. All of these processes require 
significant protein:RNA interactions and are highly regulated and complex. Many of the 
regulatory elements for this process lie within the 3’ and 5’ untranslated regions (UTRs) 
of the mRNA. Coding sequence for regulatory microRNAs (miRNAs) have been located 
in coding regions of exons, the introns and exons of non-coding genes and also in repeti-
tive elements. An increased emphasis has been placed on the significance of the non-
coding RNAs and their roles in cellular regulation and disease states. However, tools for 
the study of critical protein:RNA interactions have been limited. The UTR regions of 
mRNA contain sequence elements that recruit RNA-binding proteins for post-
transcriptional regulation and protein translation.  
In addition, these elements promote transcript stability or degradation and can direct sub-
cellular localization of the RNA. These RNA regulatory elements vary in length, but rely 
on both primary and secondary structure for RNA-protein binding interactions. The 5’ 
and 3’ ends of nucleic acid are common sites for labeling with biotin, since labeling at 
these sites  minimizes the steric hindrance. In order to examine the interaction of full 
length HCV NS3-1a protein with the full length HCV JFH-1 RNA and the 3’ end of 
negative strand HCV RNA, electromobility shift assays were performed using bioti-
nylated RNA probes corresponding to the full length JFH-1 (2a) with the full length NS3-
1a protein.  
For the full length JFH-1 RNA experiment, 7% native acrylamide gel was used and 10% 
native acrylamide gel was used for the 3’ end. Equal mole fractions of bound and free 
RNA which was 55 pmol, were combined with different  concentrations of NS3-1a pro-
tein ranging from 100 to 600 nm. The RNA was  mixed in binding buffer with NS3 pro-
tein, Poly (I:C) was added as a competitor and the mixture was equilibrated for 30 
minutes at 4ºC. As demonstrated in (Figure 3.14.A) lane 1, contains free RNA in binding 
buffer, it shows high signal intensity, lane 2; contains RNA and 100 nM of NS3-1a pro-
tein, the intensity of the biotin began to fade with increased protein concentration, which 
indicates binding of RNA and protein. However, the reaction showed slight shift. Binding 
of the RNA to the protein was assessed by measuring the decrease of chemoluminescence 
Results 
 114 
(CL) signal intensity of the RNA bands using Image J. Software (Figure 3.14 C). Figure 
3.14 C shows a histogram presenting  relative intensity for each reaction band. Figure 
3.12.A shows the interaction of full length HCV NS3-1a protein with the full length JFH-
1. The intensity of the biotin began to fade with increased protein concentration, which  
indicates binding of RNA and protein. Similar results were seen in (Figure 3.15.A) for 
the interaction of 3’ end of the negative RNA strand and HCV NS3-1a protein.   
 
 
 RNA/Protein mixture Intensity reading 
Lane 1 Free RNA 100.00 
Lane 2 55pmol RNA with 100 nM NS3 49.001550 
Lane 3 55pmol  RNA with 200 nM NS3 41.904120 
Lane 4 55pmol RNA with 400 nM NS3 25.545980 
Lane 5 55pmol  RNA with 600 nM NS3 9.900023 
1 2 3  4  5 
A 
JFH-1 RNA   
(9.6 kb) 
B 
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Figure  3.11. Electro mobility shift assay of the interaction of JFH-1 RNA and NS3 pro-
tein. A. RNA-protein interaction was detected by adding 55pmol fraction of biotinylated 
of RNA to different NS3 protein concentrations ranging from 100-600 nM, in binding 
buffer at 4ºC for 30 min and loaded into 7% acrylamide gel, lane 1; free RNA, lane 2-5 
different NS3 protein concentrations. B. Representation of quantification of each band 
of RNA/Protein was calculated using the Image-J program. C. Histogram presents rela-
tive intensity for each band. 
 
 
 
 
 
              1             2             3               4              5 
C 
A 
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 RNA/Protein mixture Intensity reading 
Lane 1 RNA / Protein 100.00 
Lane 2 55pmol  RNA with 100 nM NS3 85.28867 
Lane 3 55pmol  RNA with 200 nM NS3 70.05097 
Lane 4 55pmol  RNA with 400 nM NS3 61.74514 
Lane 5 55pmol  RNA with 600 nM NS3 19.26387 
 
 
 
 
 
 
 
  
 
 
Figure  3.12. Electromobility shift assay of the interaction of 3’ end of the negative RNA 
strand and NS3 protein. A. RNA-protein interaction was detected  by adding 55pmo 
fraction of  biotinylated  RNA to different NS3 protein concentrations ranging from 
100-600 nM in binding buffer at 4ºC for 30 min and loaded into 10% acrylamide gel, 
lane 1; free RNA, lane 2-5 different NS3 protein concentrations. B. Representation of 
quantification of each band of  RNA/Protein was calculated using the Image-J program. 
Relative Intensity was calculated by dividing the absolute intensity of each sample band 
(on the table) of each band by the absolute intensity of control. C. Histogram presents 
relative intensity for each band. 
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3.2 The interaction of NS3 protein with Host proteins  
NS3 has been shown to be present in HCV RNA complexes and to interact with several 
HCV non-structural proteins; NS4A, NS5A and NS5B [273-275]. Host proteins are also 
likely to play a role in these RNA replication complexes and to interact with the viral pro-
teins [276]. Recombinant adenoviruses that express NS3 and NS3/4A proteins from dif-
ferent HCV genotypes were used to investigate the interaction of NS3 with host proteins 
that may be important for HCV RNA replication and their stabilizing effects on NS3. 
3.2.1 Expression of target protein in recombinant adenoviral vector 
Adenoviral vectors (AdV) have been used to express a wide variety of viral and cellular 
genes in mammalian cells. Proteins produced with the adenovirus expression system have 
been used for biochemical characterization of proteins as well as in gene therapy experi-
ments. Generally, the adenoviral vectors used are based on human adenovirus serotypes 2 
(Ad2) and 5 (Ad5) of subgroup C. The most widely used adenoviral vectors for gene de-
livery are the called “first-generation” replication-deficient vectors, in which the E1 re-
gion of the genome is deleted. Deletion of the E1 region, while retaining the ITR and 
packaging signal, is designed to prevent expression of the E2 genes and thus block viral 
DNA replication and the synthesis of late structural proteins.  
E1-deleted Ad vectors are therefore propagated in complementing human cell lines that 
provide the E1 proteins in trans. In order to provide additional cloning space in the vec-
tor, the E3 region, which is not necessary for viral replication in culture, is also com-
monly deleted. Because adenoviruses can encapsidate DNA ranging from 75 to 105% of 
the length of the wild-type viral genome, these modifications allow up to 7.5 kb of for-
eign DNA to be accommodated. Adenoviral vectors allow for transmission of their genes 
to the host nucleus but do not insert them into the host chromosome. The 293A cell line is 
used for viral production. This is a human kidney cell line which has been stably trans-
fected with the E1A region of the adenoviral genome. This allows the vector to be made 
and matured within the 293A cell, although, vectors prepared from this cell line will lack 
the E1A region and they are replication-deficient. Adenoviral vectors enables generation 
of high titer adenoviral stocks and are capable of containing DNA inserts up to 7.5 kilo-
bases, and can infect both replicating and differentiated cells.  
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3.2.2 Adenovirus stock amplification 
In this study, adenoviruses containing individual NS3 and NS3/NS4A inserts from geno-
types 1a, 1b and 2a containing V5 were constructed, Al-Hababi, 2008 [277], using the 
Vira Power Adenovirus Expression System (Invitrogen), and stored at - 80ºC. All adeno-
virus stocks containing HCV NS3 and NS3/NS4A inserts from genotypes 1a, 1b and 2a 
were used to generate new high titre viral stocks. 293A cells were infected with the Ade-
novirus vectors which bind to the Coxsackie/Adenovirus Receptor (CAR) [278]. Adeno-
viruses are then internalized via integrin-mediated endocytosis [279], followed by active 
transport to the nucleus. Within the nucleus the early events of gene expression are initi-
ated i.e. transcription and translation of the adenovirus early proteins, followed by ex-
pression of the adenoviral late genes and viral replication. These events depend on E1 
that is produced by the 293A cells.  
After 24 hours post infection, morphological changes appear in 293A cells. These show-
ing discrete large rounded cells together with some normal cells. After approximately 48 
hours 80-90% of the cells were rounded up and became detached from tissue culture 
flask. By 96 hours post infection, all the cells were floating which indicates that cells are 
filled with adenoviral particles. The cells were then harvested and the titers were deter-
mined by plaque assay (Figure  3.13). 
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Figure  3.14. Infection of 239A cell with adNS3-1a. A- non-infected 293A cells, B- 24 
hours after infection with NS3-1a virus, discrete large rounded cells are present with 
some normal cells. C- 48 hours after infection with NS3-1a, 80-90% of the cells were 
rounded up and becoming detached from the tissue culture flask. D- 96 hours after in-
fection, cells were floating which indicates that cells are filled with adenoviral particles. 
 
3.2.3 Determination of adenovirus titer by plaque assay 
In order to determine the optimum quantity of virus needed to produce proteins  in the 
expression experiments, plaque assay was used. The assay was carried out using a 293A 
cells monolayer. These cells were infected with a 10- fold serial dilutions ranging from 
104 to 1013 of adenovirus stock, and the cells were then covered with a pre-warmed 4% 
agarose overlay, and incubated for 8-10 days until the plaques were visible. In this ex-
periment early cytopathic effects (CPE) started to appear by day 3. Early cytopathic signs 
A 
B 
C 
C
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appear as patches of rounding dying cells. As the infection proceeds, cells containing vi-
ral particles lyse and infect neighbouring cells. By day 10 plaques are clearly visible 
(Figure 3.17). 
Once the plaques were visible and distributed all over the wells, they were stained with 
1% neutral red and incubated for 3 hours at 37°C in a humidified CO2 incubator. The vi-
rus plaques appeared as clear areas with clear plaques surrounded by a pink monolayer of 
infected cells, since only live cells take up the dye. The plaques were counted and the 
titer of adenoviral stocks concentration was determined between 107-108 plaque forming 
unit (pfu) as shown in (Figure 3.18).   
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Figure  3.17. Plaque formation in 293A cells infected with AdNS3-1a. A. Day 3 post in-
fection, cells producing adenovirus first appear as patches of rounding, dying cells. B. 
Day 6-8 post-transfection, cells containing viral particles lyse and infect neighboring 
cells and plaques begins to form. C. Day 8-10 post-transfection, infected neighboring 
cells lyse, forming a plaque that is clearly visible. 
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Construct 
 
Titer 
NS3/1a 9.8x107      pfu/ml 
 
NS3/4A/1a 3.9x108        pfu/ml 
 
NS3/1b 1.2x108      pfu/ml 
 
NS3/4A/1b 3.5x108      pfu/ml 
 
NS3/2a 2.0x108       pfu/ml 
 
NS3/4A/2a 7.0x107      pfu/ml 
 
LAC Z 4.1x108      pfu/ml 
 
 
Figure  3.18. Titres of recombinant adenoviruses. The Ad NS3, NS3/4A and Ad LacZ 
adenovirus vectors were titrated by plaque assay.  
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3.2.4 Determine transduction efficiency (multiplicity of infection) by 
flow cytometry 
Multiplicity of infection was determined using flow cytometry. Different M.O.I doses 
ranging from 10-200 of six AdNS3, AdNS3/4A adenoviruses carrying the V5 epitope 
were added to Huh 7 cells. The amount of virus needed to add for a certain MOI was cal-
culated as described in section 2.3.13.2. After 48 hours the cells were trypsinsed and 
washed and all the subsequent staining was performed. Firstly, the cells were fixed by 4% 
paraformadlehyde to preserve the general structure of cellular organelles, and then per-
meabilized with 0.1% Triton X- 100 to allow the primary antibody to penetrate the cells. 
The primary and secondary antibodies were titered before staining, to find the optimal an-
tibody concentration. Anti-V5 mouse monoclonal IgG2a antibody of   a dilution of 1:300 
in PBS, was found to be the optimal concentration. The secondary antibody gave good 
results at 1: 800. Before performing the experiment, the C6 Flow Cytometer (Accuri, Cy-
tometers) was validated using validation beads containing a mixture of fluorophores that 
enable their excitation with the blue laser (488 nm) to validate the channels of flow cy-
tometers. The controls used in this experiment were, 1) Isotype antibody control IgG2a, 
to confirm that the primary antibody binding is specific and not the non-specific Fc re-
ceptor binding or other protein interactions. 2) Cells only as a negative and background 
autofluoresence control and for gating the cell population. 3) Treated secondary antibody 
for non-specific binding of secondary antibody on treated cells. However, in this experi-
ment Isotype was also used as the control in flow cytometry experiments to distinguish 
between the positive and negative cells (Figure 3.19). 
 
3.2.5 Detection of recombinant NS3 protein expression by 
Immunofluroscent staining 
Recombinant adenovirus vectors containing coding sequences for HCV NS3 and 
NS3/4A from genotypes 1a, 1b and 2a and LacZ recombinant proteins were used to 
transduce Huh7 cells at 100 MOI for 48 hours. To determine the percentage of Huh7 
cells expressing HCV NS3 or NS3/4A, indirect immunofluroscent staining was per-
formed. Mouse monoclonal anti-V5 antibody followed by Alexafluor 945 donkey anti 
mouse antibody was used to detect the recombinant proteins. The staining indicated that 
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most of the cells were transduced with the recombinant adenovirus vectors to express 
HCV NS3 or NS3/4A protein (Figure 3.20). Control Huh 7 cells without NS3 protein, 
did not show fluorescence with tag V5 antibodies. 
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Figure  3.19. Determination of transduction efficiency (multiplicity of infection) by flow 
cytometry. Upper panel (M2) Marker M2 is used to identify the positive stained cells. 1; 
Untransduced Huh 7 cells (Black), 2; Huh 7 cells transduced with Ad NS3-1a stained 
for isotype  IgG (Red) ,3; Huh 7 cells transduced with Ad NS3-1a stained with anti V5 
tag antibody and secondary antibody (Blue), 4; Transduced Huh 7 cells with Lac Z 
stained (Yellow). FACS panels shows the genotype and MOI titre. Lower panel Shows 
the mean florescence intensity of adenovirus stock. 
Results 
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G H I 
 
 
 
 
 
 
 
Figure  3.15. Immunofluroscence staining of Huh-7 cells transduced with adenovirus ex-
pressing NS3 and NS3/4A protein tagged with V5 epitope. Staining of V5 tagged pep-
tide (red) with anti-V5 antibody to localize HCV-antigen expression. Each slide repre-
sent expressed NS3 or NS3/4A from different genotype as indicated. Huh7 cells trans-
duced with V5 tagged LacZ (A-C), Huh 7 negative control (D-F), Huh 7 transduced with 
adenovirus NS3-1a (G-I). Huh 7 transduced with NS3/4A-1a (J-L), Huh 7 transduced 
with NS3-2a (M-O), Huh 7 transduced with NS3/4A-2a( P-R), Huh 7 transduced with 
NS3-1b (S-U) Huh 7 transduced with  adenovirus vector expressing NS3/4A-1b (V-X), 
first column, DAPI nucleus staining, second column V5 tag antibody staining, third col-
umn merged images. 
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3.2.6 Silencing of host cell gene expression by siRNA 
Previously a study using siRNA silencing found a number of cellular genes which are in-
volved in virus replication and secretion, these include TXNIP, RAB27A/B, RAB40 and 
Staufen 1. However, the precise role of these genes in HCV replication cycle is not 
known. Also, it is not known if their inhibition would have direct effects on NS3 protein 
expression or stability. siRNA knockdown of RAB27B, RAB 40B TXNIP and Staufen 1 
was carried out to determine the effects on NS3 expression [230]. 
The efficiency of gene silencing in cells transduced with adenovirus expressing NS3 was 
tested, using targeting siRNA and non-targeting siRNAs as a negative control (“scram-
bled RNA sequence” termed SiCon). Cells were transfected with 25nM of the HCV 
siRNA or 25nM of the non-targeting siRNAs for 48h hours using Lipofectamine 2000 re-
agent (Invitrogen). Additionally, the non-targeting siRNAs were used to compare the ef-
fect on cells transfected with non-targeting siRNA or cells transfected with siRNA 
knockdown and to ensure non-specific changes in cellular gene expression did not occur 
either due to the transfection process or the toxic effect of siRNA used in the culture me-
dium. After transfection, qRT-PCR was used to quantify intracellular target gene RNA 
U T S 
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levels. Some difficulties were encountered due to variation in cell density at the time of 
transfection. Low cell density resulted in poor recovery of RNA from the transfected cells 
while a high cell density resulted in the inhibition of cell growth. To obtain an optimal 
cell density of 90–95% confluence after 48 hours, the cell density at the time of transfec-
tion was optimised at around 50% confluence.  
Changes in gene expression due to the knockdown of host genes with specific siRNAs 
were compared to GAPDH which was used as a reference gene and its expression was 
considered as a value of 1. Following transfection with the siRNA the effect of the 
knockdown and changes in gene expression were measured against this reference point 
using the ∆∆CT equation. Changes in gene expression below 1 show a successful knock-
down for the target whilst the changes above 1 indicate the knockdown was unsuccessful. 
Figure 3.21 shows the levels of gene silencing using siRNA specific for RAB 27B. It 
showed decrease of 98% in both NS3-1a and NS3/4A-1a. Also, RAB 27B silencing 
showed a reduction in the levels of RAB 27B by 86% in genotype NS3-2a and by 94% in 
genotype NS3/4A-2a. RAB 27B levels showed a decrease in NS3-1b and NS3/4A-1b 
genotypes of 92% and 88%, respectively, compared with the negative control. 
Figure 3.22 RAB 40B RNA reduced gene expression of 78% in cells carrying genotypes 
NS3/1A and by 96% in cells that express genotype NS3/4A-1a . RAB 40B silencing 
showed a reduction in the level of RAB 40B of 84% in genotype NS3-2a and by 95% in 
genotype NS3/4A-2a. RAB 40B levels showed a decrease in NS3-1b and NS3/4A-1b 
genotypes of 97% and 85%, respectively, compared with the control non-targeting 
siRNA (siCon) control. Figure 3.23 the Staufen 1 reduced gene expression of 88% in 
genotype NS3/1A and by 98% in genotype NS3/4A-1a. Also, Staufen 1 silencing showed 
a reduction of 82% in genotype NS3-2a and by 83.6% in genotype NS3/4A-2a.               
Staufen 1 levels showed a reduction in cells with NS3/1A and NS3/4A-1b of 77% and 
92%, respectively, compared with the control. 
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Figure  3.21. Quantification  of RAB 27B siRNAs inhibition levels. Huh7 cells  trans-
duced with adenovirus expressing NS3 were transfected with specific siRNA in tripli-
cate and 48 hours post transfection, the target genes were quantified by qRT-PCR. 
GAPDH siRNA was used to measure the efficiency of transfection. Control non-
targeting duplex siRNA (siCon), with a scrambled sequence, was used as negative con-
trol. 
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Figure  3.22. Quantification of RAB 40B siRNAs  inhibition levels. Huh7 cells trans-
duced with adenovirus expressing NS3 were transfected with specific siRNA in tripli-
cate and 48 hours post transfection, the target genes were quantified by qRT-PCR. 
GAPDH siRNA was used to measure the efficiency of transfection. Control non-
targeting duplex siRNA (siCon), with a scrambled sequence, was used as negative con-
trol. 
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Figure  3.23. Quantification of Staufen 1 siRNAs inhibition  levels. Huh7 cells trans-
duced with adenovirus expressing NS3 were transfected with specific siRNA in tripli-
cate and 48 hours post transfection, the target genes were quantified by qRT-PCR. 
GAPDH siRNA was used to measure the efficiency of transfection. Control non-
targeting duplex siRNA (siCon), with a scrambled sequence, was used as negative con-
trol. 
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Figure  3.24. Quantification of TXNIP siRNAs inhibition levels. Huh7 cells transduced 
with adenovirus expressing NS3 were transfected with specific siRNA in triplicate and 48 
hours post transfection, the target genes were quantified by qRT-PCR. GAPDH siRNA 
was used to measure the efficiency of transfection. Control non-targeting duplex siRNA 
(siCon), with  a scrambled sequence, was used as negative control.  
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Figure 3.24 shows TXNIP gene was with a decrease of 85% and 95% respectively, in 
both genotypes NS3-1a and NS3/4A-1a. Also, TXNIP silencing shows reduction in the 
levels of TXNIP by 86% in genotype NS3-1a and by 94% in genotype NS3/4A-2a. On 
the other hand, TXNIP levels showed decrease in cells expressing both NS3/1b and 
NS3/4A-1b genotypes by 82% and 88%, respectively, compared with the control. 
3.2.6.1 Effect of RAB 27B gene silencing on NS3 protein expression  
The RAB family of proteins is a member of the Ras superfamily of monomeric                  
G proteins. RAB GTPases regulate many steps of membrane trafficking, including vesi-
cle formation, vesicle movement along actin and tubulin networks, and membrane fusion.  
It is expressed in platelets, the stomach, pituitary, and bladder [200]. 
To determine whether or not RAB27B gene knockdown has effects on HCV NS3 expres-
sion, Huh7 cells were transfected with 25nm RAB27B siRNAs for 24 hours followed by 
transduction with adenovirus expressing HCV NS3 protein at MOI of 100 for 48 hours. 
The levels of NS3 and NS3/4A gene expression were determined by qRT-PCR. Figure 
3.25 shows the effect of RAB 27B knockdown on NS3 and NS3/4A protein expression. 
The NS3-1a and NS3/4A-1a showed decrease in expression by 25% and 33%, respective-
ly, while the effect of silencing RAB 27B was 26% on genotype NS3-2a and 36% on 
genotype NS3/4A-2a compared to the negative controls transfected with scrambled 
siRNA (siCon). The levels of genotypes NS3-1b and NS3/4A-1b were also determined 
and they showed reduction in their levels by 40% and 37%, respectively.  
3.2.6.2 Effect of RAB 40B gene silencing on NS3  expression 
RAB40B was found expressed in E14.5 embryonic and adult mouse brain, inner ear and 
heart tissues, the role of this protein in HCV replication is still unknown, also it is un-
known whether this protein has direct interaction with HCV protein [207]. As shown in 
(Figure 3.26), there was a decrease of 36% in NS3-1a expression, while the effect of 
RAB 40B silencing was 28% on NS3/4A-1a expression. The genotype NS3-2a and 
NS3/4A-2a showed decreases in their expression by 27% and 15%, respectively. The 
genotype NS3-1b also showed a considerable decrease of 40%, while NS3/4A-1b showed 
a reduction of 37%.  
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Figure  3.25. The effect of RAB 27B siRNA on adenovirus expressing NS3 and NS3/4A 
genotypes 1a,1b and 2a. Huh7 cells were transduced with adenoviruses expressing NS3 
and NS3/4A genotypes 1a,1b and 2a. Total cellular RNA was extracted and qRT-PCR 
was used to quantify the changes in gene expression. Fold change in NS3 expression 
was normalized using GAPDH. 
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Figure  3.16. The effect of RAB 40B siRNA on adenovirus expressing NS3 and NS3/4A 
genotypes 1a, 1b and 2a. Huh7 cells were transduced with adenoviruses expressing NS3 
and NS3/4A genotypes 1a,1b and 2a. Total cellular RNA was extracted and qRT-PCR 
was used to quantify changes in gene expression. Fold change in NS3 expression was 
normalized using GAPDH. 
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3.2.6.3 Effect of Staufen 1 gene silencing on NS3 expression  
Staufen 1 is a dsRNA-binding protein, localised to the rough endoplasmic reticulum in 
ribonucleoprotein complexes, it play a role in the degradation, translation and trafficking 
of mRNA molecules. As shown in (Figure 3.27), there is decrease in NS3-1a level by 
16%, while the effect of staufen 1 gene silencing was 23% on NS3/4A-1a expression. 
NS3-2a and NS3/4A-2a show reductions in their expression by 40% and 39%, respec-
tively. On the other hand, NS3-1b was also showed decrease in its level by 37%, 
whereas, NS3/4A-1b showed less reduction levels by 17%.  
3.2.6.4 Effect of TXNIP Gene Silencing on NS3 expression 
Thioredoxin-interacting protein (TXNIP) is encoded by the TXNIP gene. TXNIP has 
multiple fuctions. Silencing of TXNIP gene (Figure 3.28) showed reduction of 18% on 
NS3-1a and 20% for NS3/4A-1a following the knockdown. Reduction of NS3-2a was 
achieved by 30%, whereas, the NS3/4A-2a levels lowered by 25%, which was almost the 
same level in reduction of full length NS3 or with full length with NS3/4A. Silencing of 
TXNIP showed a reduction of 20% in NS3-1b and 25% in NS3/4A-1b. 
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Figure  3.27. The effect of Staufen 1 siRNA on adenovirus expressing NS3 and NS3/4A 
genotypes 1a, 1b and 2a. Huh7 cells were transduced with adenoviruses expressing NS3 
and NS3/4A genotypes 1a, 1b and 2a. Total cellular RNA was extracted and qRT-PCR 
was used to quantify fold change in gene expression. Fold change in NS3 expression 
was normalized using GAPDH. 
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Figure  3.28. The effect of TXNIP siRNA on adenovirus expressing NS3 and NS3/4A 
genotypes 1a, 1b and 2a. Huh7 cells were transduced with adenoviruses expressing NS3 
and NS3/4A genotypes 1a,1b and 2a. Total cellular RNA was extracted and qRT-PCR 
was used to quantify fold change in gene expression. Fold change in NS3 expression 
was normalized using GAPDH. 
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3.2.7 Flow cytometry analysis of V5 tag NS3 protein expression 
Flow cytometry analysis was carried out on Huh7 cells transduced by NS3 or NS3/4A 
adenovirus vector. To determine the effect of host proteins RAB 27B, RAB 40B, TXNIP 
and Staufen 1 on V5 tagged NS3 protein expression. Huh7 cells previously transduced 
with the adenovirus vectors were transfected with target siRNA and then stained using an 
anti-V5 tag antibody for tagged NS3 protein using the protocol described in section 
2.3.13.2. An isotype antibody which has no specificity for target protein, was run along-
side each knockdown sample as a negative control. Figure 3.29 shows a FACS plot gen-
erated for gene silencing. For each cell line unstained Huh 7 cells were used to gate the 
population of live cells (Black). Transduced Huh 7 cells with Ad-NS3-1a were used as a 
positive reference and run with each set of siRNA samples also with Isotype antibody as 
a negative control. FACS analysis was performed in order to detect V5 tagged NS3 in 
Huh 7 cells. Cells were stained with monoclonal anti-V5 antibody and secondary anti-
mouse Alexa-Flour 594 to detect V5 tagged NS3. The positive cells were identified by a 
shift towards the right of the plot (M2) (Blue), when compared to stained cells with the 
secondary antibody (Red) or with the isotype control (Yellow). The results were pre-
sented as the mean florescence intensity (MFI) measured by Accuri flow cytometry soft-
ware and reported in arbitrary units.  
 
  
Marker M2 is used to identify the positive 
stained cells. 1; Untransduced Huh 7 cells 
(Black), 2; Huh 7 cells transduced with Ad 
NS3-1a stained for Alexa-Fluor 594 conju-
gated IgG (Red) ,3; Huh 7 cells transduced 
with Ad NS3-1a stained with anti V5 tag 
antibody and secondary antibody (Blue), 
4p; Transduced Huh 7 cells with Ad NS3-
1a protein stained for Isotype IgG (Yel-
low). 
Figure  3.29.  FACS plot of positive staining for NS3 protein. 
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3.2.7.1 Silencing effect of host genes RAB 27B and RAB 40B on V5 tag NS3 protein 
Fig 3.30 A shows the effect of silencing of RAB27B on Huh 7 cells transduced with dif-
ferent adenovirus genotypes. Transduced cells were stained intracellularly with mouse 
anti-V5 tag antibody and a secondary anti-mouse Alexa-Flour 594antibody. Panels (i-vi) 
shows the flow cytometry analysis of RAB 27B gene silencing, each panel defines a spe-
cific genotype, all genotypes show a shift to the right compared with the NS3 positive 
positive untreated control, which indicates that silencing of RAB27B was up regulating 
NS3 protein expression. To detect whether this shift is significant or not, the results were 
analyzed as the mean florescence intensity (MFI) of each genotype, also the level of ex-
pression was compared to its specific positive untreated control, the results were analysed 
using analysis of variance (ANOVA), all of the genotypes showed significant difference 
compared with the control indicating ( Fig 3.30. B). Additionally, silencing of RAB 40B 
was also tested for its effect on NS3 protein in different genotypes. (Figure 3.31.A) pan-
els (i-vi) represent the result of the flow cytometry which shows detectable positive shift 
on all genotypes but the shift was higher above the control positive in Huh 7 cells trans-
duced with genotypes NS3-1a, NS3/4A-1a, NS3-2a and NS3/4A-1b. The MFI of these 
genotypes was analyzed and showed statistical significantly change (P ˃ 0.05) (Figure 
3.31.B). 
3.2.7.2 Silencing Effect of Host Genes TXNIP and Staufen 1 on V5 tag NS3 protein  
Fig 3.32 A shows the effect of TXNIP on NS3 V5 tagged protein. Flow cytometry panels 
(i-vi) shows analysis of TXNIP host gene silencing, each panel defines specific genotype, 
all genotypes did not shows positive shift to the right which indicate that silencing of 
TXNIP has no effect on NS3 and NS3/4A protein. The MFI of the samples was meas-
ured; the level of expression was compared to the positive control, which showed no sig-
nificant change in NS3 protein all of the genotypes (Figure 3.32 B). Staufen 1 gene 
knockdown was also tested for its effect on all transduced cells with all NS3 protein gen-
otypes. Figure 3.33. A shows the effect of Staufen 1 on NS3 protein, which did not show 
changes in NS3 protein expression above the normal levels of NS3 protein control.  
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Figure  3.30. Flow cytometry analysis of the effect of RAB 27B silencing on NS3 V5 
tagged protein. (A) Panels (i-vi) show the effect of RAB 27B gene silencing on NS3 V5 
tagged protein stained with anti-V5 antibody and anti-mouse Alexa-Flour 594, each 
panel represents a specific NS3 or NS3/4A genotype. Changes in expression of NS3 
protein (showed as shift to the right in the flow cytometry plots) compared to the con-
trol. (B) The (MFI) of NS3 and NS3/4A protein genotypes showed significant changes 
in their levels compared to the control (P ˃ 0.05). The mean florescence intensity (MFI) 
represented in arbitrary units, and the error bars represent the standard deviation from 
two independent experiments. 
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Figure  3.31. Flow cytometry analysis of the effect of RAB 40B silencing on NS3 V5 
tagged protein. (A) Panels (i-vi) shows the effect of RAB 40B gene silencing on NS3 V5 
tagged protein, each panel represents a specific NS3 or NS3/4A genotype. Changes in 
expression of NS3 protein (showed as shift to the right in the flow cytometry plots) 
compared to the control. (B) The MFI shows significant change in genotypes NS3-1a, 
NS3/4A-1a, NS3-2a and NS3/4A-1b (P˃ 0.05). The mean florescence intensity (MFI) 
represented in arbitrary units, and the error bars represent the standard deviation from 
two independent experiments.  
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Figure  3.32. Flow cytometry analysis of the effect of TXNIP on V5 tag NS3 protein 
stained with anti-V5 antibody and anti-mouse Alexa-Flour 594. (A) Panels (i-vi) shows 
flow cytometry analysis of TXNIP gene silencing on NS3 V5 tagged protein, each panel 
represents a specific NS3 or NS3/4A genotype. (B) Shows the (MFI) of NS3 and 
NS3/4A protein genotypes did not show significant changes in their levels compared 
with the control. The mean florescence intensity (MFI) represented in arbitrary units, 
and the error bars represent the standard deviation from two independent experiments. 
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Figure  3.33. Flow cytometry analysis of the effect of Staufen 1 on V5 tag NS3 protein 
stained with anti-V5 antibody and anti-mouse Alexa-Flour 594. (A) Panels (i-vi) shows 
flow cytometry analysis of Staufen 1 gene silencing on NS3 V5 tagged protein, each 
panel represents a specific NS3 or NS3/4A genotype. B. Shows the (MFI) of NS3 and 
NS3/4A protein genotypes did not show significant changes in their levels compared 
with the control. The mean florescence intensity (MFI) represented in arbitrary units, 
and the error bars represent the standard deviation from two independent experiments 
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3.3 Effects of inhibition of NS3 protease activity on interferon pathway 
gene expression 
NS3 protease activity has been shown to inhibit the interferon response pathway by pro-
teolysis of the signalling intermediates, TRIF and MAVS. Evidence that NS3 can also in-
hibit the expression of interferon response pathway genes has recently been obtained            
Al-Hababi, 2011 [277]. To investigate whether this inhibition is due to the NS3 protease, 
the effect of the NS3 specific protease inhibitor BILN 2061 on host gene expression was 
examined. 
3.3.1 Effect of protease inhibitor BILN 6021 on NS3 protein expression 
and IFN pathway 
To investigate the effect of antiviral protease inhibitor BILN 6021 on the IFN pathway 
cytoplasmic receptors, MAVS, RIG-I and MDA5, in cells expressing NS3 and NS3/4A. 
BILN 2061 (10μM)  were added to the culture medium of Huh7 cells transduced with ad-
enovirus expressing NS3 and NS3/4A for 24 hours. The antiviral activity of BILN 2061 
compound alone and with addition of poly (I:C) for each genotype to stimulate the toll-
like receptor (TLR) 3 was confirmed by measuring mRNA levels by qRT-PCR. Data 
were analysed using one-way analysis of variance (ANOVA), and Bonnferroni post-tests.  
Figure 3.34.A  showed  slight reduction in expression of  NS3-1a when treated with 
BILN 2061. Additionally, BILN 2061 reduced the expression of MAVS, RIG-I and 
MDA5 genes significantly compared to the control levels. Moreover, the effect of BILN 
2061 and poly (I:C) showed  slight changes  in MAVS, RIG-I and MDA5 expression lev-
els. Treatment of  Huh7 expressing NS3/4A-1a with BILN 2061 showed significant de-
crease in NS3/4A-1a expression (P ˂0.05) in comparison to the control, whereas, RIG-I, 
MDA5 and MAVS host genes showed significant reduction in comparison with the con-
trol levels. The effect of BILN 2061 and poly (I:C) reversed MAVS, RIG-I and MDA5  
genes to  control  levels (Figure 3.34.B). 
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Figure  3.34. Effects of BILN 2061 on HCV NS3-1a (A) and NS3/4A-1a (B) on MAVS, 
RIG-I and MDA5 and expression. Huh7 cells were grown in 24 well plates followed by 
transduction with AdNS3, AdNS3-4a for 48 hour. Cells were stimulated with poly (I:C) 
(5ng/μl) for 8 hours. Total RNA was extracted, and the mRNA expression was deter-
mined by real-time PCR and normalized using GAPDH. 
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Figure  3.35. Effects of BILN 2061 on HCV NS3-2a (A) and NS3/4A-2a (B) on MAVS, 
RIG-I and MDA5 expression. Huh7 cells were grown in 24 well plates followed by 
transduction with AdNS3, AdNS3/4A for 48 hour. Cells were stimulated with poly              
(I: C) (5ng/μl) for 8 hours. Total RNA was extracted, and the mRNA expression was de-
termined by real-time PCR and normalized using GAPDH. 
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Figure 3.35.A shows slight reduction in NS3-2a levels treated with protease inhibitor 
BILN 2061. MAVS, RIG-I and MDA5 genes did not show significant changes in their 
expression levels when treated with BILN 2061 or with a combination of  BILN 2061 
and poly (I:C). NS3/4A-2a treated with BILN 2061 showed significant decrease in 
NS3/4A-2a expression (P ˂0.05) compared to the control. MAVS, RIG-I and MDA5 
gene expression levels were  reduced when treated with BILN2061. Additionally, BILN 
2061 and poly (I:C) combination  reversed  MAVS, RIG-I  and MDA5 genes to the con-
trol levels in response to poly (I:C) stimulation (Figure 3.35.B). 
 Figure 3.36.A shows slight reduction in NS3-1b levels when treated with BILN 2061. In 
addition, BILN 2061 did not show significant changes on MAVS, RIG-I and MDA5 
genes, whereas, BILN 2061  and  poly (I:C)  reversed slightly  MAVS, RIG-I and MDA5 
genes. NS3/4A-1b treated with BILN 2061 showed significant reduction in NS3/4A-1b 
expression (P ˂0.05) in comparison to the control levels. Additionally, MAVS, RIG-I and 
MDA5 showed significant reduction when treated with protease inhibitor BILN2961, 
whereas, BILN 2061 and poly (I:C)  reversed MAVS, RIG-I and MDA5  genes in re-
sponse to poly(I:C) stimulation. (Figure 3.36. B). 
 
 
 
 
 
 
 
 
Results 
 150 
 
 
Figure  3.36. Effects of BILN 2061 on HCV NS3-1b (A), and NS3/4A-1b (B) on MAVS, 
RIG-I and MDA5 expression. Huh7 cells were grown in 24 well plates followed by 
transduction with AdNS3, AdNS3/4A for 48 hour. Cells were stimulated with poly (I: 
C) (5ng/μl) for 8 hours. Total RNA was extracted, and the mRNA expression was de-
termined by real-time PCR and normalized using GAPDH. 
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3.4 Summary of the interaction of NS3-1a protein with JFH-1 RNA 
Full-length NS3 [1027-1657], has been expressed as a histidine-tagged fusion protein in 
E. coli and isolated from inclusion bodies and purified under denaturing conditions using 
chaotropic agents urea and imidazole. Expression of NS3 protein was confirmed as a 
band of approximately 70 kDa observed by SDS-PAGE analysis and Western blotting 
(Figure 3.5). The NS3 protein was then refolded by sequential dialysis to remove the urea 
and imidazole. A colorimetric assay for NS3 protein ATPase activity showed a linear 
relationship between, the time of the reaction between enzyme substrate, and the level of 
ATPase activity demonstrating that the NS3 protein was enzymatically active. To deter-
mine the interaction of full length HCV NS3-1a protein with the full length HCV JFH-1 
RNA, an electro mobility shift assay (EMSA) was used, at different concentrations of 
HCV NS3-1a protein, ranging from 100nM to 600nM, and 55pmol of full length bioti-
nylated JFH-1 RNA. The results showed a decrease in the chemoluminescence signal in-
tensity of the biotinylated RNA and NS3 protein complex with an increase in NS3 protein 
concentration, which indicated binding between RNA and NS3-1a protein. The RNA pro-
tein complex showed a slight migration compared with the control; however this was not 
significant (Figure 3.14). Similar results were seen for the interaction of the biotinylated 
3’end HCV the negative strand RNA and HCV NS3-1a protein (Figure 3.15).  
 
3.5 Summary of silencing effect of host genes RAB 27B, RAB 40B, 
Staufen 1 and TXNIP on NS3 and NS3/4A protein expression 
Adenovirus stocks containing individual NS3 and NS3/NS4A inserts from genotypes 1a, 
1b and 2a containing a V5 tag were used to generate high titre viral stocks and titered by 
plaque assay. An MOI (multiplicity of infection) of 100 was determined to be appropriate 
for use in subsequent experiments. These stocks of adenovirus vectors that express HCV 
NS3 and NS3/NA4A proteins were used to test the effect of the silencing of host protein 
genes, RAB 27B, RAB 40B, TXNIP and Staufen 1 on NS3 stability. Firstly, the effi-
ciency of RAB 27B, RAB 40B, TXNIP and Staufen 1 gene silencing by siRNAs was 
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quantified using qRT-PCR and all of the host genes showed a significant decrease in ex-
pression.  
The effect of host gene RAB27 knockdown on NS3 gene expression was determined and 
it showed a decrease in transcript levels in all NS3 genotypes. The NS3-1a and NS3/4A-
1a genotypes showed a decrease in expression by 25% and 33%, respectively, while the 
decrease in expression was 26% for NS3-2a and 36% for NS3/4A-2a compared to the 
negative control. The NS3-1b and NS3/4A-1b gene expression showed a greater decrease 
in their levels, by 40% and 37%, respectively (Figure 3.24). RAB 40B gene silencing 
showed decrease of 36% in NS3-1a expression and 28% in NS3/4A-1a gene expression. 
NS3-2a and NS3/4A-2a showed decreases in their expression of 27% and 15%, respec-
tively. Additionally, NS3-1b showed a considerable decrease in NS3 expression by 40%, 
while NS3/4A-1b showed a reduction in expression by 37% (Figure 3.25). RAB 27B and 
RAB 40B host gene knockdown both lowered the expression levels of all NS3 genotypes, 
which indicate that these proteins may be required by functional HCV NS3 protein.             
Silencing of the Staufen 1 gene gave a 16% decrease in NS3-1a a 23% decrease in 
NS3/4A-1a expression. NS3-2a and NS3/4A-2a showed reductions in their expression by 
40% and 39%, respectively. NS3-1b expression was reduced by 37%, whereas, NS3/4A-
1b only showed a reduction of 17% (Figure 3.26). Moreover, silencing of host gene 
TXNIP showed a reduction of 18% on NS3-1a and 20% for NS3/4A-1a following the 
knockdown, whereas, NS3-2a showed a reduction of 30%. The NS3/4A-2a  levels were 
lowered by 25%, which was similar to the level of reduction by full length NS3. Silenc-
ing of TXNIP showed a reduction of 20% in NS3-1b and 25% in NS3/4A-1b (Figure 
3.27), these results showed that both Staufen 1 and TXNIP reduced the levels of gene ex-
pression in all NS3 genotypes. The effect of host gene proteins RAB 27B, RAB 40B, 
TXNIP and Staufen 1 knockdown was also tested for all V5 tagged NS3 at the protein 
level by flow cytometry. Knockdown of RAB 27B and RAB 40B showed a detectable in-
crease in the levels of NS3 and NS3/4A proteins in all genotypes, whereas, silencing of 
Staufen 1 and TXNIP had no detectable effect on HCV NS3 protein levels in all geno-
types. 
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3.6 Summary of the effect of protease inhibitor BILN 2061 on NS3 and 
NS3/4A protein expression and IFN pathway  
Huh 7 cells expressing NS3-1a, NS3-2a and NS3-1b protein treated with the antiviral 
protease inhibitor BILN 2061 showed slight reduction  in expression levels of these 
genes, whereas, Huh 7 cells expressing NS3/A-1a, NS3/A-2a and NS3/A-1b protein 
showed significant reduction in NS3/A-1a, NS3/A-2a and NS3/A-1b expression levels. 
The high reduction in NS3/4A-1a, 2a and 1b genotypes expression levels could be due to 
the presence of the co-factor NS4A. The effect of the antiviral protease inhibitor BILN 
2061 on cytoplasmic receptor components of the IFN pathway, namely MAVS, RIG-I 
and MDA5, were tested in Huh 7 cells expressing NS3 and NS3/4A. Cells expressing 
NS3-1a, NS3-2a and NS3-1b genotypes treated with BILN 2061,  showed little reduction 
in expression of MAVS, RIG-I and MDA5 levels compared to control levels, whereas 
BILN2061 and poly (I:C)  reversed MAVS, RIG-I and MDA5. Treatment of  Huh7 cells 
expressing NS3/4A-1a, NS3/4A-1b protein with BILN 2061 showed  significant changes 
in expression levels of MAVS, RIG-I and MDA5 genes, and slight reduction in NS3/4A-
2a,  whereas, BILN 2061 and poly (I:C) reversed RIG-I, MDA5 and MAVS  levels to in 
response to poly(I:C).  (Figures 3.34, 3.35, 3.36). 
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4. Discussion 
4.1 RNA-protein interactions 
RNA–protein interactions are important in many biological processes, such as all the 
steps in gene expression and its regulation. Generally the genomes of positive-stranded 
RNA viruses are involved in at least three major processes: They act as mRNAs to direct 
the synthesis of viral proteins; they serve as templates for genome replication; and they 
are packaged along with structural proteins during viral assembly [74]. Studies on HCV 
replication have been expanded after the discovery of HCV strain JFH-1 (genotype 2a) 
that can be grown in cell culture. The HCV genome contains important elements which 
are critical for virus viability, for instance; the NS3 helicase, which is responsible for un-
winding of the viral RNA during replication, the NS5B polymerase which is required for 
viral RNA replication and 5’ and 3’ UTRs which do not encode any viral proteins but act 
as functional elements essential for regulating translation and initiating replication [280]. 
NS3 protein contains a serine protease activity at its N-terminal end, which is responsible 
for the downstream cleavage in the nonstructural region, thus playing a fundamental role 
in viral RNA replication [31, 50]. Additionally, The X-ray crystallography structure of 
NS3 and structure-based mutagenesis of NS3 has identified important amino acid resi-
dues required for helicase and ATPase activities [9, 29, 37, and 59]. Generally, Helicases 
are involved in many RNA metabolic processes, such as transcription, RNA splicing, 
RNA export, translation, and RNA degradation [275].  
A recent study showed that DDX3 which is a cellular helicase is involved in HCV repli-
cation, and thus might also be involved in HCV assembly. Moreover, it may be incorpo-
rated into the HCV virion by interacting with the core to act as a chaperone [239]. How-
ever, viral helicases are also found to play a role in viral replication. A study on NS3 of 
Yellow Fever Virus (YFV) reported that a mutation of conserved tryptophan 349 in the 
helicase domain of NS3 impeded the production of virus particles, thus indicating that 
NS3 might play a role in the virus assembly, in addition to its known enzymatic proper-
ties [281].  
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In this study we demonstrated that the HCV NS3 protein from amino acid [1027-1657] 
was expressed as a histidine-tagged fusion protein in E. coli. It was then isolated and pu-
rified from inclusion bodies [264]. The purification of NS3 protein was achieved using a 
Ni-NTA column under denaturing conditions and imidazole, and the expression of NS3 
was confirmed by SDS-PAGE analysis and Western blot. However, despite all the ad-
justments that were made to produce pure NS3 protein e.g. varying the imidazole concen-
trations in the elution buffer, and purification at 4ºC, it was difficult to produce high lev-
els of pure NS3 protein. This could be due to several reasons e.g. the position of the 6X 
His tag may influence the ability of NS3 to bind to the Ni-NTA column or the interaction 
of NS3 with other proteins when expressed at high levels which might even influence it 
solubility. However, detection of NS3-1a protein unbound to nickel in flow-through was 
detected previously [268]. It was observed that large amounts of NS3-1a precipitated dur-
ing the refolding process, this aggregation of protein during refolding may be due to the 
absence of cellular factors such as chaperones and cell organelles e.g. ER which would be 
present during viral RNA translation, or viral proteins which would normally be present 
during viral RNA translation. Additionally, other viral proteins which would normally be 
present during HCV replication such as NS4A which is known to associate strongly with 
NS3 protein [282] [283], may also be required for the correct NS3 folding. SDS PAGE 
analysis demonstrated that the refolded protein was partially purified i.e. with some cellu-
lar protein contaminants, however, several studies have previously used partially purified 
protein to successfully study RNA–protein interactions [284]. 
Generally, RNA helicases of DEAD-box protein family possess an ATPase activity that 
is dependent on, or stimulated by RNA. However, ATPase activity does not require         
a specific RNA substrate [88]. Several studies revealed cooperativity between RNA bind-
ing and ATP binding with the binding of RNA being stronger in the presence of ATP 
[88]. The characterization of the full-length NS3-1a protein was studied previously by       
Wardell et al. 1999 [268], NS3 was able to hydrolyse a variety of NTPs and dNTPs and 
showed a preference for ATP. The biochemical characteristics of HCV helicase and 
NTPase activity were similar to those of other viral and non-viral RNA helicases, for ex-
ample the yeast protein PRP22 [285], and the bluetongue virus VP6 protein [286], which 
both exhibited polynucleotide stimulated ATPase activity. In this study the ATPase activ-
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ity of NS3 protein was tested and a linear relationship was demonstrated between the 
time of the reaction between enzyme and substrate and the level of ATPase activity. This 
showed that the protein possesses ATPase activity indicating that the refolding process 
was successful in producing functionally active NS3 protein. 
Electrophoretic mobility shift assays (EMSA) are used to detect a complex of proteins 
bound to a labelled RNA probe. The RNA–protein complex is separated by agarose gel 
electrophoresis and transferred to a positively charged nylon membrane. Although, the 
sensitivity of the biotin-labelled EMSA is not as high as that with radioisotope labelling, 
there are practical advantages with this technique. Biotin-labelled RNA probes avoid the 
hazard and inconvenience of RNA probes with radioisotope labelling [287] [288]. In this 
study we found that there is binding activity between the full length JFH-1 RNA and 
NS3-1a protein which was detected by a decrease in the chemiluminescence signals of 
the labelled JFH-1 RNA. The interaction between the full length NS3-1a and the 3’ end 
of the negative strand was also detected by observing a reduction in the biotin intensity 
also; the band shifts were more obvious compared to the full length JFH-1 RNA.  
Shifting of  JFH-1 RNA-NS3-1a protein complex  bands was not great which may be at-
tributed to the differences in the RNA-protein ratio [287]. Moreover, the observed bind-
ing between JFH-1 RNA and NS3-1a and the 3’ end of the negative strand with NS3-1a 
protein indicates that the interaction between NS3 protein and JFH-1 RNA (genotype 2a) 
is not genotype specific. Studies using 32P-labelled RNA have reported that NS3 protein 
specifically binds to the 3′ ends of both the positive- and negative-strand RNAs of HCV 
[289]. However, in the present study the observed interactions between the JFH-1 RNA 
and genotype 1a NS3 protein may indicate that NS3-RNA interactions are not dependent 
on highly conserved nucleic acid sequences.  
There are many possible reasons why NS3-1a protein may be flexible in the sequences 
that it can bind. One possibility is that although that 3’ and 5’ terminal sequences are well 
conserved, in quasispecies that are generated during HCV replication they have sequence 
mismatches compared to the canonical genotype sequence. However, flexibly in           
sequence recognition by the HCV RNA replication machinery would help to ensure that 
they can also be replicated. It is also possible that cell-free protein nucleic acid binding 
Discussion 
 158 
experiments lack other host or virus components, or the physiological conditions needed 
to replicate in the intracellular environment. The binding of NS3 to viral genome           
sequences directly implicates NS3 protein in the multiple processes within the viral life           
cycle involving the genome (translation, RNA replication, and assembly). In this regard, 
the interaction of NS3 with the 3′ end negative strand and the full-length JFH-1 could be 
a valid target for antiviral intervention.  
 
4.2 Host genes involved in Protein–Protein interaction 
Many biological functions involve the formation of protein-protein complexes. Protein-
protein interactions play important roles at several levels of cell function e.g. in the struc-
ture of sub-cellular organelles, the transport machinery across the various biological 
membranes, packaging of chromatin, the network of sub-membrane filaments and signal 
transduction and regulation of gene expression [290]. The regulation of cell function 
brought about by the interactions of these proteins is balanced by the relative affinities of 
the various protein partners and the modulation of these affinities by the binding of 
ligands, other proteins, nucleic acids, ions such as Ca2+, and covalent modification, such 
as specific phosphorlyation or acetylation [290].Microarray analysis study published by 
Dr McGarvey’s group [271], found that several host genes play a role in the replication of 
HCV. It was shown that HCV infection altered the expression level of about 2000 host 
genes; subsequent siRNA knock down analysis showed that several of these appeared to 
be important for HCV replication. One possibility is that some of these host proteins may 
play a role in the formation of HCV RNA replication complexes and that knocking out 
the expression of these genes could destabilize these replication complexes and increase 
the turnover of HCV proteins involved in RNA replication. NS3 or NS3/4A protein is 
thought to be important in the replication complexes.   Therefore, this study looked at the 
alterations in NS3 levels when host genes TXNIP, Staufen 1, RAB278 or RAB40B ex-
pression were knockdown.Thioredoxin-interacting protein (TXNIP) is a multifunctional 
protein which regulates critical biological processes, such as inflammation, stress, and 
apoptosis. It also has a tumor-suppressive function is under-expressed in some human 
cancers. Moreover, it has been found that TXNIP down regulation may play a role in 
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liver carcinogenesis, because TXNIP deficiency is able to induce HCC in experimental 
mice [291]. In addition, TXNIP is involved in the regulation of lipid metabolism and may 
therefore impact on the HCV [271].  Moreover, TXNIP was identified through microar-
ray analyses, validated by qRT-PCR, and recognized as highly up regulated during HCV-
infection. The knockdown of TXNIP by RNA interference inhibits HCV replication by 
up to 90%, this implies that TXNIP is required for HCV replication [230].  In this study, 
the effect of TXNIP silencing on NS3 and NS3/4A gene expression from different geno-
types in siRNA transfected cells was measured. A reduction in NS3 and NS3/4A levels 
was found in genotypes 1a, 2a and 1b. Despite the variation in the level of reduction, this 
was not significant between each genotype. It is not known whether TXNIP knockout 
suppresses NS3 expression directly or indirectly. Directly, in which TXNIP itself sup-
presses IL-3 receptor and cyclin A2 promoter activity, or the silencing of TXNIP may 
downregulate directly the NS3 expression or indirectly by suppressing other cellular 
genes which have a regulatory effect on NS3[292]. 
The RAB proteins are involved in membrane transport regulation. They are membrane 
secretory vesicle proteins and are thought to be involved in releasing mature virus parti-
cles from within an infected cell [271]. Silencing of both host genes RAB 27B and RAB 
40B showed a reduction in NS3 levels. The genotypes NS3-1b and NS3/4A-1b showed 
considerable decreases of 40% and 37% respectively. Also, NS3-1a levels reduced to 
36%. However, silencing RAB27B and RAB40B also had a considerable effect on the in-
tracellular JFH-1 RNA levels, indicating that these factors may play multiple roles in the 
HCV replication cycle [271]. 
Staufen1 is an RNA-binding protein that controls the translation, trafficking and degrada-
tion of cellular mRNA molecules [209]. Staufen 1 has been shown to facilitate virus par-
ticle assembly in the replication cycles of HIV and Influenza A [216, 293] and to stimu-
late translation of the HIV genome. Previous investigations to identify RNA binding pro-
teins that interact with the HCV genome have also demonstrated that Staufen1 binds di-
rectly to the HCV genome, at the 3’UTR of the positive RNA strand and 5’UTR of the 
negative RNA strand [294]. The effect of Staufen 1 silencing on Huh 7 cells transduced 
with NS3 and NS3/4A protein demonstrated that Staufen 1 knockdown reduces the levels 
of NS3 proteins in all genotypes. The largest reduction was found with NS3-2a and 
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NS3/4A-2a genotypes showing reductions in their expression by 40% and 39%, respec-
tively. Staufen 1 knockdown  also reduced NS3 levels in JFH-1 infected Huh 7 cells, 
which replicates the complete cycle of HCV [230]. 
The levels of RAB27B and RAB40B gene expression were investigated for their effects 
on NS3 protein expression and stability.  Huh7 cells transduced with adenovirus 1a, 2a, 
and 1b were transfected with the RAB27B and RAB40B siRNA’s. Following transfection 
the cells were stained and analyzed using flow cytometry analysis. FACS analysis re-
vealed that the RAB27B knockdown and RAB40B median fluorescence intensity (MFI) 
staining signals showed that high levels of NS3 protein were expressed in both RAB27B 
and RAB40B knockdown experiments.  
RAB27B and RAB40B have important roles in regulating the trafficking of secretory 
vesicles. Additionally, the expression of RAB27B was found to increase significantly 
during JFH-1 infection, which indicates that RAB27B play role in the trafficking of sec-
retory vesicles to the plasma membrane, which may be important for virus replication 
[230]. Moreover, reduced levels of RAB27B and RAB40B may prevent NS3 from being 
transported to intracellular locations that required for RNA replication or even virus par-
ticle assembly. However, NS3 may still be expressed and remain at sites which increase 
its stability. 
The expression of TXNIP was also found to be elevated significantly during JFH-1 infec-
tion [271]. Efficient silencing of TXNIP protein expression was observed following 
transfection of Huh7 cells with TXNIP siRNA. The effect of TXNIP silencing on NS3 
protein expression was determined, the MFI signals did not show significant differences 
in NS3 expression compared to the positive control. This suggests TXNIP may reduce 
overall HCV replication but may not have direct effect on NS3 stability. The effect of 
Staufen 1 silencing on NS3 protein expression was investigated and the intensity of the 
MFI did not show statistical differences in NS3 expression compared to the positive con-
trol. This could be because the localization of Staufen 1 has a discrete position rather than 
adjacent to the target protein NS3, which minimize its effect on NS3. Moreover, a study 
conducted on Staufen 1 of  Drosophila embryogenesis found that the localization of 
Staufen 1 and Prospero protein which are cellular proteins in drosophila co- localized 
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[295]. It seems that Staufen 1 may not associate directly with NS3 or other cellular or vi-
ral proteins which may play a role to co-localize Staufen 1 to NS3 protein. 
 
4.3 Effect of NS3 on IFN pathway gene expression 
Pegylated interferon and ribavirin is the standard combination treatment for HCV.                  
The Efficacy of  treatment  is 80% in patients infected  by HCV genotype 2 or 3, 
whereas in patients infected by HCV genotype 1 the response to treatment is less than 
50% [296-298]. BILN 2061 is a potent antiviral developed to inhibit HCV NS3/4A ser-
ine protease. BILN 2061 was used to study its effect on NS3 and NS3/4A protein ex-
pression and IFN pathway. In this study, Huh 7 expressing NS3-1a, NS3-2a and NS3-1b  
treated with the antiviral protease inhibitor BILN 2061 showed slight reduction  in their  
expression levels, whereas Huh 7 cells expressing NS3/A-1a, NS3/A-2a and NS3/A-1b 
showed significant reduction in expression levels. These differences could be due to the 
presence  of  co-factor NS4A. It was reported that  all  inhibitors have  higher affinity 
for NS3 in the presence of NS4A [299].  The result demonstrated  that BILN 2061 has 
direct effect on NS3 protein especially NS3/4A-1a, 2a and 1b genotypes. Additionally, 
the results did not show genotypic specificity in inhibition with BILN 2016.                            
HCV NS3/4A complex can inhibit host cell adaptors proteins of   the innate immune re-
sponse TRIF and MAVS [300]. In this study, treatment of Huh 7 cells expressing 
NS3/A-1a, NS3/A-2a and NS3/A-1b protein with BILN 2061 reduced the expression 
levels of RIG-I, MAVS and MDA5 more efficiently than in Huh 7 cells expressing 
NS3-1a, NS3-2a  and NS3-1b  protein, and  reversed the NS3/4A-mediated inhibition of 
RIG-I, MDA5 and MAVS signaling in response to poly (I:C) stimulation.  These results 
may indicate the role of  NS3 protein in the inhibition of  IFN induction  mediated by 
dsRNA stimulation. Although, the role  of HCV NS3/4A protein has been detected in 
IFN inhibition by direct targeting both TRIF and MAVS adaptors proteolysis [300-302].  
However, the mechanism of how NS3/4A inhibit IFN components at transcription level 
is still unclear. It has been found  in a  previous study using subgenomic HCV RNA  
replicons  that the expression of NS3 and NS3/4A proteins, using adenovirus vectors, 
restored  RIG-I, MDA5 and MAVS expression levels in response to dsRNA stimulation, 
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indicating that the NS3 protein may have a role in regulating the expression of these 
host genes [277]. Additionally, BILN 2061 has been shown to have  some  inhibitory ef-
fect on  RIG-I, MAVS and MDA5, this could be due to dose toxicity of this compound  
or, the NS3 protein may have  more complex role in the regulation of expression of 
these genes. 
  
In conclusion, this study aimed to investigate whether there is an interaction between re-
combinant HCV NS3-1a and full length HCV JFH-1 RNA and 3’ end of JFH-1 negative 
strand RNA. It can be concluded that although there was little altered migration of the 
RNA-protein complexes, the binding between NS3-1 protein and the target HCV RNAs 
JFH-1 and the 3’ negative RNA strand was clearly shown. It was also demonstrated that 
gene silencing of RAB27B and RAB40B had an effect on HCV NS3 and NS3/4A ex-
pressed by adenovirus vectors, but that silencing of Staufen 1 and TXNIP did not.             
The NS3 protease inhibitor BILN 2061 was  to shown inhibit  NS3 and NS3/4A  suppres-
sion of RIG-I, MDA5 and MAVS gene expression. This was contrary to the expected 
outcome which indicates that NS3 protein may have  more complex role in the regulation 
of expression of these genes than was originally thought. Additionally, It was found that 
the expression of NS3 and NS3/4A proteins, using adenovirus vectors, restored  RIG-I, 
MDA5 and MAVS expression levels in response to dsRNA stimulation, indicating that 
the NS3 protein may have a role in regulating the expression of these host genes.  
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6. Appendix 
 
6.1 RNA and DNA molecular weight ladders 
 
Ambion Millennium RNA ladder (Ambion)                1KB DNA ladder (Promega) 
 
Figure  6.1. RNA and DNA molecular weight ladders 
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6.2 Protein molecular weight ladders 
 
7. SDS-PAGE prestained molecular weight marker (Invitro-
gen) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ori- entation band (pink) 
 
Figure  7.1. SDS-PAGE prestained molecular weight marker (Invitrogen) 
 
  
Band Number 
 
Molecular 
Weight 
1 180 kDa  
2 115 
3 82 
4 64 
5 49 
6 37 
7 26 
8 19 
9 15 
10 6 
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8. SDS-PAGE molecular weight marker (Invitrogen) 
 
 
 
 
Figure  8.1. SDS-PAGE molecular weight marker (Invitrogen) 
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6.3 DNA plasmid map 
pET16b expression vector containing His-tagged fragment of pAW3 [1027-1657] used to 
produce full length HCV NS3 protein. 
 
 
                                     Figure  8.2. DNA plasmid map 
